## Audit Committee

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| Published Book or Book Chapter | Comprehensive Data verification and scientific auditing  
|                | Weiss RB                            |
|                | Citation: Budman, D. Handbook of Anticancer Drug Development. Lippincott Williams & Wilkins; 395-398, 2003 |
**Study**

**Published Manuscript**

**7581**

Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: A study by the Cancer and Leukemia Group B


Citation: Journal of Clinical Oncology 21(9):1825-1835, 2003

http://jco.ascopubs.org/cgi/content/full/21/9/1825

**7581, 8082, 8541, 9344**

Adjuvant chemotherapy in older and young women with lymph node-positive breast cancer


Citation: Journal of the American Medical Association 293(9):1073-1081, 2005

http://jama.ama-assn.org/cgi/content/full/293/9/1073

**7581, 9671**

Long-term adjustment of survivors of early stage breast cancer 20 years after adjuvant chemotherapy: Companion to CALGB 7581


Citation: Cancer 98(4):679-689, 2003

http://www3.interscience.wiley.com/cgi-bin/fulltext/104540345/HTMLSTART

**79804**

Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer:

CALGB 79804

Katz ML, Donohue KA, Alfano CM, Day JM, Herndon II JE

Citation: Cancer 115(3):480-488, 2009

http://www3.interscience.wiley.com/journal/121634208/abstract?CRETRY=1&SRETRY=0

**8081, 8281, 8642, 9140**

High-dose vs standard chemotherapy in metastatic breast cancer: Comparison of Cancer and Leukemia Group B trials with autologous blood and marrow transplant registry


Citation: Journal of Clinical Oncology 20(3):743-750, 2002

http://jco.ascopubs.org/cgi/content/full/20/3/743

**8082**

Association of angiogenesis in lymph node metastases with outcome of breast cancer


Citation: Journal of the National Cancer Institute 92(6):486-492, 2000

**8541**

Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: Study 8541 from the Cancer and Leukemia Group B


Citation: Journal of Clinical Oncology 26(14):2364-2372, 2008

http://jco.ascopubs.org/cgi/content/full/26/14/2364
Topoisomerase II alpha amplification does not predict benefit from dose-intense cyclophosphamide, 

Harris LN, Broadwater G, Abu-Khalaf MM, Cowan DW, Thor AD, Budman DR, Cirrincione CT, Berry DA, 
Wu ED, Hudis CA, Hayes DM, Friedman PN, Ellis MJ, Dressler LG 
Citation: Journal of Clinical Oncology 27(21):3430-3436, 2009 
http://jco.ascopubs.org/cgi/content/full/27/21/3430

Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with 
adjuvant cyclophosphamide, doxorubicin, and fluorouracil: A Cancer and Leukemia Group B correlative 
science study from protocols 8541/8869 
Citation: Journal of Clinical Oncology 20(3):732-742, 2002 
http://jco.ascopubs.org/cgi/content/full/20/3/732

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict 
benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients 
Dressler LG, Berry DA, Broadwater G, Cowan DW, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, 
Citation: Journal of Clinical Oncology 23(19):4287-4297, 2005 
http://jco.ascopubs.org/cgi/content/full/23/19/4287

HER-2/neu and p53 expression vs. tamoxifen resistance in estrogen-receptor-positive node-positive breast cancer 
Berry DA, Muss HB, Thor AD, Dressler LG, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos MP, 
Hayes DF, Norton L 
Citation: Journal of Clinical Oncology 18(20):3471-3479, 2000 
http://jco.ascopubs.org/cgi/content/full/18/20/3471

HER2 and response to paclitaxel in node-positive breast cancer 
Hayes DF, Thor AD, Dressler LG, Weaver DL, Edgerton S, Cowan DW, Broadwater G, Goldstein L, Martino 
Citation: New England Journal of Medicine 357(15):1496-1506, 2007 
http://content.nejm.org/cgi/content/abstract/357/15/1496

Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: 
The Cancer and Leukemia Group B (CALGB) experience 
Muss HB, Berry DA, Cirrincione CT, Budman DR, Henderson IC, Citron MA, Norton L, Winer EP, Hudis CA 
Citation: Journal of Clinical Oncology 25(24):3699-3704, 2007 
http://jco.ascopubs.org/cgi/content/full/25/24/3699

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer 
Berry DA, Cirrincione CT, Henderson IC, Citron MA, Budman DR, Goldstein L, Martino S, Perez E, Muss 
HB, Norton L, Hudis CA, Winer EP 
Citation: Journal of the American Medical Association 295(14):1658-1667, 2006 
http://jama.ama-assn.org/cgi/content/full/295/14/1658
Circulating HER2/c-neu extra cellular domain (ECD/HER2) as a prognostic factor in patients with metastatic breast cancer: A Cancer and Leukemia Group B study


Citation: Clinical Cancer Research 7(9):2703-2711, 2001

An intensive sequenced adjuvant chemotherapy regimen for breast cancer

Bhardwaj S, Duggan D, Cirrincione C, Holland JF, Kirshner JJ, Berry DA, Norton L, Henderson IC

Citation: Cancer Therapy 5, 2007

Association of angiogenesis in lymph node metastases with outcome of breast cancer


Citation: Journal of the National Cancer Institute 92(6):486-492, 2000
http://jnci.oxfordjournals.org/cgi/content/full/92/6/486

Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: A phase II trial (CALGB 8944)


Citation: Breast Cancer Research and Treatment, 2008
http://www.springerlink.com/content/e77257177118235/

A prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082


Citation: Journal of Clinical Oncology 23(10):2191-2200, 2005
http://jco.ascopubs.org/cgi/content/full/23/10/2191

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140

Parnes H, Cirrincione CT, Aisner J, Berry DA, Abrams J, Chuang E, Cooper MR, Perry MC, Duggan DB, Szatrowski TP, Henderson IC, Norton L

Citation: Journal of Clinical Oncology 21(9):1819-1824, 2003
http://jco.ascopubs.org/cgi/content/full/21/9/1819

Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel


Citation: Cancer Treatment and Reviews 34(3):223-230, 2008
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
Citation: Journal of Clinical Oncology 21(6):976-983, 2003
http://jco.ascopubs.org/cgi/content/full/21/6/976
Breast Committee

Study

Published Manuscript

9344, 70101
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344)
Lamont EB, Herndon II JE, Weeks JC, Henderson C, Earle CC, Schilsky RL, Christakis NA
Citation: Journal of the National Cancer Institute 98(18):1335-1338, 2006
http://jnci.oxfordjournals.org/cgi/content/full/98/18/1335

9741
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741
Citation: Journal of Clinical Oncology 21(8):1431-1439, 2003
http://jco.ascopubs.org/cgi/content/full/21/8/1431

9840
Randomized phase III trial of weekly compared with every 3 weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressers: Final results of Cancer and Leukemia Group B protocol 9840
Citation: Journal of Clinical Oncology 26(10):1642-1649, 2008
http://jco.ascopubs.org/cgi/content/full/26/10/1642

9872
Factor V leiden mutation and the risk of thromboembolic events in women receiving adjuvant tamoxifen for breast cancer: Results from CALGB 9872
Citation: Journal of the National Cancer Institute 102(13):942-949, 2010
http://jnci.oxfordjournals.org/content/102/13/942.long

Comprehensive

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197
Goldstein L, O’Neil A, Sparano JA, Perez EA, Shulman LN, Martin S, Davidson N
Citation: Journal of Clinical Oncology 26(25):1-12, 2008

Comprehensive
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Citation: New England Journal of Medicine 357(26):2666-2676, 2007
http://content.nejm.org/cgi/content/abstract/357/26/2666

Comprehensive
The Cancer and Leukemia Group B Breast Committee: Decades of progress and plans for the future
Hudis CA, Winer EP
Citation: Clinical Cancer Research 12:3576s-3580s, 2006
http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3576s
Breast Committee

Study

Published Abstract

150002
CALGB 150002: Correlation of HER-2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840: Paclitaxel (P) +/- T in HER-2(+) and (-) metastatic breast cancer (MBC)
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I (June 20 Supplement) 25(18S):1009, 2007
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32254

150007
Discovery of a new phosphoHER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 25(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32961

150007
Functional pathway mapping of human glioblastoma multiforme and brain metastases for patient tailored therapy
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 27(15s):2076, 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33209

150007
Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 25(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=35157

150007
Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 27(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31279

150007
Evaluation of the effect of screening on the detection of good and poor prognosis breast cancers
Vant Veer L, Esserman LJ, Linn S, Rutgers E, Knauper M, Retel V, Davis SE, Lin C
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 27(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34916

150007
Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY trial
DeMichele A, Dunn L, Gimotty P, Livasy C, Perou CM, Carey LA, Esserman LJ
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 27(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=35378
Breast Committee

Study

Published Abstract

150007

Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657
Citation: Cancer Research 69(2):6043, 2009
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6043?sid=004eb342-f307-4803-be0d-b9a812c72cd7

150007

MRI assessment of breast cancer response to neoadjuvant chemotherapy: Preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657
Citation: Radiological Society of North America 94th Scientific Assembly and Annual Meeting SSA01-01, 2008
http://rsna2008.rsna.org/event_display.cfm?em_id=6006524

150007, 150012

MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN trial 6657/CALGB 150007
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 25(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34898

150007, 150012

Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY Trial (CALGB 150007/150012, ACRIN 6657)
Esserman LJ, Perou CM, Cheang M, DeMichele A, Carey LA, van't Veer LJ, Gray JW, Petricoin E, Conway KM, Berry DA
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 27(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=35410

150007, 150012

Sentinel node biopsy performed in the neoadjuvant setting for Breast Cancer: Results from the CALGB 150007 & 150012/ACRIN 6657 I-SPY TRIAL
Citation: Cancer Research 69(2):202, 2009
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/202?sid=dfd128c8-a508-4980-97a8-14cf1e590bee

150007, 150012

UCSC cancer genomics browser
Citation: Cancer Research 69(2):2022, 2009
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/2022?sid=ed24d6fc-62ae-4169-ac2c-fb8b99c6df1

40101

Four vs 6 cycles of doxorubicin and cyclophosphamide (AC) or paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101 - A 2x2 factorial phase III trial: First results comparing 4 vs 6 cycles of therapy
Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan RM, Martino S, Atkins JN, Hudis CA, Winer EP
Citation: San Antonio Breast Cancer Symposium S6-3, 2010
40101

CALGB 40101: Cyclophosphamide and doxorubicin (AC x 4 cycles) vs Paclitaxel (P x 4 cycles) as adjuvant therapy for breast cancer for women with 0-3 positive axillary lymph nodes: A randomized phase III study
Shulman LN, Berry DA, Cirrincione CT, Kroetz DL, Bunnell CA, Becker HP, Hudis CA, Winer EP
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):3021, 2010

40101, 60202

Inherited genetic variation in EPHA5, FGD4 and NRDG1 and paclitaxel (P) induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101
Citation: Journal of Clinical Oncology 28(15s):3021, 2010
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=49598

40302

Fulvestrant with or without lapatinib as therapy for hormone receptor positive advanced breast cancer: A double-blinded, placebo-controlled, randomized phase III study
Citation: San Antonio Breast Cancer Symposium PD05-01, 2010

40603

CALGB 40603: Randomized phase II 2x2 factorial trial of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC in hormone receptor-poor/HER2-negative resectable breast cancer
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):TPS110, 2010
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS110?sid=33bef702-6a74-44bd-8197-cbd2402ee9e7

49907

Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 26(May 20 Supplement):507, 2008
http://www.abstract.asco.org/AbstView_55_30857.html

7581, 8082, 8541, 9344

Older women with node positive breast cancer get similar benefits from adjuvant chemotherpav as younger patients: The Cancer and Leukemia Group B (CALGB) experience
Citation: Proceedings of the American Society of Clinical Oncology 22:11, 2003
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
Breast Committee

Study

Published Abstract

9342, 159806

Microarray profiling is feasible using archived tissue from a cooperative group clinical trial: Results from a pilot study in CALGB 9342


Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 23(16s):545, 2005

9342, 9840

Genome-wide profiling of archived material from CALGB 9840 and 9342 for paclitaxel (P) and trastuzumab (T) response biomarkers using gene expression and copy number analysis


Citation: San Antonio Breast Cancer Symposium:4032, 2009

9342, 9840

Pacilitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age


Citation: Cancer Research 69(2 Supplement):6112, 2009
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6112?sid=0453b8c6-44d7-461e-a91e-131eebca3dc02

9342, 9840

Understanding racial differences in outcome from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840


Citation: Proceedings of the 28th San Antonio Breast Cancer Symposium :3097, 2005

9343

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer

Hughes KS, Schnaper L, Cirrincione CT, Berry DA, McCormick B, Hudis CA, Winer EP

Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):507, 2010
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=50014

9343

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: A report of further follow-up


Citation: Breast Cancer Research and Treatment 10(1):11, 2006
http://www.springerlink.com/content/d113417955451w/fulltext.html

9343

Comparison of lumpectomy plus tamoxifen with and without irradiation in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER+) carcinoma of the breast


Citation: Proceedings of the American Society of Clinical Oncology 20:93, 2001
9344 HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Part I 24(18s):510, 2006
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010/vgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=31390

9344 Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control for node positive breast cancer in CALGB 9344
Sartor C, Fitzgerald TJ, Laurie F, Peterson BL, Woof SH, Henderson IC, Turrisi AT, Muss HB, Norton L
Citation: Proceedings of the American Society of Clinical Oncology 22:38, 2003

9344 Cost-effectiveness of the sequential addition of paclitaxel to doxorubicin plus cyclophosphamide in the adjuvant chemotherapy of patients with node positive breast cancer
Annemans L, Moermans K, Henderson IC, Berry DA, Martin C, Norton L
Citation: Proceedings of the American Society of Clinical Oncology 19:1752, 2000
http://pediatricsc.ca.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010/vgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=2&index=y&abstractID=201822

9344, 9730, 70101 Measuring clinically significant chemotherapy-related toxicities using Medicare claims from CALGB breast and lung cancer trial participants
Lamont EB, Herndon II JE, Weeks JC, Henderson IC, Lilienbaum RC, Schilsky RL, Christakis NA
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I (June 20 Supplement) 25(18s):6595, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=33992

9741 Five-year follow-up of Intergroup C9741: Dose-dense chemotherapy is safe and effective
Citation: Proceedings of the 28th San Antonio Breast Cancer Symposium :41, 2005

9741 Dose-dense (DD) AC followed by paclitaxel is associated with mild, frequent anemia compared to sequential (S) and/or less DD treatment: Update by CALGB on Breast Cancer Intergroup trial C9741 with ECOG, SWOG, and NCCTG
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 23(16s):620, 2005
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010/vgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=31387
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 9741  | Superiority of dose dense over conventionally scheduling and equivalence of sequential vs. combination adjuvant hemotherapy for node-positive breast cancer: CALGB 9741/Intergroup 9741  
Citation: Proceedings of the 25th San Antonio Breast Cancer Symposium :15, 2002 |
| 9740  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
| 9840  | Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840  
Citation: Cancer Research 69(2 Supplement):6046, 2009  
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6046?sid=7985d6c1-929f-4abd-aead-514f4e06ca4e |
Breast Committee

Study

Published Abstract

Comprehensive

Toxicity of older and younger patients treated with intensive adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B (CALGB) experience
Muss HB, Berry DA, Cirrincione CT, Budman DR, Henderson IC, Citron MA, Norton L, Winer EP, Hudis CA
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Part I 24(18S):559, 2006
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=30709

Comprehensive

An innovative expressive writing intervention for young breast cancer patients: Feasibility, preference, and psychosocial effects
Citation: Psycho-Oncology 16(S1-S110):PVII-16, 2007

Comprehensive

A web-based expressive writing intervention for young women with newly diagnosed breast cancer
Citation: Oncology Nursing Forum 34(1):88, 2007

http://ons.metapress.com/content/6m4573vk66l1433q/?p=d909384b95a24b178a8ca25c9f990afc&pi=21

Accepted Manuscript

150007

Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy for breast cancer
Citation: Journal of the American Medical Association, 2011

360701

Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840
Lichtman SM, Humia A, Cirrincione CT, Seidman AD, Winer EP, Hudis CA, Cohen HJ, Muss HB
Citation: Annals of Oncology, 2011
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comprehensive</td>
<td>39801</td>
</tr>
</tbody>
</table>
## Cancer and Leukemia Group B

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| Comprehensive   | Genetic associations with taxane-induced neuropathy by genome wide association study (GWAS) in E5103  
Schneider BP, Li L, Miller K, Flockhart DA, Radovich B, Hancock BA, Kessem N, Foroudi T, Koller D, Badve  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 2011 |
| Comprehensive   | Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant  
(adj) chemotherapy (chemo) with or without bevacizumab  (B) for completely resected early stage non-small  
cell lung cancer (NSCLC)  
Wakelee HA, Dahlberg SE, Gandara D, Graziano SL, Adjei A, Schiller JH  
Citation: ASCO:81235, 2011 |
Study Publication

Published Other

70305 Breast cancer-related lymphedema: Attention to a significant problem resulting from cancer diagnosis
Paskett ED
Citation: Journal of Clinical Oncology 26(35):5666-5667, 2008
http://jco.ascopubs.org/content/26/35/5666.long

Published Manuscript

309801 Determination of utility scores for control of chemotherapy-induced nausea or vomiting: CALGB 309801
Citation: Journal of Supportive Oncology 7(5):W17¿W22, 2009

70601 Differences in clinical trial patients attributes and outcomes according to enrollment setting
Citation: Journal of Clinical Oncology 28(2):215-221, 2009

79804 Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804
Oliver JM, Day JM, Alfano CM, Hemdon II JE, Katz ML, Biltoni MA, Donohue KA, Paskett ED
Citation: Journal of Cancer Survivorship 2(4):233-242, 2008
http://www.springerlink.com/content/147836321r0j404/
### Study Control and Health Outcomes Committee

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 79804 | Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804  
Alfano CM, Day JM, Katz ML, Herndon II JE, Bittoni MA, Oliveri JM, Donohue KA, Paskett ED  
Citation: Psycho-Oncology 18(2):128-133, 2008  
http://www3.interscience.wiley.com/cgi-bin/fulltext/119815598/PDFSTART |
| 79804 | Economic outcomes of breast cancer survivorship; CALGB 79804  
Hensley ML, Dowell JM, Herndon II JE, Winer EP, Stark NN, Weeks JC, Paskett ED  
Citation: Breast Cancer Research and Treatment 91(2):153-161, 2005  
http://www.springerlink.com/content/r330207n0235t987/ |
| 79809 | Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809  
Citation: European Journal of Cancer 47(5):683-689, 2011  
http://www.ejcancer.info/article/S0959-8049%2810%2901147-0/fulltext |
| 8541, 79804 | Health-related quality of life in long-term breast cancer survivors: Differences by adjuvant chemotherapy dose in CALGB study 8541  
Citation: Cancer 115(5):1109-1120, 2009  
http://www3.interscience.wiley.com/journal/121660437/abstract |
| 8541, 79804 | Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804  
Citation: Psycho-Oncology 17(11):1108-1120, 2008  
http://www3.interscience.wiley.com/cgi-bin/abstract/117925353/ABSTRACT |
| 89803 | Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803  
Citation: Journal of Clinical Oncology 24(22):3535-3541, 2006  
http://jco.ascopubs.org/cgi/content/full/24/22/3535 |
| 9066 | Quality of life among patients with stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy  
Citation: Cancer 104(5):1580-1589, 2005 |
| 9221 | Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study  
Citation: Journal of Clinical Oncology 20(10):2441-2452, 2002 |
### Cancer Control and Health Outcomes Committee

**Study** | **Publication**
--- | ---
9270 | **A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer**
Citation: New England Journal of Medicine 348(10):883-890, 2003
http://content.nejm.org/cgi/content/full/348/10/883

9344, 9730, 70101 | **Criterion validity of Medicare chemotherapy claims in breast and lung cancer patients**
Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilienbaum RC, Schilsky RL, Christakis NA
Citation: Journal of the National Cancer Institute 97(14):1080-1083, 2005
http://jnci.oxfordjournals.org/cgi/content/full/97/14/1080

9473 | **Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia**
Burns CP, Halabi S, Clamon GH, Kaplan EB, Hohl RJ, Atkins JN, Schwartz MA, Wagner BA, Paskett ED
Citation: Cancer 101(2):370-378, 2004
http://www3.interscience.wiley.com/cgi-bin/abstract/109076583/ABSTRACT?CRETRY=1&SRETRY=0

Comprehensive | **Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition**
Yee LD, Lester JL, Cole RM, Richardson JR, Hsu JC, Li Y, Lehman A, Belury MA, Clinton SK
Citation: The American Journal of Clinical Nutrition 91(5):1185-1194, 2010

Comprehensive | **Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study**
Citation: Cancer Epidemiology Biomarkers Prevention 18(5):1379-1385, 2009
http://cebp.aacrjournals.org/cgi/content/full/18/5/1379

Comprehensive | **Dietary intervention after definitive therapy for localized prostate cancer: Results from a pilot study**
Citation: The Canadian Journal of Urology 16(3):4648-4654, 2009
http://www.canjurol.com/result.php?version=2.0&keyword=&SrchOption=Article&SearchBox=dietary+intervention+after+definitive+therapy&SearchGo=Find

Comprehensive | **Breast cancer-related lymphedema: Attention to a significant problem resulting from cancer diagnosis**
Paskett ED
Citation: Journal of Clinical Oncology 26(35):5666-5667, 2008
http://jco.ascopubs.org/cgi/content/full/26/35/5666

Comprehensive | **Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants**
Lamont EB, Herndon JE, Weeks JC, Henderson C, Lilienbaum RC, Schilsky RL, Christakis NA
Citation: Medical Care 46(3):303-308, 2008
## Cancer Control and Health Outcomes Committee

<table>
<thead>
<tr>
<th>Study</th>
<th>Published Manuscript</th>
</tr>
</thead>
</table>
| Comprehensive | Survivorship resources for post-treatment cancer survivors  
Tesauro GM, Rowland JH, Lustig C  
Citation: Cancer Practice 10(6):277-283, 2002  
| Comprehensive | Behavioral activation treatment for depression: Returning to contextual roots  
Jacobson N, Martell CR, Dimidjian S  
Citation: Clinical Psychology: Science and Practice 8(3):255-270, 2001  
| Comprehensive | Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy  
Citation: Journal of Clinical Oncology 25(34):5374-5380, 2007  
http://jco.ascopubs.org/cgi/content/full/25/34/5374 |
| Comprehensive | Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks  
Citation: Journal of Clinical Oncology 25(32):5051-5057, 2007  
http://jco.ascopubs.org/cgi/content/full/25/32/5051 |
| Comprehensive | Dietary modification in patients with prostate cancer on active surveillance: A randomized, multicentre feasibility study  
Citation: BJU International 101(10):1227-1231, 2008  
http://www.blackwell-synergy.com/toc/bju/ |
| Comprehensive | Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.  
Shapiro CL, Manola J, Leboff M  
Citation: Journal of Clinical Oncology 19(14):3306-3311, 2001  
http://jco.ascopubs.org/cgi/content/full/19/14/3306 |
| Comprehensive | The men's eating and living (MEAL) study: A Cancer and Leukemia Group B pilot trial of dietary intervention for the treatment of prostate cancer  
Parsons JK, Newman V, Mohler JL, Paskett ED, Pierce JP, Marshall JR  
Citation: Urology 72(3):633-637, 2008  
http://bit.ly/btkKg8 |
| Comprehensive | Funding patient-reported outcomes in cancer clinical trials  
Moinpour CM, Denicoff AM, Watkins Bruner D, Kornblith AB, Land SR, O'Mara A, Trimble E  
Citation: Journal of Clinical Oncology 25(32):5100-5105, 2007  
http://jco.ascopubs.org/cgi/content/full/25/32/5100 |
| Comprehensive | Cancer and Leukemia Group B Cancer Control and Health Outcomes Committee: Origins and accomplishments  
Paskett ED, Schrag D, Kornblith AB, Lamont EB, Weeks JC, Marshall JR, Shapiro CL, Holland JC  
Citation: Clinical Cancer Research 12(11, Part 2):3601s-3605s, 2006  
http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3601s |
Cancer Control and Health Outcomes Committee

Published Book or Book Chapter

Comprehensive

Aging well: Surprising guideposts to a happier life from the landmark Harvard study of adult development
Vaillant GE

Citation: Vaillant, G. Aging well: Surprising guideposts to a happier life from the landmark Harvard study of adult development. 1st. , NY: Little, Brown and Company, 2002

Published Abstract

119901

Factors contributing to cancer screening in African Americans
Ferrans CE, Ryan C, Archer LE, Freels, Ph.D. S, Lan L, Paskett ED, Hurd DD, Molokie RE, Komblith AB

Citation: Journal of Clinical Oncology 26(5):6514, 2008
http://www.abstract.asco.org/AbstView_55_35926.html

60104

Adherence, persistence and toxicity with oral CMF in older women with early stage breast cancer in CALGB 49907 (adherence companion study 60104)

Citation: San Antonio Breast Cancer Symposium P5-10-12, 2010

70602

Differences in clinical trial patient attributes and outcomes according to trial enrollment setting: Analyses from 10 CALGB lung cancer trials
Lamont EB, Archer LE, Lan L, Vokes EE, McNeil BJ, Keating NL, Landrum M

Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 26(5):6517, 2008
http://www.abstract.asco.org/AbstView_55_33570.html

79804

Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804
Alfano CM, Dowell JM, Katz ML, Herndon II JE, Bittoni MA, Abbott JM, Paskett ED

Citation: Cancer Survivorship, 2006

79804

Arm and hand swelling among long-term breast cancer survivors: CALGB 79804
Paskett ED, Abbott JM, Katz ML, Dowell JM, Rosner G

Citation: Psycho-Oncology 15(S2):848, 2006
http://www3.interscience.wiley.com/journal/113374478/issue

79804

Arm swelling and psychological well-being among long-term breast cancer survivors
Abbott JM, Day J, Alfano CM, Rosner G, Katz ML, Bittoni ML, Paskett ED

Citation: American Public Health Association Annual Meeting 135:163789, 2007
http://apha.confex.com/apha/135am/techprogram/paper_163789.htm

79809

Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop arm swelling and psychological well-being among long-term breast cancer survivors

Citation: Journal of Clinical Oncology, ASCO Annual Proceedings 26(May 20 Supplement):512, 2008
http://www.abstract.asco.org/AbstView_55_31982.html

Published Abstract

70602

Differences in clinical trial patient attributes and outcomes according to trial enrollment setting: Analyses from 10 CALGB lung cancer trials
Lamont EB, Archer LE, Lan L, Vokes EE, McNeil BJ, Keating NL, Landrum M

Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 26(5):6517, 2008
http://www.abstract.asco.org/AbstView_55_33570.html
## CALGB Publications

**Published and Accepted Documents**

**01/01/2000 - 4/30/2011**

### Cancer Control and Health Outcomes Committee

<table>
<thead>
<tr>
<th>Study Number</th>
<th>Published Abstract</th>
</tr>
</thead>
</table>
| 9344, 9730, 70101 | Criterion validity of medicare chemotherapy claims in breast and lung cancer patients  
Lamont EB, Herndon II JE, Weeks JC, Henderson IC, Lilienbaum RC, Schilsky RL, Christakis NA  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I of II (June 1 Supplement)  
23(16s):6022, 2005  
| 9872 | Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women on adjuvant tamoxifen  
Garber JE, Halabi S, Kaplan EB, Edge SB, Dressler LG, Paskett ED, Berliner N  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I of II (June 1 Supplement)  
23(16s):508, 2005  
http://www.asco.org/portal/site/ASCO/menuitem.34d60f624ba07fd506f310ee37a01d/?vgnextoid=76f6201eb61a701050VC1M100000ed730ad12RCD&vmview=abst_detail_view&confID=34&abstractID=34276 |
| Comprehensive | The role of patient advocates in clinical trials: Perspectives from investigators and advocates in the Cancer and Leukemia Group B (CALGB)  
Katz ML, Archer LE, Peppercorn JM, Kereakoglow S, Collyar D, Burstein HJ, Schilsky RL, Partridge AH  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):6148, 2010  
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=50686 |
| Comprehensive | CALGB physician and nurse practices and attitudes regarding offering trial results to study participants  
Citation: Proceedings of the American Society of Clinical Oncology 22:2104, 2003  
http://www.asco.org/ASCOAbstracts+%26%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=100159 |

### Accepted Abstract

<table>
<thead>
<tr>
<th>Study Number</th>
<th>Published Abstract</th>
</tr>
</thead>
</table>
| 119901 | Quality of life of African-American cancer survivors  
Ferrans CE, Archer LE, Ryan C, Freels, Ph.D. S, Lan L, Paskett ED, Molokie RE, Reid T, Hurd DD, Kornblith AB  
Citation: 4th Biennial NCI Cancer Survivorship Research Conference, 2008 |
### Cancer in the Elderly Committee

#### Study

**Published Manuscript**

**119801**

- **Published Manuscript**
  - **Study**
  - **Publication**
    - Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: A Cancer and Leukemia Group B study
      - **Kornblith AB, Dowell JM, Hemdon II JE, Engelman B, Bauer-Wu SM, Small EJ, Morrison VA, Atkins JN, Cohen HJ, Holland JC**
      - **Citation:** Cancer 107(11):2706-2714, 2006
      - **http://www3.interscience.wiley.com/cgi-bin/fulltext/113446449/HTMLSTART**

**360001**

- **360001**
  - **Study**
  - **Publication**
    - Improving accrual of older persons to cancer treatment trials: a randomized trial of the Cancer and Leukemia Group B comparing an educational intervention with standard information
      - **Kimmick GG, Peterson BL, Kornblith AB, Mandelblatt J, Johnson JL, Wheeler JD, Heinze RV, Cohen HJ, Muss HB**
      - **Citation:** Journal of Clinical Oncology 23(10):2201-2207, 2005
      - **http://jco.ascopubs.org/cgi/content/full/23/10/2201**

**360401**

- **Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401**
  - **Citation:** Journal of Clinical Oncology 29(10):1290-1296, 2011
  - **http://jco.ascopubs.org.proxy.uchicago.edu/content/early/2011/02/22/JCO.2010.30.6985.full.pdf+html**

**360401**

- **Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401**
  - **Citation:** Journal of Clinical Oncology 29(10):1290-1296, 2011
  - **http://jco.ascopubs.org.proxy.uchicago.edu/content/early/2011/02/22/JCO.2010.30.6985.full.pdf+html**

**360401**

- **Developing a cancer-specific geriatric assessment: A feasibility study**
  - **Citation:** Cancer 104(9):1998-2005, 2005
  - **http://www3.interscience.wiley.com/cgi-bin/fulltext/112099387/HTMLSTART**

**369901**

- **Breast cancer adjuvant chemotherapy decisions in older women: The role of patient preference and interactions with physicians**
  - **Citation:** Journal of Clinical Oncology 28(19):3146-3153, 2010
  - **http://www3.interscience.wiley.com/cgi-bin/fulltext/113446449/HTMLSTART**

**49907**

- **Adjuvant chemotherapy in older women with early-stage breast cancer**
  - **Citation:** New England Journal of Medicine 360(20):2055-2065, 2009
  - **http://content.nejm.org/cgi/content/full/360/20/2055**
### Cancer in the Elderly Committee

**Study**

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>9670</td>
<td>Barriers to clinical trial participation of older women with breast cancer&lt;br&gt;<strong>Kemeny MM, Peterson BL, Muss HB, Kornblith AB, Wheeler JD, Cohen HJ, Levine E, Bartlett NL, Fleming G</strong>&lt;br&gt;Citation: Journal of Clinical Oncology 21(12):2268-2275, 2003&lt;br&gt;<a href="http://jco.ascopubs.org/cgi/content/full/21/12/2268">http://jco.ascopubs.org/cgi/content/full/21/12/2268</a></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>Lifestyle intervention development study to improve physical function in older adults with cancer: Outcomes from Project LEAD&lt;br&gt;<strong>Demark-Wahnefried W, Clipp EC, Morey MC, Pieper CF, Sloane R, Snyder DC, Cohen HJ</strong>&lt;br&gt;Citation: Journal of Clinical Oncology 24(21):3465-3473, 2006&lt;br&gt;<a href="http://jco.ascopubs.org/cgi/content/full/24/21/3465">http://jco.ascopubs.org/cgi/content/full/24/21/3465</a></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>The Cancer and Leukemia Group B Cancer in the Elderly Committee: Addressing a major cancer need&lt;br&gt;<strong>Cohen HJ, Muss HB</strong>&lt;br&gt;Citation: Clinical Cancer Research 12:(11, Part 2):3606s-3611s, 2006&lt;br&gt;<a href="http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3606s">http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3606s</a></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>Clinical research in the older cancer patient&lt;br&gt;<strong>Muss HB, Cohen HJ, Lichtman SM</strong>&lt;br&gt;Citation: Hematology Oncology Clinicians North America 14(1):283-291, 2000</td>
</tr>
</tbody>
</table>

**Published Abstract**

<table>
<thead>
<tr>
<th>Published Abstract</th>
<th>Citation</th>
</tr>
</thead>
<tbody>
<tr>
<td>119801</td>
<td>Telephone monitoring: Early identification of psychological, physical and social distress in advanced stage cancer patients 65 or more years old&lt;br&gt;<strong>Kornblith AB, Dowell JM, Hemdon II JE, Rosenberg S, Engelman B, Small EJ, Morrison VA, Atkins JN, Muss HB, Holland JC</strong>&lt;br&gt;Citation: Psycho-Oncology 15(S21-S22):VIII, 2006</td>
</tr>
<tr>
<td>360701</td>
<td>Paclitaxel in older women with breast cancer: Combined analysis of CALGB 9342 and 9840 with a focus on age&lt;br&gt;<strong>Lichtman SM, Humia A, Cirrincione CT, Seidman AD, Winer EP, Hudis CA, Cohen HJ, Muss HB</strong>&lt;br&gt;Citation: Cancer Research 69(2 Supplement):6112, 2009&lt;br&gt;<a href="http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6112">http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/69/2_MeetingAbstracts/6112</a></td>
</tr>
</tbody>
</table>
Cancer in the Elderly Committee

Study                  Publication
Published Abstract

369901  Patient preference as a determinant of breast cancer adjuvant chemotherapy use in older women: CALGB 369901
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 27(15s):9544, 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31902

9670  Barriers to participation of older women with breast cancer in clinical trials
Kemeny MM, Muss HB, Kornblith AB, Peterson B, Wheeler JD, Cohen HJ
Citation: Proceedings of the American Society for Clinical Oncology 19:602a-2371, 2000
CARE - Committee on Advocacy, Research Communication

Published Manuscript

Comprehensive

Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants


Citation: Journal of the National Cancer Institute 96(8):629-632, 2004

Comprehensive

Managing accrual in cooperative group clinical trials


Citation: Journal of Clinical Oncology 22(15):2997-3002, 2004

Published Article

Comprehensive

A survey of survivors

Stark NN

Citation: Applied Clinical Trials, 2007

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comprehensive</td>
<td>Cancer and Leukemia Group B Clinical Research Associates Committee</td>
</tr>
<tr>
<td></td>
<td>Price KC, Barrett BK, Roark JM</td>
</tr>
<tr>
<td>Citation:</td>
<td>Clinical Cancer Research 12;(11, Part 2):3642s-3644s, 2006</td>
</tr>
<tr>
<td></td>
<td><a href="http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3642s">http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3642s</a></td>
</tr>
</tbody>
</table>
80001  Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: Results of Cancer and Leukemia Group B trial 80001
Citation: Annals of Surgery 240(4):624-628, 2004

80003  A phase 2 trial of gemcitabine, 5-florouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003
Citation: Cancer 117(Epub), 2010

80303  Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: A phase III trial of the Cancer and Leukemia Group B
Kindler HL, Niedzwiecki D, Hollis DR, Sutherland SL, Hunwitz H, Innocenti F, Mulcahy M, O'Reilly EM, Schilsky RL, Goldberg RM
Citation: Journal of Clinical Oncology 28(22):3617-3622, 2010
http://jco.ascopubs.org/content/28/22/3617.long

80405  Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 trial: A phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma
Venook AP, Blanke C, Niedzwiecki D, Lenz H, Taylor JR, Hollis DR, Sutherland SL, Goldberg RM
Citation: Clinical Colorectal Cancer 6(7):536-538, 2007

80405  Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer
Venook AP, Blanke C, Goldberg RM, Reineke DK, Sutherland SL, Taylor JR, McAllister P, Schilsky RL
Citation: Community Oncology 3(9):593-598, 2006
http://www.communityoncology.net/journal/articles/0309593.pdf
### GI Committee

#### Study

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 80405 | Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: A phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma  
Venook AP, Blanke C, Niedzwiecki D, Lenz H, Taylor JR, Hollis DR, Sutherland SL, Goldberg RM  
Citation: Clinical Colorectal Cancer 5(4):292-294, 2005  
| 80603 | A Cancer and Leukemia Group B Phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603)  
Citation: The Oncologist 15(12):1310-1319, 2010  
http://theoncologist.alphamedpress.org/cgi/content/full/15/12/1310 |
| 8896, 89803, 89804 | Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials  
Citation: Journal of Clinical Oncology 23(34):8664-8670, 2005  
http://jco.ascopubs.org/cgi/content/full/23/34/8664 |
| 88986, 89804 | End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group  
Citation: Journal of Clinical Oncology 25(29):4569-4574, 2007  
http://jco.ascopubs.org/cgi/content/full/25/29/4569 |
| 89803 | Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery  
Citation: The Oncologist 15(4):390-404, 2010  
http://theoncologist.alphamedpress.org/cgi/content/full/15/4/390 |
| 89803 | Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer  
Citation: Journal of Clinical Oncology 28(28):4354-4363, 2010  
http://jco.ascopubs.org/cgi/content/full/28/28/4354 |
| 89803 | KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803  
Citation: Clinical Cancer Research 15(23):7322-7329, 2009  
http://clincancerres.aacrjournals.org/content/15/23/7322.full |
<table>
<thead>
<tr>
<th>Study</th>
<th>Published Manuscript</th>
</tr>
</thead>
<tbody>
<tr>
<td>89803</td>
<td>Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from Cancer and Leukemia Group B 89803&lt;br&gt;&lt;br&gt;Meyerhardt JA, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS&lt;br&gt;&lt;br&gt;Citation: Journal of Clinical Oncology 26(25):4109-4115, 2008&lt;br&gt;&lt;br&gt;<a href="http://jco.ascopubs.org/cgi/content/full/26/25/4109">http://jco.ascopubs.org/cgi/content/full/26/25/4109</a></td>
</tr>
<tr>
<td>89803</td>
<td>p27Kip1 in stage III colon cancer: Implications for outcome following adjuvant chemotherapy in Cancer and Leukemia Group B protocol 89803&lt;br&gt;&lt;br&gt;Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall MJ, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M&lt;br&gt;&lt;br&gt;Citation: Clinical Cancer Research 15:2116-2122, 2009&lt;br&gt;&lt;br&gt;<a href="http://clincancerres.aacrjournals.org/content/15/6/2116.long">http://clincancerres.aacrjournals.org/content/15/6/2116.long</a></td>
</tr>
<tr>
<td>89803</td>
<td>Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803&lt;br&gt;&lt;br&gt;Saltz LB, Niedzwiecki D, Hollis DR, Goldberg RM, Hantel A, Thomas J, Fields A, Mayer RJ&lt;br&gt;&lt;br&gt;Citation: Journal of Clinical Oncology 25(23):3456-3461, 2007&lt;br&gt;&lt;br&gt;<a href="http://jco.ascopubs.org/cgi/content/full/25/23/3456">http://jco.ascopubs.org/cgi/content/full/25/23/3456</a></td>
</tr>
</tbody>
</table>
Local excision of distal rectal cancer: An update of Cancer and Leukemia Group B 8984  
Greenberg JA, Shibata D, Herndon II JE, Steele GD, Mayer RJ, Bleday R  
Citation: Diseases of the Colon and Rectum 51(8):1185-1191, 2008  
http://www.springerlink.com/content/vh10485810007117/  

Phase III study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901  
Ryan DP, Niedzwiecki D, Hollis DR, Miedema BW, Wadler S, Tepper JE, Goldberg RM, Mayer RJ  
Citation: Journal of Clinical Oncology 24(16):2557-2562, 2006  
http://jco.ascopubs.org/cgi/content/full/24/16/2557  

A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: Cancer and Leukemia Group B study 89903  
Citation: Annals of Surgical Oncology 15(1):158-164, 2008  
http://www.springerlink.com/content/j8j561r455jj5204/  

A randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer (CALGB 89904)  
Citation: Journal of Clinical Oncology 27(33):5506-5512, 2009  
http://jco.ascopubs.org/cgi/content/full/27/33/5506  

Analysis of surgical salvage after failure of primary therapy in rectal cancer: Results from Intergroup Study 0114  
Tepper JE, O'Connell MJ, Hollis DR, Niedzwiecki D, Cooke EA, Mayer RJ  
Citation: Journal of Clinical Oncology 21(19):3623-3628, 2003  
http://jco.ascopubs.org/cgi/content/full/21/19/3623  

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis  
Citation: Journal of Clinical Oncology 22(10):1768-1796, 2004  
http://jco.ascopubs.org/cgi/content/full/22/10/1785  

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from intergroup trial 0114  
Citation: Journal of Clinical Oncology 22(4):648-657, 2004  
http://jco.ascopubs.org/cgi/content/full/22/4/648
Study: 9081
Published Manuscript

Adjuvant therapy in rectal cancer: Analysis of stage, sex and local control: Final report of intergroup 0114/CALGB 9081
Tepper JE, O’Connell M, Niedzwiecki D, Hollis DR, Benson AB, Cummings B, Gunderson LL, MacDonald JS, Martenson JA, Mayer RJ
Citation: Journal of Clinical Oncology 20(7):1744-1750, 2002
http://jco.ascopubs.org/cgi/content/abstract/20/7/1744

Impact of number of nodes retrieved on outcome in patients with rectal cancer
Tepper JE, O’Connell MJ, Niedzwiecki D, Hollis DR, Mayer RJ, Cummings B, Gunderson L, MacDonald JS
Citation: Journal of Clinical Oncology 19(1):157-163, 2001
http://jco.ascopubs.org/cgi/content/abstract/19/1/157?ijkey=fc4ef7e0327bd139f15074192d328686d5d85&keytype2=tf_ipsecsha

Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: Findings from the Intergroup 0114 study
Citation: Journal of Clinical Oncology 22(1):166-174, 2004
http://jco.ascopubs.org/cgi/content/full/22/1/166

Induction therapy for poor prognosis anal canal carcinoma: A phase II study of the Cancer and Leukemia Group B (CALGB 9281)
Citation: Journal of Clinical Oncology 26(19):3229-3234, 2008
http://jco.ascopubs.org/cgi/content/full/26/19/3229

An analysis of multiple staging management strategies for carcinoma of the esophagus: Computed tomography, endoscopic ultrasound, positron emission tomography and thoracoscopy/laparoscopy: CALGB 9380
Citation: Annals of Thoracic Surgery 74(4):1026-1032, 2002

A prospective trial of the feasibility of thoracoscopy/laparoscopy in staging for esophageal cancer: A phase II study
Krasna MJ, Reed CE, Niedzwiecki D, Hollis DR, Luketich JD, DeCamp M, Mayer RJ, Sugarbaker DJ
Citation: Annals of Thoracic Surgery 71(4):1073-1079, 2001

Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)
Citation: Journal of Clinical Oncology 24(9):1395-1403, 2006
http://jco.ascopubs.org/cgi/content/full/24/9/1395

A novel single nucleotide polymorphism within the 5’ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity
Citation: Cancer Research 63(11):2898-2904, 2003
http://cancerres.aacrjournals.org/cgi/content/full/63/11/2898
Study
Published Manuscript

9481
Thymidylate synthase gene polymorphism determines thymidylate synthase mRNA levels and outcome of metastatic colorectal carcinoma treated with 5-fluorouracil
Citation: Pharmacogenomics J 1(1):65-70, 2001

9683
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer
Meropol NJ, Niedzwiecki D, Hollis DR, Schilsky RL, Mayer RJ
Citation: Cancer 91(7):1256-1263, 2001

9781
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781
Tepper JE, Krasna MJ, Niedzwiecki D, Hollis DR, Reed CE, Goldberg RM, Kiel K, Willett C, Sugarbaker DJ, Mayer RJ
Citation: Journal of Clinical Oncology 26(7):1086-1092, 2008
http://jco.ascopubs.org/cgi/content/full/26/7/1086

9865
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer
Citation: Gastroenterology 132(1):127-138, 2007
http://linkinghub.elsevier.com/retrieve/pii/S0016-5085(06)02078-6

9865
Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers
Citation: International Journal of Cancer 112(5):754-759, 2004
http://www3.interscience.wiley.com/cgi-bin/abstract/109561112/ABSTRACT?CRETRY=1&SRETRY=0

9865
Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer
Arnold CN, Goel A, Compton CC, Marcus V, Niedzwiecki D, Dowell JM, Wasserman L, Inoue T, Mayer RJ, Bertagnolli MM, Boland CR
Citation: Cancer Biology & Therapy 3(1):73-78, 2004
http://www.landesbioscience.com/journals/cbt/abstract.php?id=590

9865
Characterization of sporadic colon cancer by patterns of genomic instability
Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton CC, Mayer RJ, Bertagnolli MM, Boland CR
Citation: Cancer Research 63(7):1608-1614, 2003
http://cancerres.aacrjournals.org/cgi/content/full/63/7/1608
GI Committee

Study
Published Manuscript

9865
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers
Goel A, Arnold CN, Niedzwiecki D, Carethers J, Dowell JM, Wasserman L, Compton CC, Mayer RJ, Bertagnolli MM, Boland CR
Citation: Cancer Research 64(9):3014-3021, 2004
http://cancerres.aacrjournals.org/cgi/content/full/64/9/3014

Comprehensive
A phase III trial assessing bevacizumab in stage II and III carcinoma of the colon: Results of NSABP Protocol C-08
Citation: Journal of Clinical Oncology 29(1):11-16, 2010
http://jco.ascopubs.org/content/29/1/11.long

Comprehensive
Cancer and Leukemia Group B Gastrointestinal Cancer Committee
Goldberg RM, Niedzwiecki D, Bertagnolli MM, Blackstock AW, Tepper JE, Mayer RJ
Citation: Clinical Cancer Research 12(11 Pt 2):3589-3595, 2006
http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3589s

Published Abstract

150105
Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+)
Heinrich MC, Shoemaker JS, Corless C, Hollis DR, Demetri GD, Bertagnolli MM, Fletcher JA
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 23(16s):7, 2005
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07f65068e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=26&abstractID=3594

80001
Sentinel node staging of resectable colon cancer: Results of a multicenter study
Citation: Meeting of the American Surgical Association: 122, 2004
http://www.annalsofsurgery.com/pt/re/annos/abstract.00153307-200401220-00024.htm?sessionid=LGNNpJNzJNbl1xXz2zDSByRtljQgnmcGhCyF2Yn6LypnhJQwhb5MtT774718804181956298091?index=1&database=ppvovft&results=1&count=10&searchid=3&nav=search

80001
Sentinel node staging of resectable colon cancer: Results of CALGB 80001
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22(14s):3506, 2004
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07f65068e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=26&abstractID=3594
**Study Committee**

**Study**

**Published Abstract**

80003

Preliminary analysis of Cancer and Leukemia Group B (CALGB) 80003: A phase II trial of gemcitabine, 5-fluorouracil (5FU), and radiation therapy (RT) in locally advanced non-metastatic pancreatic adenocarcinoma

Mamon H, Niedzwiecki D, Hollis DR, Tan BR, Smith J, Blackstock AW, Tepper JE, Goldberg RM, Mayer RJ, Fuchs CS

Citation: International Journal of Radiation Oncology, Biology, Physics 63(Supplement 1):S13, 2005
http://www.redjournal.org/article/S0360-3016(05)01195-8/abstract

80101

Postoperative adjuvant chemoradiation for gastric or gastroesophageal adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Interim toxicity results from Intergroup trial CALGB 80101


Citation: ASCO, Gastrointestinal Cancers Symposium :61, 2006
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=41&abstractID=294

80203

Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203

Meyerhardt JA, Jackson NA, Niedzwiecki D, Hollis DR, Venook AP, Mayer RJ, Goldberg RM

Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 27(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33181

80203

Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203

McLeod HL, Owzar K, Kroetz DL, Innocenti F, Das S, Friedman PN, Giacomini K, Goldberg RM, Venook AP, Ratain MJ

Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 26(20s):3513, 2008
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=31778

80203

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (mCRC); CALGB 80203 preliminary results

Venook AP, Niedzwiecki D, Hollis DR, Sutherland SL, Goldberg RM, Alberts S, Benson III AB, Wade J, Schilsky RL, Mayer RJ

Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 24(18s):3509, 2006
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=30649

80303

Heritable interleukin-17F (IL17F) gene variation is associated with overall survival (OS) in pancreatic cancer patients: Results from a genome-wide association study (GWAS) in CALGB 80303


Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 27(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34157
80303
A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study 80303
Schrag D, Archer LE, Wang X, Romanus D, Mulcahy M, Goldberg RM, Kindler HL
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 25(18s):4524, 2007
http://www.asco.org/ASCOAbstracts%26Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32547

80303
Does health-related quality of life (HRQL) improve for patients who respond to chemotherapy? Analysis of patients with advanced pancreas cancer (APC) receiving gemcitabine on Cancer and Leukemia Group B (CALGB) study 80303
Romanus D, Archer LE, Wang X, Goldberg RM, Mulcahy M, Kindler HL., Schrag D
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 25(18s):9008, 2007
http://www.asco.org/ASCOAbstracts%26Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32547

80303
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB)
Kindler HL, Niedzwiecki D, Hollis DR, Oraefo EA, Schrag D, Hurwitz HI, McLeod HL, Mulcahy M, Schilsky RL, Goldberg RM
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 25(18s):4508, 2007
http://www.asco.org/ASCOAbstracts%26Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32921

80402
LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin CALGB 80402
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 26(20s):4109, 2008
http://www.abstract.asco.org/AbstrView_55_35166.html

80403
CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer
Enzinger PC, Burtmeier B, Hollis DR, Niedzwiecki D, Ilson DH, Benson AB, Mayer RJ, Goldberg RM
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):4006, 2010
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4006?sid=4e81dd1e-c87c-44e8-ad77-cae5eb47403a

80405
Clinical trial participants' strategies for coping with prescription drug costs: A companion study to CALGB 80405
Schrag D, Naughton MJ, Kesselheim A, Archer LE, Niedzwiecki D, Romanus D, Goldberg RM, Venook AP
Citation: Journal of Clinical Oncology 27(15S), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34985
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603
O'Reilly EM, Gilman-Rosen LF, Niedzwiecki D, Hollis DR, Sutherland SL, Overcash FM, Goldberg RM
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 26(20s):4515, 2008
http://www.abstract.asco.org/AbstView_55_32729.html

Dietary and lifestyle determinants of colon cancer recurrence and survival
Fuchs CS, Meyerhardt JA, Ng K, Niedzwiecki D, Hollis DR, Ogino S, Chan AT, Wolpin BM, Bertagnolli MM,
Giovannucci E, Goldberg RM
Citation: NCI Translational Science Meeting:181, 2008
http://ncitranslates.nci.nih.gov/2008/Poster_Session.htm

KRAS mutation is not associated with recurrence or survival in 508 stage III colon cancers: Findings from
multicenter adjuvant trial CALGB 89803
Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Schaefer P, Whittem R,
Hantel A, Benson AB, Goldberg RM, Bertagnolli MM, Fuchs CS
Citation: Annual Meeting Association of Molecular Pathology STO2, 2009
http://www.amp.org/2009/list.htm

Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II / III
colon cancer: Findings from the ACCENT Database
Jackson NA, Meyerhardt JA, Green E, Yothers G, DeGramont A, Van Cutsem E, O'Connell M, Twelves C,
Saltz LB, Sargent DJ
Citation: Journal of Clinical Oncology 27(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34878

KRAS mutation, cancer recurrence and patient survival in stage III colon cancer: Findings from CALGB 89803
Fuchs CS, Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Bertagnolli MM
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 27(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34539

Use of two or three year disease free survival (DFS) is an appropriate Primary Endpoint in Stage III Adjuvant
Colon Cancer Trials with fluoropyrimidines with or without Oxaliplatin or Irinotecan: New data from 12,676
patients from MOSAIC, C-06, C-07, and C89803
Sargent DJ, Yothers G, Van Cutsem E, Saltz LB, Wolmark N, Bot B, Shi Q, Buyse M, de Gramont A
Citation: Journal of Clinical Oncology 27(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33401

Association between 3 year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved
survival after recurrence (rec) in patients receiving cytotoxic adjuvant therapy for colon cancer: Updated
findings from the 20,800 patient (pt) ACCENT dataset
Sargent DJ, de Gramont A
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 26(20s):4007, 2008
http://www.abstract.asco.org/AbstView_55_35362.html
GI Committee

Study Published Abstract

89803 Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: Lessons from the 20,800 patient ACCENT dataset
Sargent DJ
Citation: ASCO, Gastrointestinal Cancers Symposium :274, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=45&abstractID=10547

89803 Survival following recurrence in patients with adjuvant colon cancer: Findings from the 20,800 patient ACCENT dataset
O’Connell MJ
Citation: ASCO, Gastrointestinal Cancers Symposium :277, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=45&abstractID=10578

89803 Outcomes in white (W) patients (pts) and those of African (A) descent receiving adjuvant therapy for colon cancer (CC)
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 25(18s):4017, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=35013

89803 The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer; Findings from Intergroup trial CALGB 89803
Jackson NA, Fuchs CS, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Meyerhardt JA
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 26s:4039, 2008
http://www.abstract.asco.org/AbstView_55_33374.html

89803 Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 24(18s):10003, 2006
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=32665

89803 The impact of dietary patterns on cancer recurrence and survival in patients with stage III colon cancer:
Meyerhardt JA, Niedzwiecki D, Hollis DR, Saltz WB, Willett WC, Mayer RJ, Fuchs CS
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 25(18s):4019, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=31609

89803 Endpoints for colon adjuvant clinical trials: Recommendations based on individual patient data from 20898 patients and 18 randomized trials
Sargent DJ
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 23(16s):3512, 2005
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=34&abstractID=31738
Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
Blackstock AW, Tempero MA, Niedzwiecki D, Hollis DR, Mayer RJ, Tepper JE
Citation: International Journal of Radiation Oncology*Biology*Physics 51(3):31, 2001
http://www.sciencedirect.com/science/journal/03603016

Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
Blackstock AW, Tempero MA, Niedzwiecki D, Hollis DR, Mayer RJ, Tepper JE
Citation: Proceedings of the American Society of Clinical Oncology 20:627, 2001

Local excision of distal rectal cancer: An update of Cancer and Leukemia Group B 8984
Greenberg JA, Shibata D, Herron II JE, Steele GD, Mayer RJ, Bleday R
Citation: The American Society of Colon and Rectal Surgeons 50(5):S9, 2007
http://www.fascrs.org/annual_meeting/
A phase III study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901

Ryan DP, Niedzwiecki D, Miedema BW, Hollis DR, Wadler S, Tepper JE, Mayer RJ

Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14s):3580, 2004

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000e730ad1RCRD&vmview=abst_detail_view&confId=26&abstractId=1534

Phase II trial of 5-fluorouracil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy

Clark JW, Niedzwiecki D, Hollis DR, Mayer RJ

Citation: Proceedings of the American Society of Clinical Oncology 22:3584, 2003

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractId=102392

A phase II prospective, multi-institutional trial (CALGB 89903) of adjuvant active specific immunotherapy following curative resection of colorectal cancer (CRC) hepatic metastases

Posner MC, Niedzwiecki D, Venook AP, Hollis DR, Schlisky RL, Goldberg RM, Mayer RJ

Citation: Annals of Surgical Oncology 15(1):158-164, 2007

http://www.springerlink.com/content/j8j561r455jj5204/?p=7304239dc66744b9bd3b0b9e3f6b8b37&pi=0

A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904)

Kulke MH, Niedzwiecki D, Tempero MA, Hollis DR, Mayer RJ

Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14s):4011, 2004

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000e730ad1RCRD&vmview=abst_detail_view&confId=26&abstractId=2428

Impact of TN stage and treatment on survival and relapse in adjuvant rectal cancer pooled analysis


Citation: Proceedings of the American Society of Clinical Oncology 22:1008, 2003

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractId=102392

Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer: An analysis of Intergroup 0114

Meyers MO, Hollis DR, Mayer RJ, Benson III AB, Goldberg RM, Cummings B, Gunderson L, Martenson J, MacDonald JS, O’Connell MJ, Tepper JE

Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 25(18s):4006, 2007

http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confId=47&abstractId=34627
9081 Final report of INT 0114 adjuvant therapy in rectal cancer: Analysis by treatment, stage and gender
Tepper J, O'Connell M, Niedzwiecki D, Hollis D, Mayer RJ, Benson AB, Cummings B, Gunderson LL, 
MacDonald JS, Martenson JA
Citation: Proceedings for American Society of Clinical Oncology 20:489a, 2001 
http://pediatricca.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506f310ee37a01d/?vgnextoid=76 
f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=10&index=y&abstract 
ID=489

9081 Analysis of surgical salvage after failure of primary therapy in rectal cancer: Results from Intergroup 
0114/CALGB 9081
Tepper J, O'Connell M, Hollis D, Niedzwiecki D, Cooke E, Mayer RJ
Citation: Proceedings for the American Society of Clinical Oncology 21:507a, 2002 
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506f310ee37a01d/?vgnextoid=76f8201 
eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=16&abstractID=507

9281 Combined-modality therapy of poor prognosis anal canal carcinoma: A phase II study of the Cancer and 
Leukemia Group B (CALGB)
Meropol NJ, Niedzwiecki D, Shank BM, Colacchio T, Ellerton JA, Valone FH, Hollis DR, Budinger SC, Dowell 
JM, Mayer RJ
Citation: American Society of Clinical Oncology, ASCO., Gastrointestinal Cancers Symposium :238, 2005 
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506f310ee37a01d/?vgnextoid=76f8201 
eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=36&abstractID=10130

9380 The feasibility of thoracoscopy/laparoscopy in the staging of esophageal cancer: Results of a prospective 
multicenter phase II trial (CALGB 9380)
Krasna MJ, Reed CE, Hollis DR, Niedzwiecki D, Luketch J, DeCamp MM, Mayer RJ, Sugarbaker DJ
Citation: Proceedings of the American Society of Clinical Oncology 19:924, 2000

9481 Final analysis of hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from 
colorectal cancer: A CALGB randomized trial of efficacy, quality of life (QOL), cost effectiveness, and 
molecular markers
C, Mayer RJ
Citation: ASCO, Gastrointestinal Cancers Symposium :183, 2005 
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506f310ee37a01d/?vgnextoid=76f8201 
eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=36&abstractID=10086

9481 Hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer: 
A CALGB randomized trial of efficacy, quality of life (QOL), cost effectiveness, and molecular markers 
Citation: Proceedings of the American Society of Clinical Oncology 22:1010, 2003 
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID= 
23&abstractID=100496
Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781


Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 24(18s):4012, 2006
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=26&abstractID=2995

Trimodality therapy is superior to surgery alone in esophageal cancer: Results of CALGB 9781

Krasna MJ, Tepper JE, Niedzwiecki D, Hollis DR, Reed CE, Goldberg RM, Rich TA, Sugarbaker DJ, Mayer RJ

Citation: ASCO, Gastrointestinal Cancers Symposium :4, 2006
http://www.asco.org/ASCOv2/Meetings/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=35520

Evaluation of microsatellite instability, HMLH1 expression and HMLH1 promoter hypermethylation in defining the phenotype of colorectal cancer: A study from CALGB 9865

Arnold CN, Goel A, Compton CC, Marcus V, Niedzwiecki D, Wasserman L, Mayer RJ, Bertagnolli MM, Boland CR

Citation: Proceedings of Digestive Disease Week Gastroenterology 24(Supplement 4):100611, 2003
http://www.ddw.org/wmspage.cfm/?parm1=679#

RUNX3: A novel tumor suppressor gene frequently silenced by promoter hypermethylation in sporadic colon cancers: Results from CALGB 9865


Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 23(16s):3530, 2004
<table>
<thead>
<tr>
<th>Study</th>
<th>Published Abstract</th>
</tr>
</thead>
</table>
| 9865  | APC promoter hypermethylation contributes strongly to loss of APC expression in colorectal cancers with allelic loss on 5q  
Arnold CN, Goel A, Compton C, Niedzwicki D, Mayer RJ, Bertagnolli MM, Boland CR  
Citation: Gastroenterology 122(5A):S886, 2002  
http://www.gastrojournal.org/issues#2002 |
| 9865  | Promoter hypermethylation plays a principal role in colon carcinogenesis in chromosomally and microsatellite stable tumors  
Citation: Gastroenterology 122(5A):M906, 2002  
http://www.gastrojournal.org/issues#2002 |
| 9865  | Tumor suppressor genes are a target of promoter hypermethylation in MSI-H sporadic colorectal cancers: New insights into the mechanism of colon carcinogenesis  
Citation: Gastroenterology 122(5A):133, 2002  
http://www.gastrojournal.org/issues#2002 |
| 9865  | Frequent inactivation of PTEN by promoter methylation in the microsatellite-high (MSI-H) sporadic colorectal cancers  
Citation: Gastroenterology 122(5A):S899, 2002  
http://www.gastrojournal.org/issues#2002 |
| 9865  | A panel of mono and di nucleotide microsatellite markers is required for reliable determination of the MSI status in colorectal cancer  
Citation: Gastroenterology 120(5A):599, 2001  
http://www.gastrojournal.org/issues#2001 |
| 9865  | Somatic frameshift mutations in MBD4 (MED1) are not exclusively associated with microsatellite high (MSI-H) colorectal tumors  
Citation: Gastroenterology 120(5A):293, 2001  
http://www.gastrojournal.org/issues#2001 |
| 9865  | Chromosomal vs microsatellite instability in colorectal cancers: Evidence for previously unrecognized pathways  
Goel A, Arnold CN, Chang DK, Ricciardiello L, Chauhan DP, Carethers JM, Wasserman L, Bertagnolli MM, Boland CR  
Citation: Gastroenterology 120(5A):163, 2001  
http://www.gastrojournal.org/issues#2001 |
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accepted Manuscript</td>
<td>Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase III trial (CALGB 80303). Roberts A, Campa M, Gottlin E, Jiang C, Owzar K, Kindler HL, Venook AP, Goldberg RM, O'Reilly EM, Patz EF. Citation: Cancer, 2011</td>
</tr>
<tr>
<td>Accepted Manuscript</td>
<td>Impact of statin use on cancer recurrence and survival among patients with stage III colon cancer: Results from CALGB 89803. Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Holiss DR, Saltz LB, Mayer RJ, Benson III AB, Schaefer P, Whittem R, Hartel A, Goldberg MM, Bertagnolli MM, Venook AP, Fuchs CS. Citation: Journal of the National Cancer Institute, 2011</td>
</tr>
</tbody>
</table>
### GI Committee

#### Study

<table>
<thead>
<tr>
<th>Study</th>
<th>Acceptance Status</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 9581  | Accepted Manuscript | Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after randomization to adjuvant treatment with edrecolomab or observation (CALGB 9581)  
Citation: Journal of Clinical Oncology, 2011 |

#### Accepted Book or Book Chapter

| Comprehensive | Drug development in colorectal cancer: Viewpoint of the United States cooperative groups  
Grinblatt DL, Schilsky RL  
Citation: Grinblatt, D. Drug development in colorectal cancer: Viewpoint of the United States cooperative groups. 1st. Colorectal Cancer: A clinical guide to therapy; 615-622, 2001 |

#### Accepted Abstract

- **80101**  
Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 2011

- **80303**  
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 2011

- **80405, 89803**  
Comparison of dietary and lifestyle habits among Stage III and metastatic colorectal cancer patients  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 2011

- **89803**  
Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer  
Ng K, Meyerhardt JA, Chan JA, Niedzwiecki D, Hollis DR, Saltz LB, Mayer RJ, Benson AB, Bertagnolli MM, Goldberg RM, Fuchs CS  
Citation: Cancer, 2009

- **9581**  
Validation of a 12-gene colon cancer recurrence score (RS) in stage II colon cancer (CC) patients (pts) from CALGB 9581  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings:77737, 2011

- **9581**  
Validation of a 12-gene colon cancer recurrence score (RS) in stage II colon cancer (CC) patients (pts) from CALGB 9581  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings:77737, 2011
CALGB Publications
Published and Accepted Documents
01/01/2000 - 4/30/2011

GU Committee

Study

Published Manuscript

90003

CALGB 90003: Adaptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: An Intergroup phase II study
Citation: Biology of Blood and Marrow Transplantation 12(7):778-785, 2006

90004

A phase II study of estramustine, docetaxel and exisulind in patients with hormone-refractory prostate cancer (HRPC): Results of Cancer and Leukemia Group B (CALGB) 90004
Citation: Clinical Genitourinary Cancer 6(2):110-116, 2008

90006

A phase II study of estramustine, docetaxel, and bevacizumab in men with castrate resistant prostate cancer: Results of Cancer and Leukemia Group B (CALGB) 90006
Citation: Cancer 117(3):526-533, 2011

90008

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: A report of Cancer and Leukemia Group B protocol 90008
Stadler WM, Halabi S, Rini BI, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ
Citation: Cancer 107(6):1273-1279, 2006
http://www3.interscience.wiley.com/cgi-bin/abstract/112750734/ABSTRACT?CRETRY=1&SRETRY=0

90102

Cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: A phase II trial by Cancer and Leukemia Group B (CALGB 90102)
Philips GK, Halabi S, Sanford BL, Bajorin DF, Small EJ
Citation: BJU International 101(1):20-25, 2008

90206

Phase III trial of bevacizumab plus interferon alpha versus interferon alpha monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206
Citation: Journal of Clinical Oncology 28(13):2137-2143, 2010
http://jco.ascopubs.org/cgi/content/full/26/33/5422

90206

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
Citation: Journal of Clinical Oncology 28(33):5422-5428, 2008
http://jco.ascopubs.org/cgi/content/full/26/33/5422
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>90206</td>
<td>Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha Rini BI, Halabi S, Taylor JR, Small EJ, Schilsky RL Citation: Clinical Cancer Research 10(8):2584-2586, 2004 <a href="http://clincancerres.aacrjournals.org/cgi/content/full/10/8/2584">http://clincancerres.aacrjournals.org/cgi/content/full/10/8/2584</a></td>
</tr>
<tr>
<td>9181</td>
<td>Serum prostate specific antigen as a predictor of survival in patients treated with second-line hormonal therapy. CALGB 9181 Halabi S, Conaway MR, Small EJ, Vogelzang NJ, Dawson NA Citation: The Prostate Journal 3:18-25, 2001</td>
</tr>
<tr>
<td>9181, 9182, 9480, 9583, 9680, 9780</td>
<td>Importance of serum hemoglobin in hormone refractory prostate cancer Vollmer RT, Kantoff PW, Dawson NA, Vogelzang NA Citation: Clinical Cancer Research 8(4):1049-1053, 2002 <a href="http://clincancerres.aacrjournals.org/cgi/content/full/8/4/1049">http://clincancerres.aacrjournals.org/cgi/content/full/8/4/1049</a></td>
</tr>
<tr>
<td>9181, 9182</td>
<td>A prognostic model for predicting overall survival in men with hormone refractory metastatic prostate cancer Halabi S, Kantoff PW, Small EJ, Kattan MW, Kaplan EB, Dawson NA, Levine E, Blumenstein B, Vogelzang NJ Citation: Journal of Clinical Oncology 21(7):1232-1237, 2003 <a href="http://jco.ascopubs.org/cgi/content/full/21/7/1232">http://jco.ascopubs.org/cgi/content/full/21/7/1232</a></td>
</tr>
</tbody>
</table>
**GU Committee**

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 9480  | The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from CALGB 9480  
Shepard TF, Shepard TF, Kantoff PW, George DJ, Small EJ, Vogelzang NJ, Halabi S, Sanford BL  
Citation: Clinical Cancer Research 11(5):1815-1820, 2005  
http://clincancerres.aacrjournals.org/cgi/content/full/11/5/1815 |
| 9480  | Prognostic significance of plasma chromogranin A levels hormone-refractory prostate cancer patients treated on CALGB 9480  
Taplin ME, George DJ, Halabi S, Sanford BL, Febbo PG, Hennessey KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW  
Citation: Urology 66(2):386-391, 2005  
| 9480  | Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: Results of CALGB 9480/Intergroup 0159  
Citation: Journal of Clinical Oncology 20(16):3369-3375, 2002  
http://jco.ascopubs.org/cgi/content/full/20/16/3369 |
| 9480  | Prognostic significance of plasma vascular endothelial growth factor (VEGF) levels in patients with hormone-refractory prostate cancer: CALGB 9480  
George DJ, Halabi S, Shepard TF, Hayes DF, Vogelzang NJ, Small EJ  
Citation: Clinical Cancer Research 7(7):1932-1936, 2001  
http://clincancerres.aacrjournals.org/content/7/7/1932.long |
| 9480  | Prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) for prostate specific antigen (PSA) in men with hormone refractory prostate cancer (HRPC)  
Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ  
Citation: Journal of Clinical Oncology 19(12):3025-3028, 2001  
http://jco.ascopubs.org/cgi/content/full/19/12/3025 |
| 9480  | VEGF and bFGF urine levels as predictors of outcome in hormone refractory prostate cancer patients: A CALGB study  
Citation: Cancer Research 61:2533-2536, 2001  
http://cancerres.aacrjournals.org/cgi/content/full/61/6/2533 |
| 9480, 150005 | Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: Results from CALGB 150005/9480  
Humphrey PA, Halabi S, Picus J, Sanford BL, Vogelzang NJ, Small EJ, Kantoff PW  
Citation: Clinical Genitourinary Cancer 4(4):269-274, 2006 |
| 9583  | Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from Cancer and Leukemia B study 9583  
Ryan CJ, Ou S, Vogelzang NJ, Halabi S, Kantoff PW, Small EJ  
Citation: Clinical Cancer Research 13(7):2030-2037, 2007  
http://clincancerres.aacrjournals.org/cgi/content/full/13/7/2030 |

Page 48
GU Committee

Study

Published Manuscript

9583

A phase III trial of antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: Results of CALGB 9583
Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable PS, Torti FM, Kaplan EB, Vogelzang NJ
Citation: Journal of Clinical Oncology 22(6):1025-1033, 2004
http://jco.ascopubs.org/cgi/content/full/22/6/1025

9583

Prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) for prostate specific antigen (PSA) in metastatic prostate cancer: A nested study within CALGB 9583
Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW
Citation: Journal of Clinical Oncology 21(3):490-495, 2003
http://jco.ascopubs.org/cgi/content/full/21/3/490

9663

Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer - A Cancer and Leukemia Group B study
Citation: Clinical Cancer Research 11(22):8109-8113, 2005
http://clincancerres.aacrjournals.org/cgi/content/full/11/22/8109

9663

Androgen receptor mutations in androgen independent prostate cancer: Cancer and Leukemia Group B study 9663
Citation: Journal of Clinical Oncology 21(14):2673-2678, 2003
http://jco.ascopubs.org/cgi/content/full/21/14/2673

9680

Higher doses of mitoxantrone among men with hormone refractory prostate cancer: A Cancer and Leukemia Group B study
Levine E, Halabi S, Kaplan EB, Roberts JD, Rago R, Atkins JN, Vogelzang NJ
Citation: Cancer 94(3):665-672, 2002
http://www3.interscience.wiley.com/journal/90011426/abstract?CRETRY=1&SRETRY=0

9682

Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant hormonal therapy for higher-risk prostate cancer and recurrence in men managed using radiation therapy
D'Amico AV, Halabi S, Temppany C, Titelbaum D, Philipps GK, Loffredo MJ, McMahon EK, Sanford BL, Vogelzang NJ, Small EJ

9682, 159807

p53 protein expression status and recurrence in men treated with radiation and hormonal therapy for high-risk prostate cancer: A prospective phase II Cancer and Leukemia Group B study (CALGB 9682)
D'Amico AV, Halabi S, Vollmer RT, Loffredo MJ, McMahon EK, Sanford BL, Archer LE, Vogelzang NJ, Small EJ, Kantoff PW
Citation: Urology 71(5):933-937, 2008
A phase II study of docetaxel, estramustine, and low dose hydrocortisone in men with hormone refractory prostate cancer: CALGB 9780
Citation: Journal of Clinical Oncology 19(9):2509-2516, 2001
http://jco.ascopubs.org/cgi/content/full/19/9/2509

Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate risk prostate cancer: An initial report of CALGB 99809
Citation: International Journal of Radiation Oncology*Biology*Physics 72(3):814-819, 2008

Multi-center phase II study of neo-adjuvant paclitaxel, estramustine phosphate, and carboplatin (TEC) plus androgen deprivation prior to radiation therapy in patients with unfavorable-risk localized prostate cancer
Citation: Cancer 113(11):3137-3145, 2008
http://www3.interscience.wiley.com/journal/121501605/abstract?CRETRY=1&SRETRY=0

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of 7 prospective clinical trials
Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry DA, Urakami S, Kikuno N, Oh WK
Citation: The Annals of Oncology 21(2):312-318, 2010
http://annonc.oxfordjournals.org/content/21/2/312.long

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813
Oh WK, Halabi S, Kelly WK, Werner CP, Godley PA, Vogelzang NJ, Small EJ
Citation: Cancer 98:(12):2592-2598, 2003
http://www3.interscience.wiley.com/cgi-bin/abstract/106564002/ABSTRACT?CRETRY=1&SRETRY=0

9-nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901
Amin A, Halabi S, Gelmann EP, Stadler WM, Vogelzang NJ, Small EJ
Citation: Urologic Oncology 22:(5):398-403, 2004

Arsenic trioxide in recurrent urothelial cancer: A Cancer and Leukemia Group B phase II trial 99903
Bajorin DF, Halabi S, Small EJ
Citation: Clinical Genitourinary Cancer 7(3):E66-E70, 2009
http://cigjournals.metapress.com/content/n57628n121l15025/

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
Citation: Journal of Clinical Oncology 27(15):2450-2456, 2009
http://jco.ascopubs.org/content/27/15/2450.long
GU Committee

Study

Published Manuscript

Comprehensive

- Pain predicts overall survival in men with metastatic castrate refractory prostate cancer (CRPC)
  
  Halabi S, Vogelzang NJ, Kornblith AB, Ou S, Kantoff PW, Dawson NA, Small EJ
  
  Citation: Journal of Clinical Oncology 26(15):2544-2549, 2008
  
  http://jco.ascopubs.org/cgi/content/full/26/15/2544

Comprehensive

- Clinical outcomes by age in men with hormone refractory prostate cancer: A pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies
  
  Halabi S, Vogelzang NJ, Ou S, Kelly WK, Small EJ
  
  Citation: Journal of Urology 176(1):81-86, 2006
  
  http://www.jurology.com/article/S0022-5347%2806%2900566-0/abstract

Comprehensive

- Impact of race on survival in men with metastatic hormone-refractory prostate cancer
  
  Halabi S, Small EJ, Vogelzang NJ, Barrier R, George SL, Gilligan TD
  
  Citation: Urology 64(2):212-217, 2004
  
  http://bit.ly/bDCHhA

Comprehensive

- Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer
  
  Halabi S, Ou S, Vogelzang NJ, Small EJ
  
  Citation: Cancer 110(7):1478-1484, 2007
  
  http://www3.interscience.wiley.com/cgi-bin/fulltext/114298617/HTMLSTART

Comprehensive

- Activities and accomplishments of the Cancer and Leukemia Group B Genitourinary Committee
  
  Small EJ, Halabi S, Kantoff PW, D’Amico AV, Stadler WM, Kelly WK, Mohler JL, Bajorin DF, Vogelzang NJ
  
  Citation: Clinical Cancer Research 12:(11 Pt 2):3596s-3600s, 2006
  
  http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3596s

Comprehensive

- Overview of bladder cancer trials in the Cancer and Leukemia Group B
  
  Small EJ, Dalbagni G, Pruthi RS, Philips GK, Edelman MJ, Bajorin DF
  
  Citation: Cancer 97(8 Supplement):2090-2098, 2003
  
  http://www3.interscience.wiley.com/cgi-bin/fulltext/104086602/HTMLSTART

Comprehensive

- Hormone refractory prostate cancer: Current status and future directions within the Cancer and Leukemia Group B (CALGB)
  
  Vogelzang NJ
  
  Citation: Reviews in Urology Supplement:65-71, 2000

Published Abstract

90003

- CALGB 90003: Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: An intergroup phase II study
  
  Rini BI, Halabi S, Barrier R, Margolin K, Avigan D, Logan T, McCarthy PL, Small EJ, Linker C
  
  Citation: Blood 104(11):810, 2004
  
  http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/810?maxtoshow=10&HITS=10&hits=10&REQUEST=SEARCH&FULLTEXT=calgb+90003&searchid=1&FIRSTINDEX=0&volume=104&issue=11&resourcetype=HWCIT
Hypertension is associated with clinical outcome for patients (Pts) with metastatic renal cell carcinoma (mRCC) treated with interferon and bevacizumab on CALGB 90004

Dawson NA, Halabi S, Biggs DD, Ou S, Kelly WK, Small EJ
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 23(16S):4649, 2005
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=32271

The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: Initial results of CALGB 90006

Picus J, Halabi S, Rini BI, Vogelzang NJ, Whang YE, Kaplan EB, Kelly WK, Small EJ
Citation: Proceedings of the American Society of Clinical Oncology 22:1578, 2003
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=101428

A phase II study of bevacizumab and estramustine in prostate cancer (mRCC): A report of Cancer and Leukemia Group B 90008

Stadler WM, Halabi S, Ernstoff MS, Barrier R, Davila E, Picus J, Small EJ
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (July 15 Supplement) 22(14s):4515, 2004

Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Results of CALGB 90102

Philips GK, Halabi S, Sanford BL, Bajorin DF, Small EJ
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22(14s):4540, 2004
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=26&abstractID=824

Progression-free survival (PFS) is a statistically significant predictor of overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

Halabi S, Rini BI, Stadler WM, Archer LE, Small EJ
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):4525, 2010
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/4525?sid=15de560d-aa8f-4d87-9a7a-bd52136cf9a7

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206

Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 27(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30922
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 90206 | CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma  
*Rini BI, Halabi S, Rosenberg JE, Stadler WM, Picus J, Atkins JN, Ou S, Tanguay J, Dutcher J, Small EJ*  
*Citation: ASCO, Genitourinary Cancers Symposium :350, 2008*  
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?vmview=abst_detail_view&confID=54&abstractID=20357 |
| 90401 | A randomized double-blind placebo controlled phase III trial comparing docetaxel, prednisone and placebo with docetaxel prednisone and bevacizumab in men with metastatic castrate resistant prostate cancer (mCRPC): Survival results of CALGB 90401  
*Kelly WK, Halabi S, George DJ, Stadler WM, Kantoff PW, Morris MJ, Monk PJ, Leung EH, Small EJ*  
*Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):4511, 2010*  
http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA4511?sid=fbb8286e-a6cc-41e5-904b-d3b36d6c9ee7 |
| 9181, 9182, 9480, 9583 | A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials  
*D'Amico AV, Halabi S, Vogelzang NJ, Small EJ*  
*Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22(14s):4506, 2004*  
| 9181, 9182, 9480, 9583 | African-American race is associated with longer survival in patients with metastatic hormone-refractory prostate cancer (HRCaP) in four randomized phase III Cancer and Leukemia Group B trials 9181, 9182, 9583, 9480  
*Gilligan T, Halabi S, Dawson NA, Kaplan EB, Vogelzang NJ, Small EJ*  
*Citation: Proceedings of the American Society of Clinical Oncology 21:725, 2002*  
| 9181, 9182, 9480, 9583, 9680, 9780, 90004, 90006, 99813 | Is progression free survival a predictor of overall survival in men with castration recurrent prostate cancer (CRPC)?  
*Halabi S, Ou S, Vogelzang NJ, Small EJ*  
*Citation: American Society of Clinical Oncology, Genitourinary Cancers Symposium :150, 2008*  
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?vmview=abst_detail_view&confID=54&abstractID=20388 |
| 9480 | Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480  
*Taplin ME, George DJ, Halabi S, Sellers WR, Sanford BL, Hennessy KT, Mihos CG, Small EJ, Kantoff PW*  
*Citation: Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting Proceedings 22(14s):4557, 2004*  
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba070f506e310ee37a01d/?vgnextoid=7f8f201eb61a70f10/VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=26&abstractID=1035 |
<table>
<thead>
<tr>
<th>Study</th>
<th>Published Abstract</th>
</tr>
</thead>
</table>
| 9480  | Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782  
Picus J, Halabi S, Small EJ, Hussain A, Philips GK, Vogelzang NJ, Kaplan EB  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22(14s):4559, 2004  
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=2693 |
| 9480  | Results of CALGB 9480, a phase III trial of 3 different doses of suramin for the treatment of hormone refractory prostate cancer (HRPC).  
Citation: Proceedings of the American Society of Clinical Oncology 19:328a-1291, 2000  
| 9480  | VEGF and basic FGF urine levels as predictors of response to therapy with Suramin in CALGB 9480, a Phase III study of Hormone Refractory Prostate Cancer (HRPC) patients  
Citation: Proceedings for the American Society of Clinical Oncology 19:347a-1367, 2000  
| 9480  | RT-PCR for prostate specific antigen (PSA) in peripheral blood (PB) predicts survival duration in patients with hormone refractory prostate cancer (HRPC): A CALGB study  
Kantoff PW, Halabi S, Farmer D, Hayes DF, Vogelzang NJ, Small EJ  
Citation: Proceedings of the American Society of Clinical Oncology 19:336a-1323, 2000  
| 9480, 150005 | Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480  
Humphrey PA, Halabi S, Picus J, Vogelzang NJ, Small EJ, Kantoff PW  
Citation: Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting Proceedings 22(14s):9613, 2004  
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=2380 |
| 9583  | Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: Results from CALGB 9583  
Ryan CJ, Halabi S, Hussain A, Philips GK, Kaplan EB, Vogelzang NJ  
Citation: Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting Proceedings 22(14s):4558, 2004  
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=26&abstractID=919 |
| 9583  | A prospective randomized study of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients  
Small EJ, Halabi S, Picus J, Cen YY, Vogelzang NJ  
Citation: Proceeding of the American Society of Clinical Oncology 20:695, 2001 |
| 9583  | Reverse transcriptase polymerase chain reaction (RT-PCR) for prostate specific antigen (PSA) as a prognostic factor for survival among androgen independent prostate cancer patients (AiCaP)  
Halabi S, Small EJ, Farmer D, Paradis A, Cen YY, Hayes DF, Vogelzang NJ, Kantoff PW  
Citation: Proceedings of the American Society of Clinical Oncology 20:700, 2001 |
GU Committee
Study
Published Abstract
9583
Prospective assessment of adrenal androgen levels as predictors of survival in androgen independent prostate cancer patients treated with ketoconazole
Vogelzang NJ, Halabi S, Picus J, Gable P, Hayes DF, Kantoff PW, Small EJ
Citation: Proceedings of the American Society for Clinical Oncology 20:749, 2001
http://66.102.1.104/scholar?hl=en&lr=&q=cache:ASdeKpdSp6EJ:www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07df506fe310ee37a01d%3FabstractID%3D749%26confID%3D10%26index%3DY%26vmview=%3Dabst_detail_view+

9663
Androgen receptor mutations in androgen independent prostate cancer (AIPCA) do not correlate with anti-androgen withdrawal response: Cancer and Leukemia Group B (CALGB) 9663
Taplin ME, Halabi S, Rajeshkumar B, McQuain C, Woda BA, Picus J, Hayes DF, Vogelzang NJ, Small EJ
Citation: Proceedings for American Society of Clinical Oncology 20:1738a, 2001
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07df506fe310ee37a01d/?abstractID=1738&confID=10&index=y&vmview=abst_detail_view

9663
Androgen receptor analyses in androgen independent prostate cancer (AIPCA): Cancer and Leukemia Group B (CALGB) 9663
Citation: Proceedings for American Society of Clinical Oncology 19:330a-1297, 2000

9682, 159807
p53 protein expression status and recurrence in men treated with radiation therapy and androgen suppression therapy for higher risk prostate cancer: A prospective phase II Cancer and Leukemia Group B study
D’Amico AV, Vollmer RT, Halabi S, Loeffredo MJ, McMahon EK, Sanford BL, Archer LE, Vogelzang NJ, Small EJ, Kantoff PW
Citation: International Journal of Radiation Oncology*Biology*Physics 69(3, S333):2234, 2007
http://www.redjournal.org/article/PIS036031607026879/fulltext

9687
Management of recurrent prostate cancer after radiotherapy: Preliminary results of CALGB 9687, a contemporary salvage prostatectomy series
Citation: ASCO, Prostate Symposium :166, 2005
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=37&abstractID=20340

9782
Efficacy of peripheral androgen blockade on prostate cancer: Initial results of CALGB 9782
Picus J, Halabi S, Dawson NA, Small EJ
Citation: Proceedings of the American Society of Clinical Oncology 21:727, 2002

99811
Five-year follow-up of a multicenter phase II study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin (TEC) plus androgen-deprivation therapy (ADT) prior to radiation therapy in patients with unfavorable-risk localized prostate cancer: CALGB 99811
Kelly WK, Halabi S, Archer LE, Bogart JA, Zelefsky MJ, Small EJ
Citation: ASCO, GU Cancers Symposium:123, 2010
A phase II study of estramustine, docetaxel, carboplatin (EDC) with G-CSF support in men with hormone refractory prostate cancer: CALGB 99813

Oh WK, Halabi S, Kelly WK, Godley PA, Werner C, Vogelzang NJ, Small EJ

Citation: Proceedings of the American Society for Clinical Oncology 21:779, 2002

A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC)

Halabi S, Ou S, Vogelzang NJ, Scher HI, Small EJ

Citation: Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting Proceedings 25(18s):5113, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=33766

The effect of race on progression-free survival in patients with metastatic hormone-refractory prostate cancer (HRPC): A pooled analysis of CALGB studies

Halabi S, Small EJ, Gilligan T, George SL, Barrier R, Vogelzang NJ

Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 23(16s):4622, 2005
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=34&abstractID=33533

A model for predicting progression free survival in men with hormone refractory prostate cancer: An analysis of CALGB studies

Halabi S, Kattan MW, Small EJ, Kantoff PW, Dawson NA, Levine E, Oh WK, Kaplan EB, Vogelzang NJ

Citation: Proceedings of the American Society of Clinical Oncology 22:1597, 2003
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=101827

A model for predicting survival probability in men with hormone refractory prostate cancer (HRCaP): An analysis of CALGB studies

Halabi S, Dawson NA, Levine EG, Small EJ, Vogelzang NJ

Citation: Proceedings of the American Society for Clinical Oncology 21:2480, 2002
http://bit.ly/bMWg1O

Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: Long-term results of CALGB 99809

Hurwitz MD, Halabi S, Archer LE, McGinnis LS, Kueettel MR, DiBiase S, Small EJ

Citation: Cancer, 2011
Tumor and germline markers for gemcitabine sensitivity in pancreatic cancer
Leukemia Committee

Published Other

20502
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: Final analysis of CALGB study 10101
Citation: Journal of Clinical Oncology 28(29):4500-4506, 2010
http://jco.ascopubs.org/content/28/29/4500.long

Published Manuscript

10101
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: Final analysis of CALGB study 10101
Citation: Journal of Clinical Oncology 28(29):4500-4506, 2010
http://jco.ascopubs.org/content/28/29/4500.long

10107
Feasibility of administering oblimersen (G3139; genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia: Cancer and Leukemia Group B Study 10107
Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westervelt P, Larson RA
Citation: Leukemia and Lymphoma 49(7):1274-1278, 2008
http://www.informaworld.com/smpp/content?content=10.1080/10428190802043887

19801
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
Citation: Blood 109(12):5136-5142, 2007
http://bloodjournal.hematologylibrary.org/cgi/content/full/bloodjournal;109/12/5136?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&author1=DeAngelo%2C+DJ&title=Nelarabine&andorexacttitle=and&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=1/1/2007&tdate=11/30/2007&resourcetype=HWCIT

19803
Treatment of myelodysplastic syndrome with two schedules and doses of oral topotecan: A randomized phase II trial by the Cancer and Leukemia Group B
Citation: Cancer 115(1):84-93, 2009
http://www3.interscience.wiley.com/journal/121520052/abstract?CRETRY=1&SRETRY=0

19804
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804
Stone RM, Donohue KA, Stock W, Hars V, Linker C, Shea TC, DeAngelo DJ, Marcucci G, Bloomfield CD, Larson RA
Citation: Cancer Chemotherapy and Pharmacology 63(5):859-864, 2009
http://www.springerlink.com/content/028463h047213vu5/

19805
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: Results from Cancer and Leukemia Group B study 19805
Citation: Clinical Cancer Research 11(11):4176-4181, 2005
http://clincancerres.aacrjournals.org/cgi/content/full/11/11/4176
Leukemia Committee

Study
Published Manuscript

19901

Fludarabine followed by alemtuzumab consolidation for symptomatic, previously untreated chronic lymphocytic leukemia: Final report of CALGB study 19901
Citation: Leukemia and Lymphoma 50(10):1589-1596, 2009
http://www.informaworld.com/smpp/titinterface~content=a916245062~fulltext=713240928

19902

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B Study 19902
Citation: Leukemia Research 35(3):329-333, 2011
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B679F-50PB9MJ-3&_user=108&_coverDate=08%2F04%2F2010&_rdoc=1&_fmt=high&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&md5=5ef316d94b8abaa94b983a2d265ac9d

8461, 8811, 9111, 9311, 9511, 19802

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B study
Citation: Journal of Clinical Oncology 26(31):5078-5087, 2008
http://jco.ascopubs.org/cgi/content/full/26/31/5078

8461, 9621, 9665, 19808, 20502

Fludarabine followed by alemtuzumab consolidation for symptomatic, previously untreated chronic lymphocytic leukemia: Final report of CALGB study 19901
Citation: Leukemia and Lymphoma 50(10):1589-1596, 2009
http://www.informaworld.com/smpp/titinterface~content=a916245062~fulltext=713240928

8461, 9720, 9760

Low-dose interferon-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B study 9720
Citation: Journal of Clinical Oncology 26(25):4934-4939, 2008
http://jco.ascopubs.org/cgi/reprint/JCO.2008.17.0472v1

8661

Is family history of breast cancer a marker of susceptibility to exposures in the incidence of de novo adult acute leukemia?
Rauscher GH, Sandler DP, Poole C, Pankow J, Shore D, Bloomfield CD, Olshan AF
Citation: Cancer Epidemiology, Biomarkers & Prevention 12(4):289-294, 2003
http://cebp.aacrjournals.org/cgi/content/full/12/4/289
### Study: 8923

**Post-remission therapy in older patients with de novo acute myeloid leukemia (AML): A randomized trial of mitoxantrone/ intermediate dose cytarabine versus standard dose cytarabine (CALGB study 8923)**

**Citation:** Blood 98:548-553, 2001

http://bloodjournal.hematologylibrary.org/cgi/content/full/98/3/548

### Study: 9011

**Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011**


**Citation:** Journal of Clinical Oncology 20(18):3878-3884, 2002

http://jco.ascopubs.org/cgi/content/full/20/18/3878

### Study: 9011

**Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: An intergroup study (CALGB 9011)**

**Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Hines JD, Shepherd L, Martell RE, Larson RA, Schiffer CA**

**Citation:** Journal of Clinical Oncology 19(16):3611-3621, 2001

http://jco.ascopubs.org/cgi/content/full/19/16/3611

### Study: 9011

**Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: A CALGB (9011) coordinated intergroup study**

**Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Elias L, Shepherd LE, Hines JD, Larson RA, Schiffer CA, Hurwitz HI, Morrison VA**

**Citation:** Cancer Chemotherapy and Pharmacology 50(1):37-45, 2002

http://www.springerlink.com/content/2lk1ff5lfceuaglx/

### Study: 9011

**Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia**


**Citation:** New England Journal of Medicine 343:1750-1757, 2000

http://content.nejm.org/cgi/content/abstract/343/24/1750?maxtoshow=&HITS=10&hits=10&RESULTFORMA T=&searchid=1005342708558_20099&stored_search=&FIRSTINDEX=0&volume=343&firstpage=1750&jour nalcode=nejm

### Study: 9011, 9712

**Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011**


**Citation:** Blood 105(1):49-53, 2005

http://bloodjournal.hematologylibrary.org/cgi/content/full/105/1/49

### Study: 9013

**Risk factors for severe neuropsychiatric toxicity in patients receiving Interferon-alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: Analysis of Cancer and Leukemia Group B 9013**

**Hensley ML, Silver RT, Peterson BL, Larson RA, Szatrowski TP**

**Citation:** Journal of Clinical Oncology 18(6):1301-1308, 2000

http://jco.ascopubs.org/cgi/content/full/18/6/1301
### Leukemia Committee

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 9211  | A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: Results from CALGB study 9211  
Byrd JC, Peterson BL, Piro LD, Saven A, Vardiman JW, Larson RA, Schiffer CA  
Citation: Leukemia 17:323-327, 2003  
http://www.nature.com/leu/journal/v17/n2/abs/2402752a.html;jsessionid=4E5EC8C516437173CC1B3DF1CA94FE |
| 9221  | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B (9221)  
Citation: Journal of Clinical Oncology 20(10):2429-2440, 2002  
http://jco.ascopubs.org/cgi/content/full/20/10/2429 |
| 9420  | Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420  
Citation: Clinical Cancer Research 8(9):2812-2819, 2002  
http://clincancerres.aacrjournals.org/cgi/content/full/8/9/2812 |
| 9420, 9621, 9720, 9760 | Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?  
Larson RA  
Citation: Leukemia 17(3):488-491, 2003  
http://www.nature.com/leu/journal/v17/n3/abs/2402809a.html |
| 9620  | Autologous stem cell transplantation for acute myeloid leukemia in second remission: CALGB Study 9620  
Linker C, Ozwar K, Hurd DD, Powell BL, Damon L, Archer LE, Larson RA  
Citation: Bone Marrow Transplantation 44:353-359, 2009  
http://www.nature.com/bmt/journal/v44/n6/full/bmt200936a.html |
| 9621  | Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study  
Citation: Cancer Research 61(10):7233-7239, 2001  
http://cancerres.aacrjournals.org/cgi/content/full/61/19/7233 |
| 9621  | Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: A Cancer and Leukemia Group B study  
Citation: Journal of Clinical Oncology 19(9):2482-2492, 2001  
http://jco.ascopubs.org/cgi/content/full/19/9/2482 |
Leukemia Committee

Study
Published Manuscript

9710

Asaricin trioxide improves event-free and overall survival among adults with newly diagnosed acute promyelocytic leukemia: North American leukemia intergroup protocol C9710
Citation: Blood 116(19):3751-3757, 2010
http://bloodjournal.hematologylibrary.org/cgi/content/abstract/116/19/3751?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=Asaricin+trioxide+improves+event-free+and+overall+survival+among+adults+with+newly+diagnosed+acute+promyelocytic+leukemia%3A+North+American+leukemia+intergroup+protocol+C9710

9712

Chemothermunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: Long-term follow up of CALGB study 9712
Citation: Journal of Clinical Oncology 1(29):1349-55, 2011
http://jco.ascopubs.org.proxy.uchicago.edu/content/29/10/1349.full?sid=a0274905-7990-444e-b99e-9e11962ef9ea

9720

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720
Baer MR, George SL, Sanford BL, Mrozek KA, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, Larson RA
Citation: Leukemia(Epub), 2011
http://www.nature.com.proxy.uchicago.edu/leu/journal/vaop/ncurrent/full/leu20119a.html

9720

Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials
Citation: Journal of the National Cancer Institute 101(4):256-266, 2009
http://tinyurl.com/36tnrg8x

9720

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720
Citation: Blood 100(4):1224-1232, 2002
http://bloodjournal.hematologylibrary.org/cgi/content/full/100/4/1224

Comprehensive

FLT3-mutated acute myeloid leukemia-chemotherapy, kinase inhibitors and transplantation
Larson RA
Citation: Korean Journal of Hematology 45(Supp 1):17-19, 2010
Leukemia Committee

Study Publication

Published Manuscript

Comprehensive

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm
Walter RB, Appelbaum FR, Tallman MS, Weiss NS, Larson RA, Estey EH
Citation: Blood 116(14):2420-2428, 2010
http://bloodjournal.hematologylibrary.org/cgi/content/full/116/14/2420

Comprehensive

MicroRNAs and copy number changes: New levels of gene regulation in acute myeloid leukemia
Larson RA
Citation: Chemico-Biological Interactions: A Journal of Molecular, Cellular, and Biochemical Toxicology 184(1-2):21-5, 2010

Comprehensive

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes
Citation: Blood 114(5):937-951, 2009
http://bloodjournal.hematologylibrary.org/cgi/content/full/114/5/937?maxtoshow=&HITS=10&hits=10&RESULTSFORMAT=&fulltext=vardiman&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Comprehensive

Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
Citation: Journal of Clinical Oncology 21(24):4642-4649, 2003
http://jco.ascopubs.org/cgi/content/full/21/24/4642

Comprehensive

Clinical significance of multidrug resistance in AML: Current insights
Baer MR
Citation: Clinical Advances in Hematology and Oncology 3(12):910-912, 2005

Comprehensive

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification?
Mrozek KA, Marcucci G, Paschka P, Whitman SP, Bloomfield CD
Citation: Blood 109(2):431-448, 2007
http://bloodjournal.hematologylibrary.org/cgi/content/full/109/2/431

Comprehensive

Management of acute lymphoblastic leukemia in older patients
Larson RA
Citation: Seminars in Hematology 43(2):126-133, 2006
http://www.seminhematol.org/article/S0037-1963%2806%2900024-2/abstract

Comprehensive

Endpoints to establish the efficacy of new agents in the treatment of acute leukemia
Citation: Blood 109(5):1810-1816, 2007
http://bloodjournal.hematologylibrary.org/cgi/content/full/109/5/1810

Page 63
Leukemia Committee

Study

Published Manuscript

Comprehensive

Fifty years of clinical research by the Leukemia Committee of the Cancer and Leukemia Group B
Larson RA, Stone RM, Mayer RJ, Schiffer CA
Citation: Clinical Cancer Research 12(11 Pt 2):3556-3563, 2006
http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3556s

Comprehensive

Practice guidelines for diseases caused by aspergillus
Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey GA
Citation: Clinical Infectious Diseases 30:696-709, 2000

Comprehensive

The use of monoclonal antibodies against primary myeloid granules in normal and leukemic cells
Elghetany MT, Sullivan AK, Kurec AS, MacCallum JM, Bloomfield CD, Sobol RE, Davey FR
Citation: American Journal of Clinical Pathology 98(4):430-436, 1992

Published Book or Book Chapter

Comprehensive

Results of recent clinical trials in acute lymphoblastic leukemia by the Cancer and Leukemia Group B
Larson RA, Yu D, Sanford BL, Stock W
Citation: Faderl, S. Book Chapter in: Hematologic Malignancies: Acute Leukemias. 1. Heidelberg, Germany Springer, 137-134, 2007

Published Article

10201

G3139, a BCL-2 antisense oligo-nucleotide, in AML
Citation: Annals of Hematology 83(Supplement 1):S93-S94, 2004
http://www.springerlink.com/content/3neqv7netev3xp1/

9710

Arsenic trioxide consolidation improves event-free and overall survival among patients with newly diagnosed acute promyelocytic leukemia: North American Intergroup protocol C9710
Citation: Annals of Hematology 87(Supplement 1):S77-S78, 2008
http://www.springerlink.com/content/jf68u63275v24/?p=54483361d7324e4da368611202fb3259&pi=5

9720

Cancer and Leukemia Group B studies of recombinant Interleukin-2 maintenance therapy in acute myeloid leukemia
Baer MR, Kolitz JE, George SL, Caligiuri MA, Larson RA
Citation: Annals of Hematology 87(Supplement 1):S28-S29, 2008
http://www.springerlink.com/content/jf68u63275v24/?p=54483361d7324e4da368611202fb3259&pi=5
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comprehensive</td>
<td>What determines the outcome for adolescents and young adults with acute lymphoblastic leukemia? Larson RA Citation: American Journal of Hematology and Oncology 6(4 (Supplement 5)):S17-S19, 2007 <a href="http://ajho.epubxpress.com/wps/portal/ajho/c1/04_SB8K8xMM9MSSzPy8xBz9CP00s3iLkCAPEzcpMwMLA1M3A6MV0e3YDMnA4NpM_2CbEdFAgebKU/w7_B7TH4FH20O04F02J05TLH000G4">http://ajho.epubxpress.com/wps/portal/ajho/c1/04_SB8K8xMM9MSSzPy8xBz9CP00s3iLkCAPEzcpMwMLA1M3A6MV0e3YDMnA4NpM_2CbEdFAgebKU/w7_B7TH4FH20O04F02J05TLH000G4</a></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>Adult ALL: where are we and where are we going? Larson RA Citation: Clinical Advances in Hematology and Oncology 2(6):342-344, 2004</td>
</tr>
<tr>
<td>Comprehensive</td>
<td>Acute lymphoblastic leukemia: Older patients and newer drugs Larson RA Citation: Hematology: American Society of Hematology Education Program Book:131-136, 2005 <a href="http://asheducationbook.hematologylibrary.org/cgi/content/full/2005/1/131">http://asheducationbook.hematologylibrary.org/cgi/content/full/2005/1/131</a></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>The U.S. trials in adult acute lymphoblastic leukemia Larson RA Citation: Annals of Hematology 83(Supplement 1):S127-128, 2004 <a href="http://www.springerlink.com/content/3nevg7netvev3xp1/">http://www.springerlink.com/content/3nevg7netvev3xp1/</a></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>Management of acute lymphoblastic leukemia in older patients Larson RA Citation: Seminars in Hematology 43(2):126-133, 2006 <a href="http://www.seminhematol.org/article/S0037-1963(06)00024-2/abstract">http://www.seminhematol.org/article/S0037-1963(06)00024-2/abstract</a></td>
</tr>
<tr>
<td>Study</td>
<td>Published Abstract</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------</td>
</tr>
</tbody>
</table>
| 10002 | **Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B (CALGB) study 10002**  
Citation: Blood 116(21):858, 2010  
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/858?maxtoshow=&hits=10&RESULTFOR MAT=&fulltext=858&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resource&type=HWCIT |

| 10101 | **Consolidation therapy with subcutaneous (SC) alemtuzumab after fludarabine and rituximab (FR) induction therapy improves the complete response (CR) rate in chronic lymphocytic leukemia (CLL) and eradicates minimal residual disease (MRD) but is associated with severe infectious toxicity: Final analysis of CALGB study 10101**  
Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke EE, Bengtson EM, Atkins JN, Rai KR, Link B, Larson RA  
Citation: Blood 114(22):210, 2009  

| 10102 | **Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): Final phase I results of a Cancer and Leukemia Group B study (CALGB 10102)**  
Citation: Blood 114(22):838, 2009  

| 10104 | **Quantitative flow cytometric analysis of CD52 antigen expression on T and B lymphoblasts and residual normal T and B lymphocytes in adult acute lymphoblastic leukemia (ALL) reveals striking differences in CD52 expression**  
Citation: Blood (ASH Annual Meeting Abstracts) 108(11), 2006  
http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/2293?maxtoshow=&hits=10&RESULTFOR MAT=1&author1=Lozanski%2C+G&author2=Yu%2C+D&andorexacttitle=and&andorexacttitleabs=and&anda ngrexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resource&type=HWCIT |

| 10104 | **Racial differences in prognostic factors and outcome in acute myeloid leukemia, CALGB 10104**  
Sekeres MA, Dodge RK, Bloomfield CD, Larson RA, Stone RM  
Citation: Blood 100(Supplement 1):323, 2002  
http://bloodjournal.hematologylibrary.org/archive/2002.dtl |

| 10105 | **Pharmacokinetics of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B study 10105**  
Citation: Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting Proceedings Part 1 24(18s):6573, 2006  
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=33045 |
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>10107</td>
<td>Feasibility of administering oblimersen (G3139; Genasense) with imatinib</td>
</tr>
<tr>
<td></td>
<td>mesylate in patients with imatinib resistant chronic myeloid leukemia (CML):</td>
</tr>
<tr>
<td></td>
<td>Cancer and Leukemia Group B study 10107</td>
</tr>
<tr>
<td></td>
<td>Wetzler M, Yu D, Odenike OM, Feldman EJ, Hurd DD, Hoke EE, Hars V, Larson RA</td>
</tr>
<tr>
<td></td>
<td>Citation: Blood 106(11):1097, 2005</td>
</tr>
<tr>
<td>10301</td>
<td>Bortezomib and pegylated liposomal doxorubicin as initial therapy for adult</td>
</tr>
<tr>
<td></td>
<td>patients with symptomatic multiple myeloma: CALGB study 10301</td>
</tr>
<tr>
<td></td>
<td>Orlowski RZ, Peterson BL, Caligiuri MA, Kelly M, Larson RA</td>
</tr>
<tr>
<td></td>
<td>Citation: Blood 116(21):331, 2010</td>
</tr>
<tr>
<td></td>
<td><a href="http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/331?maxtoshow=10&amp;RESULTSFMT=fulltext=oralowski&amp;searchid=1&amp;FIRSTINDEX=0&amp;volume=116&amp;issue=21&amp;resourcetype=HWCIT">http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/331?maxtoshow=10&amp;RESULTSFMT=fulltext=oralowski&amp;searchid=1&amp;FIRSTINDEX=0&amp;volume=116&amp;issue=21&amp;resourcetype=HWCIT</a></td>
</tr>
<tr>
<td>10502</td>
<td>Dose escalation and phase II study of bortezomib added to standard</td>
</tr>
<tr>
<td></td>
<td>daunorubicin and cytarabine therapy for patients with previously untreated</td>
</tr>
<tr>
<td></td>
<td>acute myeloid leukemia age 60-75 years: CALGB study 10502</td>
</tr>
<tr>
<td></td>
<td>Attar EC, Donohue KA, Moser BK, Larson RA</td>
</tr>
<tr>
<td></td>
<td>Citation: Blood 116(21):2176, 2010</td>
</tr>
<tr>
<td></td>
<td><a href="http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/2176?maxtoshow=10&amp;RESULTSFMT=fulltext=attar&amp;searchid=1&amp;FIRSTINDEX=0&amp;volume=116&amp;issue=21&amp;resourcetype=HWCIT">http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/2176?maxtoshow=10&amp;RESULTSFMT=fulltext=attar&amp;searchid=1&amp;FIRSTINDEX=0&amp;volume=116&amp;issue=21&amp;resourcetype=HWCIT</a></td>
</tr>
<tr>
<td>10503</td>
<td>Challenges for conducting clinical trials evaluating maintenance</td>
</tr>
<tr>
<td></td>
<td>chemotherapy in acute myeloid leukemia (AML): A Cancer and Leukemia Group B</td>
</tr>
<tr>
<td></td>
<td>(CALGB) study</td>
</tr>
<tr>
<td></td>
<td>Blum WG, Donohue KA, Marcucci G, DeAngelo DJ, Uy GL, Powell BL, Stock W,</td>
</tr>
<tr>
<td></td>
<td>Baer MR, Kolitz JE, Wetzler M, Hoke EE, Moser BK, Larson RA</td>
</tr>
<tr>
<td></td>
<td>Citation: Blood 116(21):2176, 2010</td>
</tr>
<tr>
<td></td>
<td><a href="http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/2176?maxtoshow=10&amp;RESULTSFMT=fulltext=blum&amp;searchid=1&amp;FIRSTINDEX=0&amp;volume=116&amp;issue=21&amp;resourcetype=HWCIT">http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/2176?maxtoshow=10&amp;RESULTSFMT=fulltext=blum&amp;searchid=1&amp;FIRSTINDEX=0&amp;volume=116&amp;issue=21&amp;resourcetype=HWCIT</a></td>
</tr>
<tr>
<td>19801</td>
<td>Phase II study of 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-purine (506U78)</td>
</tr>
<tr>
<td></td>
<td>in patients with relapsed or refractory T-lineage acute lymphoblastic</td>
</tr>
<tr>
<td></td>
<td>leukemia (ALL) or lymphoblastic lymphoma (LBL)</td>
</tr>
<tr>
<td></td>
<td>DeAngelo DJ, Yu D, Dodge RK, Coutre SE, Mitchell BS, Stone RM, Stopeck AT,</td>
</tr>
<tr>
<td></td>
<td>Larson RA</td>
</tr>
<tr>
<td></td>
<td>Citation: Blood 100(Supplement 1):743, 2002</td>
</tr>
<tr>
<td>19802</td>
<td>Treatment of adult acute lymphoblastic leukemia (ALL): Phase II trial of</td>
</tr>
<tr>
<td></td>
<td>dose intensification of daunorubicin and cytarabine followed by high-dose</td>
</tr>
<tr>
<td></td>
<td>methotrexate and intrathecal methotrexate in place of cranial irradiation</td>
</tr>
<tr>
<td></td>
<td>Stock W, Dodge RK, Vardiman JW, Bloomfield CD, Frankel SR, Stone RM, Larson</td>
</tr>
<tr>
<td></td>
<td>RA</td>
</tr>
<tr>
<td></td>
<td>Citation: Blood 98:2472, 2001</td>
</tr>
<tr>
<td>19802, 20101</td>
<td>Clone-specific quantitative real-time CR of IgH or TCR gene rearrangements</td>
</tr>
<tr>
<td></td>
<td>in adult ALL following induction chemotherapy identifies patients with a</td>
</tr>
<tr>
<td></td>
<td>poor prognosis: Pilot study from CALGB 20101</td>
</tr>
<tr>
<td></td>
<td>Sher D, Dodge RK, Bloomfield CD, Larson RA, Stock W</td>
</tr>
<tr>
<td></td>
<td>Citation: Blood 100(153a):574, 2002</td>
</tr>
</tbody>
</table>
Leukemia Committee

Study

19803

Published Abstract

Relationships of response to oral topotecan for myelodysplastic syndrome with IPSS group and cytogenetics


Citation: Blood 100(11):3137, 2002

http://bloodjournal.hematologylibrary.org/archive/2002.dtl

19803

Two schedules of oral topotecan for myelodysplastic syndrome (MDS)-CALGB study 19803


Citation: Proceedings of the American Society of Clinical Oncology 20:1209, 2001

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=10&abstractID=1209

19804

A phase II study of homoharringtonine in combination with low-dose cytarabine via continuous IV infusion for newly diagnosed patients with chronic myeloid leukemia: CALGB 19804


Citation: Blood 100(Supplement 1):3101, 2002

http://bloodjournal.hematologylibrary.org/archive/2002.dtl

19805

Sequential phase II studies of flavopiridol by 72-hour continuous infusion and 1-hour intravenous bolus for the treatment of relapsed B-cell chronic lymphocytic leukemia: Results from CALGB study 19805


Citation: Blood 104(11):3485, 2004

http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/3485

19901

Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 19901

Rai KR, Byrd JC, Peterson BL, Larson RA

Citation: Blood 102(11):2506, 2003

http://bloodjournal.hematologylibrary.org/archive/2003.dtl

19902

A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia patients with active disease

Rai KR, Byrd JC, Peterson BL, Larson RA

Citation: Blood 100(Supplement 1):772, 2002

http://bloodjournal.hematologylibrary.org/archive/2002.dtl

8421, 8921, 9221

Transfusion independence in patients with myelodysplastic syndromes treated with azacitidine

Silverman LR, Peterson BL, Holland JF, Stone RM, Powell BL, Larson RA

Citation: Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting Proceedings Part 1 24(19s):6576, 2006

http://www.asco.org/ASCOv2/Meetings/Abstracts%26%26Virtual%26Meeting/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=30047
Response rates using International Working Group (IWG) criteria in patients with myelodysplastic syndromes (MDS) treated with azacitidine
Silverman LR, McKenzie DR, DeCastro CM, Ellerton JA, Knapp K, Beach CL, Larson RA, Peterson BL
Citation: Blood 106(11):2526, 2005
http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/2526?maxtoshow=10&hits=10&resourcetype=HWCIT

Response rates in patients with acute myeloid leukemia (AML), treated with azacitidine, using WHO and international working group (IWG) criteria for myelodysplastic syndromes (MDS)
Silverman LR, McKenzie D, Peterson BL, Stone RM, Powell BL, Mayo C, Backstrom JT, Larson RA
Citation: Blood 106(11):1848, 2005
http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/1848?maxtoshow=10&hits=10&resourcetype=HWCIT

Patients who develop therapy-related myelodysplastic syndrome and acute leukemia following breast cancer therapy have differences in cytogenetic characteristics and clinical outcomes when analyzed by age at diagnosis of breast cancer
Levitan D, Olney HJ, Huo D, Karrison T, Bloomfield CD, Larson RA, Rowley JD, Olopade O
Citation: Proceedings of the American Society of Clinical Oncology 22:2286, 2003
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=103305

Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more post-remission chemotherapy courses: Analysis of four CALGB studies
Baer MR, George SL, Sanford BL, Stone RM, Marcucci G, Mayer RJ, Larson RA
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):6531, 2010
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6531?sid=b35f0ce1-7990-412b-b5b7-94fa5eff2065

Outcome of adolescents and young adults with ALL: A comparison of Children's Cancer Group (CCG) and CALGB regimens
Stock W, Sather H, Dodge RK, Bloomfield CD, Larson RA, Nachman J
Citation: Blood 96:467a, 2000

Long-term survival analysis of the North American intergroup study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL)
Citation: Blood 114(22):539, 2009
http://bit.ly/c0JPOe

The addition of rituximab to fludarabine significantly improves progression free and overall survival in previously untreated chronic lymphocytic leukemia (CLL) patients
Citation: Blood 102(11):245, 2003
<table>
<thead>
<tr>
<th>Study</th>
<th>Published Abstract</th>
</tr>
</thead>
</table>
| 9013  | Treatment of chronic myeloid leukemia (CML) with an intermittent schedule of interferon α-B  
Silver RT, Peterson BL, Szatrowski TP, Powell BL, Bloomfield CD, Schiffer CA, Larson RA  
Citation: Proceedings of the American Society of Clinical Oncology 20, 2001  
http://bit.ly/aQbHSg |
| 9111, 9311, 9511, 19802 | Adult T-cell ALL patients whose lymphoblasts express the HOX11 oncogene have an excellent prognosis when treated with chemotherapy and are not candidates for allogeneic bone marrow transplantation in first remission  
Fernando AA, Neuberg DS, Dodge RK, Paquette E, Larson RA, Wiernik PH, Rowe JM, Bloomfield CD, Look A  
Citation: Blood 100(Supplement 1):578, 2002 |
| 9211  | Cladribine has clinical activity in patients with fludarabine refractory chronic lymphocytic leukemia who lack pre-treatment cytopenias  
Citation: Blood 98:2654, 2001 |
| 9221  | Rates of infection and bleeding are not increased in patients with myelodysplastic syndromes (MDS) treated with azacitidine compared with supportive care  
Silverman LR, McKenzie DR, Peterson BL, Otchimar-Reissig R, Hinkle R, Backstrom JT, Larson RA  
Citation: Blood 106(11):2525, 2005  
| 9221  | Azacitidine prolongs survival and time to AML transformation in high-risk myelodysplastic syndrome (MDS) patients >= 65 years of age  
Silverman LR, McKenzie DR, Peterson BL, Demakos EP, Malone N, Holland JF, Larson RA  
Citation: Blood 106(11):2524, 2005  
http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/2524?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=silverman&searchid=1&FIRSTINDEX=0&volume=106&issue=11&resourcetype=HWCIT |
| 9221  | A new validated myelodysplastic syndrome prognostic model for use when cytogenetics are unavailable  
Silverman LR, Germing U, McKenzie DR, Peterson BL, Larson RA  
Citation: Blood 106(11):2527, 2005  
| 9620  | Autologous stem cell transplantation for acute myeloid leukemia in second remission  
Linker C, George S, Hurd D, Larson RA  
Citation: Blood 98:6920a (2881), 2001 |
<table>
<thead>
<tr>
<th>Study</th>
<th>Published Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study</td>
<td>Publication</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
Leukemia Committee

Study
Published Abstract

9720, 9760

Phase III study of the multidrug resistance (MDR) modulator PSC-833 in previously untreated acute myeloid leukemia in chronic phase (CML-CP): The S0325 intergroup trial
Citation: Blood 98:1930, 2001

Comprehensive

A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia
Citation: Blood 116(21):6, 2010
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/LBA-6?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=s0325&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT

Comprehensive

Citation: Blood 116(21):924, 2010
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/924?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=Increased+incidence+of+therapy-related+myeloid&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT

Comprehensive

Tipifarnib is well tolerated as maintenance therapy in acute myeloid leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary results of the phase III intergroup trial E2902
Citation: Blood 116(21):3315, 2010
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/3315?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=Tipifarnib+is+well+tolerated&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT

Comprehensive

Outcome of adolescents and young adults (AYAs) with non-M3 acute myeloid leukemia (AML) treated on Children's Oncology Group (COG) trials compared to Cancer and Leukemia Group B (CALGB) and Southwest Oncology Group (SWOG) trials
Citation: Blood 116(21):183, 2010
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/183?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=183&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT

Comprehensive

MicroRNAs, epigenetics, and copy number changes: New levels of gene regulation in acute myeloid leukemia
Larson RA
Citation: Proceedings from Benzene Symposium, 2009
www.tum-benzenesymposium.de/AbstractBook_FINAL_082809.pdf
Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission

Larson RA

Citation: Biology of Blood Marrow Transplantation 15(1s):11-16, 2009
http://www.bbmt.org/article/S1083-8791%2808%2900511-9/fulltext
Leukemia Correlative Sciences Committee

**Study**

**Published Manuscript**

8221, 8321, 8461, 8525, 8923, 9420, 9720

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia. Results from Cancer and Leukemia Group B 8461


Citation: Blood 108(1):63-73, 2006

http://bloodjournal.hematologylibrary.org/cgi/content/full/108/1/63

8221, 8461, 8525, 8923, 9022, 9222, 9420, 9621, 9720, 10104, 19808

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia


Citation: Blood 103(11):4036-4042, 2004

http://bloodjournal.hematologylibrary.org/cgi/content/full/103/11/4036

8221, 8461, 8525, 8923, 9022, 9222, 9420, 9621, 9720, 19808

Adult de novo acute myeloid leukemia with t(8;11)(q27;q23): Results from Cancer and Leukemia Group B Study 8461 and review of the literature


Citation: Cancer 101(6):1420-1427, 2004

http://www3.interscience.wiley.com/cgi-bin/abstract/109580915/ABSTRACT

8221, 8461, 8525, 8923, 9022, 9222, 9420, 9621, 9720, 19808

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461


Citation: Journal of Clinical Oncology 22(6):1087-1094, 2004

http://jco.ascopubs.org/cgi/content/full/22/6/1087

8221, 8461, 8525, 9022, 9222, 9621, 19808

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study


Citation: Journal of Clinical Oncology 23(3):482-493, 2005

http://jco.ascopubs.org/cgi/content/full/23/3/482

8361

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: Implications for residual disease detection - Cancer and Leukemia Group B Study 8361


Citation: Blood 97:3574-3580, 2001

8364, 8461, 8762, 8763, 9311

Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B study 9311


Citation: Cancer 97(6):1471-1480, 2003

http://www3.interscience.wiley.com/cgi-bin/abstract/103521379/ABSTRACT
8461
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience
Citation: International Journal of Oncology 33(2):239-244, 2008
http://www.spandidos-publications.com/ijo/article.jsp?article_id=ijo_33_2_239

8461
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies
Citation: Leukemia 20(7):1295-1297, 2006
http://www.nature.com/leu/journal/v20/n7/full/2404233a.html

8461
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): Results from Cancer and Leukemia Group B study
Citation: Journal of Clinical Oncology 23(24):5705-5717, 2005
http://jco.ascopubs.org/cgi/content/full/23/24/5705

8461
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: Results from Cancer and Leukemia Group B study
Citation: Journal of Clinical Oncology 22(12):2410-2418, 2004
http://jco.ascopubs.org/cgi/content/full/22/12/2410

8461, 8525, 8765, 9665
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: A Cancer and Leukemia Group B study
Citation: Journal of Clinical Oncology 26(28):4603-4609, 2008
http://jco.ascopubs.org/cgi/content/full/26/28/4603
### Leukemia Correlative Sciences Committee

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 8461, 8525, 8923, 9022, 9222 | Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461)  
Citation: Blood 100(13):4325-4336, 2002  
http://bloodjournal.hematologylibrary.org/cgi/content/full/100/13/4325 |
| 8461, 8525, 8923, 9420, 9621, 9665, 9720, 10201, 19808, 20202 | Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study  
Citation: Blood 116(5):788-792, 2010  
http://bloodjournal.hematologylibrary.org/cgi/content/full/116/5/788 |
| 8461, 8525, 8923, 9621, 9665, 9720, 10201, 19808, 20202, 20502 | TET2 mutations refine the new European LeukemiaNet (ELN) risk classification of adult primary cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study  
Citation: Journal of Clinical Oncology 29(10):1373-1381, 2011  
http://jco.ascopubs.org/content/early/2011/02/16/JCO.2010.32.7742.long |
| 8461, 8525, 9222, 9621, 9665, 19808 | Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B study  
Citation: Journal of Clinical Oncology 24(24):3904-3911, 2006  
http://jco.ascopubs.org/cgi/content/full/24/24/3904 |
| 8461, 8811, 9111, 9311, 9511, 10102, 19802 | Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: A study of the Cancer and Leukemia Group B  
Wetzler M, Dodge RK, Mrozek KA, Stewart CC, Carroll AJ, Tantravahi RR, Vardiman JW, Larson RA, Bloomfield CD  
Citation: Journal of Clinical Oncology 19(12):275-288, 2004  
http://jco.ascopubs.org/cgi/content/full/19/12/275 |
| 8461, 8923, 9022, 9222 | Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461  
Citation: International Journal of Oncology 21(5):1041-1051, 2002  
http://www.intjournal.com/content/21/5/1041.long |
| 8461, 9222 | Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222  
Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schneider CJ  
Citation: Blood 105(9):3420-3427, 2005  
http://bloodjournal.hematologylibrary.org/cgi/content/full/105/9/3420 |
Leukemia Correlative Sciences Committee

Study Publication

8461, 9420, 9621, 9712, 9720, 19808 Cancer and Leukemia Group B (CALGB) multidrug resistance modulation trials in untreated acute myeloid leukemia
Kolitz JE, George SL, Baer MR, Lee EJ, Bloomfield CD, Larson RA
Citation: Annals of Hematology 85(Supplement 1):78-79, 2006
http://www.springerlink.com/content/rhr6w6mj20w2/?p=3d96fbbeb5b84f1b98e7b50d8edf39e9&pi=30

8461, 9511 Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511
Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA
Citation: Blood 109(10):4164-4167, 2007
http://bloodjournal.hematologylibrary.org/cgi/content/full/109/10/4164

8461, 9621, 9665 An 86 probe set gene expression signature can predict survival in AML with normal karyotype independently of FLT3 internal tandem duplications and NPM1 mutational status
Citation: Blood 112(10):4193-4201, 2008
http://bloodjournal.hematologylibrary.org/cgi/reprint/blood-2008-02-134411v1

8461, 9621, 9665 Molecular heterogeneity and its prognostic significance in acute myeloid leukemia (AML) with normal cytogenetics
Mrozek KA, Marcucci G, Ruppert AS, Baldus CD, Kolitz JE, Larson RA, Bloomfield CD
Citation: Annals of Hematology 85(Supplement 1):114-117, 2006
http://www.springerlink.com/content/m20m58p624010j2u/fulltext.pdf

8461, 9621, 9665 Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: A Cancer and Leukemia Group B study
Citation: Blood 108(5):1677-1683, 2006
http://bloodjournal.hematologylibrary.org/cgi/content/full/108/5/1677

8461, 9621, 9665 Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study
Citation: Journal of Clinical Oncology 23(36):9234-9242, 2005
http://jco.ascopubs.org/cgi/content/full/23/36/9234

8461, 9621, 9665 Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B study 9621
Citation: Journal of Clinical Oncology 22(21):4290-4301, 2004
http://jco.ascopubs.org/cgi/content/full/22/21/4290
## Leukemia Correlative Sciences Committee

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Published Manuscript</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 8461, 9621, 9665      | BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B study  
Citation: Blood 102(5):1613-1618, 2003  
http://bloodjournal.hematologylibrary.org/cgi/content/full/102/5/1613 |
| 8461, 9621, 9665, 19808 | Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia  
Citation: Blood 111(9):4797-4808, 2008  
http://bloodjournal.hematologylibrary.org/cgi/reprint/blood-2007-09-113027v1 |
| 8461, 9621, 9665, 19808, 20202, 20502 | Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study  
Citation: Journal of Clinical Oncology 28(36):5257-5264, 2010  
http://jco.ascopubs.org/cgi/content/full/28/36/5257.long |
| 8461, 9621, 9665, 19808, 20205, 20502 | High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study  
Citation: Journal of Clinical Oncology 25(22):3337-3343, 2007  
http://jco.ascopubs.org/cgi/content/full/25/22/3337 |
| 8461, 9621, 9665, 19808, 20502 | Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study  
Citation: Journal of Clinical Oncology 27(19):3198-3204, 2009  
http://jco.ascopubs.org/cgi/content/full/27/19/3198 |
| 8461, 9621, 9665, 19808, 20502 | Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study  
Citation: Journal of Clinical Oncology 28(28):4595-4602, 2008  
http://jco.ascopubs.org/cgi/content/full/26/28/4595 |
## Leukemia Correlative Sciences Committee

### Published Manuscript

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
Leukemia Correlative Sciences Committee

Study | Publication
--- | ---
8461, 9665 | Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia
Citation: Blood 110(5):1648-1655, 2007
http://bloodjournal.hematologylibrary.org/cgi/content/full/110/5/1648

8461, 9665 | Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes
Citation: Proceedings of the National Academy of Sciences of the USA 101(11):3915-3920, 2004
http://www.pnas.org/cgi/content/full/101/11/3915

8461, 9665 | Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation
Citation: Nature Medicine 13(1):78-83, 2006
http://www.nature.com/nm/journal/v13/n1/full/nm1512.html

8461, 9665 | Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major accomplishments and future directions
Bloomfield CD, Mrozek KA, Caligiuri MA
Citation: Clinical Cancer Research 12(11 Pt 2):3564s-3571s, 2006
http://cincancerres.aacrjournals.org/cgi/content/full/12/11/3564s

8461, 9665 | The MLL partial tandem duplication: Evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy
Citation: Blood 106(1):345-352, 2005
http://bloodjournal.hematologylibrary.org/cgi/content/full/106/1/345

8466, 9665 | Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations
Citation: Genes, Chromosomes and Cancer 42(4):427-432, 2005
http://www3.interscience.wiley.com/cgi-bin/abstract/109864264/ABSTRACT?CRETRY=1&SRETRY=0

8461, 9665, 19802 | Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia
Citation: Lancet 363(9408):535-536, 2004
http://www.thelancet.com/journals/lancet/article/PiIS0140673604155426/abstract
Leukemia Correlative Sciences Committee

### Study

#### Published Manuscript

8461, 9720, 10201, 19808, 20202

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study


Citation: Journal of Clinical Oncology 28(4):596-604, 2010
http://jco.ascopubs.org/cgi/reprint/JCO.2009.25.1496v1

8525, 8923, 9420, 9720, 10201, 20202

BAALC and ERG expression levels are associated with outcome and distinct gene- and microRNA-expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study


Citation: Blood 116(25):5660-5669, 2010
http://bloodjournal.hematologylibrary.org/cgi/content/full/116/25/5660

8583, 8712, 9013

Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: A Cancer and Leukemia Group B study


Citation: International Journal of Oncology 25(1):143-151, 2004

9011, 9712

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia


Citation: Cancer 107(5):916-924, 2006
http://www3.interscience.wiley.com/cgi-bin/abstract/112695242/ABSTRACT

9013

Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: Results from CALGB study 9013

Silver RT, Peterson BL, Szatrowski TP, Powell BL, Stock W, Carroll AJ, Bloomfield CD, Schiffer CA, Larson RA

Citation: Leukemia and Lymphoma 44(1):39-48, 2003
http://www.informaworld.com/smpp/content~db=all~content=a918053518~frm=titellink

9191, 9665

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from intergroup protocol 0129


Citation: Blood 101(7):2521-2528, 2003
http://bloodjournal.hematologylibrary.org/cgi/content/full/101/7/2521

9550, 9665

A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer

Shah M, Freud AG, Benson DM, Ferkitch AK, Dezube B, Bernstein ZP, Caligiuri MA

Citation: Clinical Cancer Research 12(13):3993-3996, 2006
http://clincancerres.aacrjournals.org/cgi/content/full/12/13/3993
Leukemia Correlative Sciences Committee

Study  | Publication
--- | ---
9621  | BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: Prognostic implications
Baldus CD, Thiede C, Soucek S, Bloomfield CD, Baldus CD, Ehninger G, Thielt E
Citation: Journal of Clinical Oncology 24(5):790-797, 2006
http://jco.ascopubs.org/cgi/content/full/24/5/790

9665  | MicroRNA fingerprints during human megakaryocytocpoiesis
Citation: Proceedings of the National Academy of Sciences of the USA 103(13):5078-5083, 2006
http://www.pnas.org/cgi/content/full/103/13/5078

9665  | Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias
Citation: Leukemia 20(11):1963-1966, 2006
http://www.nature.com/leu/journal/v20/n11/full/2404409a.html

9665  | The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
Citation: Cancer Cell 8(5):355-368, 2005

9665  | A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes
Citation: Proceedings of the National Academy of Sciences of the USA 100(24):14275-14280, 2003
http://www.pnas.org/cgi/content/full/100/24/14275

9665  | Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia
Citation: Nature Genetics 37(3):265-274, 2005
http://www.nature.com/ng/journal/v37/n3/abs/ng1521.html

9665  | Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia
Ferrando AA, Herblot S, Palomero T, Hansen M, Hoang T, Fox E, Look TA
Citation: Blood 103(3):1909-1911, 2004
http://bloodjournal.hematologylibrary.org/cgi/content/full/103/5/1909

9665  | BCR/ABL activates mdm2 mRNA translation via the La antigen
Citation: Cancer Cell 3(2):145-160, 2003
http://www.cancercell.org/content/article/abstract?uid=PIIS1535610803000205
Leukemia Correlative Sciences Committee

Study | Publication
--- | ---
9665 | Published Manuscript

**Study Number 9665**

High affinity interleukin-3 receptor expression on blasts from patients with AML correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein

**Citation:** Leukemia Research 25(10):875-881, 2001

http://bit.ly/1ayMeKF

**Study Number 9665**

Aberrant CpG-island methylation has non-random and tumour-type-specific patterns

**Citation:** Nature Genetics 25:132-138, 2000

http://www.nature.com/ng/journal/v24/n2/abs/ng0200_132.html

**Study Number 9665**

Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci

**Citation:** Blood 97(10):3226-33, 2001

**Study Number 9665**

Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics

**Citation:** Proceedings of the National Academy of Science USA 98(3):1124-1129, 2001

http://www.pnas.org/content/98/3/1124.full

**Study Number 9665**

Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples

**Citation:** International Journal of Oncology 28(5):1099-1103, 2006

http://www.splendidos-publications.com/ijo/article.jsp?article_id=ijo_28_5_1099

**Study Number 9665**

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia

**Citation:** Leukemia 21(5):956-964, 2007


**Study Number 9665**

CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia

**Citation:** Cancer Research 66(2):653-658, 2006

http://cancerres.aacrjournals.org/cgi/content/full/66/2/653

**Study Number 9665**

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy

**Citation:** Journal of Clinical Oncology 24(3):437-443, 2006

http://jco.ascopubs.org/cgi/content/full/24/3/437
**Leukemia Correlative Sciences Committee**

**Study** | **Publication**
---|---
**Published Manuscript**
9665, 9769, 20502 | DNA hypermethylation and epigenetic silencing of the tumor suppressor gene SLC5A in acute myeloid leukemia with the MLL partial tandem duplication  
*Citation*: Blood 112(5):2013-2016, 2008  
*http://bloodjournal.hematologylibrary.org/cgi/content/full/112/5/2013*

Comprehensive | FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study  
*Citation*: Blood 116(18):3622-3626, 2010  
*http://bloodjournal.hematologylibrary.org/cgi/content/full/116/18/3622*

**Published Book or Book Chapter**
8461 | Recent genetic studies of adult patients with acute myeloid leukemia performed by the Cancer and Leukemia Group B  
*Byrd JC, Carroll AJ, Larson RA, Bloomfield CD*

8461, 9665 | Cytogenetics for treatment stratification in de novo adult acute myeloid leukemia  
*Bloomfield CD, Archer KJ, Mrozek KA, Byrd JC, Whitman SP, Dodge RK, Carroll AJ, Larson RA, Caligiuri MA*  

**Published Article**
8221, 8461, 8525, 8923, 9022, 9222, 9420, 9621, 9720, 19808 | Core binding factor acute myeloid leukemia: Cancer and Leukemia Group B (CALGB) study 8461  
*Citation*: Annals of Hematology 83(Supplement 1):S84-S85, 2004  
*http://www.springerlink.com/content/3nevq7netevv3xp1/*

8461, 9420, 9621, 9665, 9720, 19808 | P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults  
*Kolitz JE, George SL, Baer MR, Lee EJ, Bloomfield CD, Larson RA*  
*Citation*: Annals of Hematology 83(Supplement 1):S103-S104, 2004  
*http://www.springerlink.com/content/3nevq7netevv3xp1/*
Leukemia Correlative Sciences Committee

Study | Publication
--- | ---

10101 | Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101
Lin TS, Donohue KA, Lucas MS, Byrd JC, Bengtson EM, Peterson BL, Larson RA
Citation: Blood 110(11):755, 2007

10105 | Application of 2008 WHO classification criteria for myelodysplastic syndromes (MDS) without excess blasts: Observations from Cancer and Leukemia Group B Study 10105
Hasserjian RP, Gupta P, Donohue KA, Owzar K, Larson RA, Racke FK, Bloomfield CD
Citation: United States and Canadian Academy of Pathology 22(Supplement 1), 2009

10201 | A phase III randomized trial of intensive induction and consolidation chemotherapy +/- oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25(18S):7012, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=30319

8221, 8461, 8525, 8923, 9022, 9222, 9420, 9621, 9720, 19808
| Comparison of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations of 11q23
Blum WG, Mrozek KA, Maharry KS, Raimondi S, Carroll AJ, Larson RA, Rowley JD, Bloomfield CD
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 23(16S):6549, 2005
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010/vgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=30099

8221, 8461, 8525, 8923, 9022, 9222, 9420, 9621, 9720, 19808
| t(8;21) acute myeloid leukemia (AML) differs from inv(16) AML in pretreatment characteristics, outcome and prognostic factors predicting outcome: A Cancer and Leukemia Group B (CALGB) study
Citation: Blood 104(11):2017, 2004
http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/2017

8221, 8461, 8525, 8923, 9022, 9222, 9420, 9621, 9720, 19808
| Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): Results from CALGB 8461
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14S):6543, 2004
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=612
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
Leukemia Correlative Sciences Committee

Study | Published Abstract
--- | ---
8461 | Secondary chromosome aberrations in adult acute lymphoblastic leukemia (ALL) with t(9;22)  
Citation: Blood 98(Supplement 1):466, 2001

8461 | Karyotype change in adult acute myeloid leukemia (AML) at first relapse  
Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Larson RA, Bloomfield CD  
Citation: Blood 96(Supplement 1):706, 3046, 2000

8461 | Isolated trisomy (IT) is an adverse prognostic factor in patients (pts) with AML: results from Cancer and Leukemia Group B (CALGB 8461)  
Citation: Proceedings of the American Society of Clinical Oncology. 20 (A-1124), 2001

8461, 10105 | A phase II study of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B Study 10105  
Citation: Blood 108(11):2665, 2006  

8461, 10502, 20202, 20502 | Increased expression of macrophage migration inhibitory factor (MIF) receptor CD74 is associated with inferior outcome in younger patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study  
Citation: Blood 114(22):1616, 2009  

8461, 19802 | Intensified daunorubicin during induction and post-remission therapy of adult acute lymphoblastic leukemia (ALL): Results of CALGB 19802  
Citation: Blood 102(11):1375, 2003

8461, 8525, 8923, 9420, 9621, 9665, 9720, 10201, 19808, 20202, 20502 | TET2 mutations occur in over 20% of adults with de novo cytogenetically normal acute myeloid leukemia, and their prevalence increases with age: A Cancer and Leukemia Group B Study  
Citation: Haematologica 95(suppl 2: 12-13):0030, 2010  
http://www.eventure-online.com/eventure/publicAbstractView.do?id=135132&congressId=3446
## Leukemia Correlative Sciences Committee

**Study** | **Publication**
---|---
8461, 8525, 8923, 9420, 9621, 9665, 9720, 10201, 19808, 20202, 20502 | Sole trisomy 8 in patients (pts) with de novo acute myeloid leukemia (AML) is associated with age-independent poor outcome that is modified by molecular markers and with unique gene- and microRNA (miR)-signatures: A Cancer and Leukemia Group B (CALGB) study
Citation: Blood 116(21):577, 2010
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/577?maxtoshow=10&RESULTFORMAT=&fulltext=577&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resource=HWCIT

8461, 8525, 8923, 9420, 9621, 9665, 9720, 10201, 19808, 20202, 20502 | IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study
Citation: Haematologica 95(suppl 2):1107, 2010
http://online.haematologica.org/EHA15/browserecord.php?action=browse&recid=7179

8461, 8525, 8923, 9420, 9621, 9665, 9720, 10201, 19808, 20202, 20502 | Incidence and clinical correlations of TET2 mutations in younger and older patients with de novo cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B Study
Citation: EBMT European Hematology Association Annual Meeting, 2010

8461, 8525, 8923, 9420, 9665, 9720, 10201, 20202, 20502 | CEBPA double mutations impact favorably on the outcome of older patients with cytogenetically normal acute myeloid leukemia and wild-type NPM1, and show distinct gene- and microRNA-expression patterns
Citation: Haematologica 95(suppl. 2):593, 2010
http://online.haematologica.org/EHA15/browserecord.php?action=browse&recid=6663

8461, 8525, 8923, 9420, 9720 | Pre-treatment cytogenetics predict complete remission and long-term outcome in patients over 60 years with acute myeloid leukemia: Results from CALGB 8461
Citation: Blood 104(11):568, 2004
http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/568?maxtoshow=10&RESULTFORMAT=&fulltext=568&searchid=1&FIRSTINDEX=0&volume=104&issue=11&resourcetype=HWCIT
Leukemia Correlative Sciences Committee

8461, 8525, 9022, 9222, 9621, 9665, 19808

Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study
Citation: Journal of Clinical Oncology, American Society for Clinical Oncology Annual Meeting Proceedings Part I 26(18s):7011, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=32908

8461, 8525, 9022, 9222, 9621, 9665, 19808

Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study
Citation: Journal of Clinical Oncology, Proceedings of the American Society of Clinical Oncology Part 1 24(18s):2, 2006
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=32943

8461, 8525, 9665

Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: A Cancer and Leukemia Group B (CALGB) study
Citation: Journal of Clinical Oncology, American Society for Clinical Oncology Annual Meeting Proceedings 23(16s):6514, 2005
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgrVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=33015

8461, 9191, 9665

Microgranular variant (M3V) of acute promyelocytic leukemia (APL) does not have a worse prognosis than classical APL in the ATRA era: A report of 153 patients treated on intergroup 0129 and PETHMA LPA96 and LPA99
Citation: Blood 104(11):394, 2004
http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/394

8461, 9621, 9665

An 86-probe gene expression signature can predict survival in AML with normal karyotype independently of FLT3 ITD and NPM1 mutation status: A collaborative study from the AMLCG and CALGB study groups
Citation: Blood 110(11):596, 2007
http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/596?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=metzeler&searchid=1&FIRSTINDEX=0&volume=110&issue=11&resourcetype=HWC
Leukemia Correlative Sciences Committee

Published Abstract

8461, 9621, 9665

High BAALC expression predicts adverse outcome in de novo acute myeloid leukemia (AML) patients: A CALGB study update
Citation: Annals of Hematology 83(Supplement 1):S13, 2004
http://www.springerlink.com/content/7dabx1vba56v89dts/?p=ee470121a6114eb2974c67fbec4ad15a&p=1

8461, 9621, 9665

Overexpression of the ERG gene is an adverse prognostic factor in acute myeloid leukemia (AML) with normal cytogenetics (NC): A Cancer and Leukemia Group B Study (CALGB)
Citation: Blood 106(11):335, 2005
http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/335?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=marcucci&searchid=1&FIRSTINDEX=0&volume=106&issue=11&resourcetype=HWCIT

8461, 9621, 9665

A novel post-remission consolidation regimen for patients with acute myeloid leukemia (AML) < 60 years old with normal or unfavorable cytogenetics: Results from CALGB 9621
Citation: Blood 102(11):609, 2003

8461, 9621, 9665

Treatment of core binding factor (CBF) acute myeloid leukemia (AML) with post-remission high-dose cytarabine (HiDAC): Results from CALGB 9621
Citation: Blood 102(11):612, 2003

8461, 9621, 9665, 19808

The high prevalence of FLT3-ITD mutations is associated with the poor outcome in adult patients with t(6;9)(p23;q34) positive AML: Results of an international metaanalysis
Citation: Blood 110(11):761, 2007
http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/761?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=thiede&searchid=1&FIRSTINDEX=0&volume=110&issue=11&resourcetype=HWCIT

8461, 9621, 9665, 19808

Acute myeloid leukemia (AML) with 9q aberrations occurring within a non-complex karyotype is highly associated with CEBPA and NPM1 mutations: A joint analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB)
Citation: Blood 110(11):2440, 2007
http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/2440?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=corbacioglu&searchid=1&FIRSTINDEX=0&volume=110&issue=11&resourcetype=HWCIT
### Leukemia Correlative Sciences Committee

<table>
<thead>
<tr>
<th>Study</th>
<th>Published Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study</td>
<td>Publication</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
Leukemia Correlative Sciences Committee

Study Publication
Published Abstract


8461, 9665 Alpha-catenin as a del(5q) suppressor in AML: Expression analysis of purified human hematopoietic stem cells and zebrafish Look TA, Liu T, Hsu K, Deng M, Becker MW, Clarke MF, Jelinek J, Issa J, Bloomfield CD Citation: Blood 104(11), 2004 http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/142


8461, 9665 Epigenetic suppression of the CTNNB1 gene, encoding the (alpha)-catenin protein, which is located in the 5q31 critical deleted region in malignant myeloid disorders with del(5q) Liu T, Becker MW, Hsu K, Jelinek J, Deng M, Bloomfield CD, Issa J, Clarke MF, Look TA Citation: Blood 104(11):203, 2004 http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/203
Leukemia Correlative Sciences Committee
Published and Accepted Documents
01/01/2000 - 4/30/2011

8461, 9665
Acute myeloid leukemia with deletion 9q is associated with CEBPA loss-of-function mutations
Citation: Blood 104(11):2896, 2004
http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/2896?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=frohling&searchid=1&FIRSTINDEX=0&volume=104&issue=11&resourcetype=HWCIT

8461, 9665
Gene expression profiles in acute myeloid leukemia (AML): From diagnosis to prognosis
Citation: Blood 106(11):2996, 2005
http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/2996

8461, 9665
FTY720, a new and alternative strategy for treating blast crisis CML and Ph1 ALL patients
Citation: Blood 108(11):288, 2006

8461, 9665
Detection of microdeletions and amplifications in primary human acute myeloid leukemia (AML) genomes using ultradense oligomer tiling path arrays and comparative genomic hybridization (CGH)
Citation: Blood 106(11):2350, 2005
http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/2350

8461, 9665
Co-expression of BAALC with ERG, TCF4, and CD133 indicates a shared pathway in acute myeloid and lymphoblastic leukemia
Baldus CD, Radmacher MD, Marcucci G, Hoelzer D, Thiel E, Bloomfield CD, Hofmann WK
Citation: Blood 106(11):2755, 2005

8461, 9665
High resolution mapping of chromosome 21 genomic dosage and gene expression studies reveal frequent amplification of the 25-30 MB region in 21q21 and overexpression of the APP gene in acute myeloid leukemia (AML) subsets
Citation: Blood 102(11):1319, 2003
## Leukemia Correlative Sciences Committee

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
### Published Abstract

**Study** | **Publication**  
---|---  
8461, 9665, 9710 | Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): Results from the North American Intergroup Trial, C9710  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 25(18s):7016, 2007  
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?vmview=abst_detail_view&confID=47&abstractID=32627  
8461, 9665, 9769 | The tumor suppressor gene SLC5A8 is selectively silenced in MLL partial tandem duplication-positive acute myeloid leukemia with normal cytogenetics  
Citation: Blood 108(11):9, 2006  
http://bit.ly/cm4psh  
8461, 9665, 9862, 10001 | Autologous stem cell transplantation (SCT) following sequential chemotherapy and imatinib for adults with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) - CALGB study 10001  
Wetzler M, Stock W, Donohue KA, Owzar K, Sher DA, Hoke EE, McCarty JM, Blum WG, Powell BL, Bloomfield CD, Linker C, Larson RA  
Citation: Blood 110(11):2869, 2007  
http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/2869?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=wetzler&searchid=1&FIRSTINDEX=0&volume=110&issue=11&resourceType=HWCIT  
8461, 9665, 9862, 10001 | Sequential imatinib and chemotherapy yield reverse-transcriptase polymerase chain reaction (RT-PCR)-negative peripheral stem cell collections in Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL): Preliminary results of CALGB 10001  
Wetzler M, Stock W, Owzar K, Sher DA, Hoke EE, Linker C, Bloomfield CD, Larson RA  
Citation: Journal of Clinical Oncology, American Society of Clinical Oncology Annual Meeting Proceedings Part I 24(18s):6549, 2006  
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?vmview=abst_detail_view&confID=40&abstractID=32875  
8461, 9665, 9862, 10102 | Quantitative measurement of CD52 expression and alemtuzumab binding in adult acute lymphoblastic leukemia (ALL): Correlation with immunophenotype and cytogenetics in patients (pts) enrolled on a phase I/II trial from the Cancer and Leukemia Group B (CALGB 10102)  
Lozanski G, Sanford BL, Mrozek KA, Edwards CG, Pearson R, Bloomfield CD, Larson RA, Stock W  
Citation: Blood 110(11):2386, 2007  
http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/2386  
8461, 9665, 9862, 10102 | Incorporation of alemtuzumab into front-line therapy of adult acute lymphoblastic leukemia (ALL) is feasible: A phase I/II study from the Cancer and Leukemia Group B (CALGB 10102)  
Citation: Blood 106(11):145, 2005  
http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/145
### Leukemia Correlative Sciences Committee

#### Study Publication

<table>
<thead>
<tr>
<th>Study</th>
<th>Published Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>8461, 9720</td>
<td>Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients &gt;=60 years (CALGB 9720) Baer MR, George SL, Sanford BL, Bothun SM, Mrozek KA, O'Loughlin KL, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, Larson RA Citation: Blood 110(11):296, 2007 <a href="http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/296">http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/296</a></td>
</tr>
<tr>
<td>8461, 9720, 10201, 20202</td>
<td>Adverse prognostic impact of FLT3 internal tandem duplication (ITD) is age-associated in older (&gt; 60 Years (Y)) de novo cytogenetically normal acute myeloid leukemia (CN-AML) patients (Pts): A Cancer and Leukemia Group B (CALGB) study Whitman SP, Margetson DP, Holland KB, Maharry KS, Radmacher MD, Becker H, Wu Y, Mrozek KA, Schwind S, Baer MR, Powell BL, Larson RA, Carroll AJ, Caligiuri MA, Marcucci G, Bloomfield CD Citation: Blood 114(22), 2009 <a href="http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/1579">http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/1579</a></td>
</tr>
<tr>
<td>8461, 9720, 10201, 20202</td>
<td>Awerent gene expression of BAALC and ERG in older (&gt;60 Years (Y)) de novo cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study Schwind S, Schwind S, Maharry KS, Mrozek KA, Radmacher MD, Holland KB, Becker H, Whitman SP, Baer MR, Powell BL, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD, Marcucci G Citation: Blood 114(22):214, 2009 <a href="http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/214">http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/214</a></td>
</tr>
<tr>
<td>8461, 9720, 10201, 20202</td>
<td>NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN-AML): Becker H, Marcucci G, Maharry KS, Margetson DP, Radmacher MD, Whitman SP, Mrozek KA, Baer MR, Larson RA, Bloomfield CD Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 27(15s):7000, 2009 <a href="http://meeting.asccpubs.org/cgi/content/abstract/27/15s/7000">http://meeting.asccpubs.org/cgi/content/abstract/27/15s/7000</a></td>
</tr>
<tr>
<td>8461, 9720, 9760</td>
<td>Treatment failure is strongly predicted by P-glycoprotein (Pgp) function, but not by multidrug resistance protein (MDR-1), breast cancer resistance protein (BCRP) or lung resistance protein (LRP) in acute myeloid leukemia (AML) patients 60 years and older receiving intensive chemotherapy: CALGB 9720/9760 Baer MR, Cuveliero NW, Shoemaker JS, Barrier R, Caligiuri MA, Kolitz JE, Powell BL, Larson RA, Bloomfield CD Citation: Blood 106(11):2349, 2005 <a href="http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/2349">http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/2349</a></td>
</tr>
</tbody>
</table>
Mutations in the TET oncogene family member 2 (TET2) gene refine the new European LeukemiaNet (ELN) risk classification of primary, cytogenetically normal acute myeloid leukemia (CN-AML) in adults
Citation: Blood 116(21):98, 2010
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/98?maxtoshow=&HITS=10&RESULTFORMAT=&fulltext=wetzler&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT

Adult T-cell ALL patients whose lymphoblasts express the HOX11 oncogene have an excellent prognosis when treated with chemotherapy and are not candidates for allogeneic bone marrow transplantation in first remission
Ferrando AA, Neuberg D, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, Bloomfield CD, Look T
Citation: Blood 100(Supplement 1):578, 2002

Alemtuzumab increases serious infections in patients with previously untreated chronic lymphocytic leukemia (CLL) receiving fludarabine-based therapy: A comparative analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901)
Morrison VA, Peterson B, Rai KR, Byrd JC, Larson RA
Citation: Blood 110(11):756, 2007
http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/756?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=morrison&searchid=1&FIRSTINDEX=0&volume=110&issue=11&resourcetype=HWCIT

Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative Oncology Group experience
Citation: Blood 106(11):546, 2005
http://abstracts.hematologylibrary.org/cgi/content/abstract/106/11/546

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia (ALL): Cancer and Leukemia Group B study 9511
Wetzler M, Sanford BL, Owzar K, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Koltitz JE, Bloomfield CD, Larson RA, DeOliveira D
Citation: Blood 106(11):1825, 2007

Morphology and CBFB/MYH11 in AML (CALGB study 9621)
Citation: Laboratory Investigation 80:165 #967, 2000
Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts)
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 27(15s):7002, 2009
http://meeting.ascopubs.org/cgi/content/abstract/27/15S/7002

Co-expression of BAALC with ERG, TCF4, and CD133 indicates a shared pathway in acute myeloid and lymphoblastic leukemia
Baldus CD, Radmacher MD, Marcucci G, Hoelzer D, Thiel E, Bloomfield CD, Hofmann WK
Citation: Annals of Hematology 85(Supplement 1):4, 2004

Methylation of the tumor suppressor gene RTPRO (receptor-type protein tyrosine phosphatase) is associated with expression of important apoptosis-related proteins in chronic lymphocytic leukemia (CLL)
Citation: Blood 104(11):2804, 2004
http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/2804?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=motiwala&searchid=1&FIRSTINDEX=0&volume=104&issue=11&resourcetype=HWCIT

Global assessment of promoter methylation in a murine model of cancer identifies ID4 as a putative novel tumor suppressor gene in human leukemia
Citation: Blood 104(11):3488, 2004
http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/3488

High affinity interleukin-3 receptor expression on blasts from patients with AML correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein
Alexander RL, Ramage J, Klein B, Kucera GL, Bloomfield CD, Frankel AE
Citation: Leukemia Research 25(10):875-881, 2001

Gene expression profiling reveals fundamental biological differences in AML with trisomy 8 and normal cytogenetics
Virtaneva KI, Wright FA, Tanner SM, Yuan B, Lemon WJ, Bloomfield CD, de la Chapelle A, Krahe R
Citation: Nature Genetics 27:65, 2001
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 9665, 10301 | Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B study 10301  
Orlowski RZ, Peterson BL, Sanford BL, Chanan-Khan AA, Zehngebot LM, Watson PR, Caligiuri MA, Larson RA  
Citation: Blood 108(11):797, 2006  
http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/797 |
| 9710 | Clonal markers in relapsed acute promyelocytic leukemia (APL): Clinicopathological associations and relation to all-trans retinoic acid (ATRA) treatment on intergroup phase III trial C9710  
Citation: Blood 116(21):1038, 2010  
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/1038?maxtoshow=10&RESULTFORMAT=&fulltext=1038&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT |
| 9712 | Select high risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia (CLL): Preliminary justification for risk-adapted therapy  
Citation: Blood 104(11):476, 2004  
http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/476 |
| 9720 | Phase III study of immunotherapy with recombinant interleukin-2 (IL-2) versus no further therapy in acute myeloid leukemia (AML) patients >= 60 years in first complete remission (CALGB 9720)  
Baer MR, George SL, Caligiuri MA, Sanford BL, O’Loughlin KL, Mrozek KA, Kolitz JE, Powell BL, Moore JO, Stone RM, Bloomfield CD, Larson RA  
Citation: Blood 108(11):424, 2006  
| 9720, 9760 | ATP-binding cassette (ABC) proteins in untreated acute myeloid leukemia (AML) in patients 60 years and older (CALGB 9760)  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 23(16s):6551, 2005  
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07d506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed73aad1RCRD&vnnid=abst_detail_view&confId=34&abstractId=30378 |
| 9769 | Activation of the silenced MLL (ALL-1) wild-type allele in acute myeloid leukemia (AML) with the MLL partial tandem duplication results in enhancement of cell death  
Citation: Blood 102(11):775, 2003 |
Leukemia Correlative Sciences Committee

Study Publication

Published Abstract

Comprehensive

Acquired copy number alterations in adult acute myeloid leukemia genomes


Citation: Proceedings for National Academy of Science USA 4(106):12950-12955, 2009
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716381/?tool=pubmed

Comprehensive

Prognostic significance of unbalanced chromosome abnormalities used by 2008 World Health Organization (WHO) classification to define "acute myeloid leukemia (AML) with myelodysplasia-related Changes" in adults: A Cancer and Leukemia Group B (CALGB) study


Citation: Blood 114(22):2602, 2009

Comprehensive

High BAALC expression identifies a new risk group of de novo acute myeloid leukemia (AML) patients: A Cancer and Leukemia Group B (CALGB) study


Citation: Proceedings of the American Society of Clinical Oncology 22(563):2266, 2003
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractId=100776
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin's lymphomas: A phase II trial of CALGB 50002

**Smith SM, Grinblatt DL, Johnson JL, Niedzwiecki D, Rizzieri DA, Bartlett NL, Cheson BD**

Citation: British Journal of Haematology 140(3):313-319, 2008

Doxorubicin, vinblastine, gemcitabine (CALGB 50203) for stage I/II non-bulky Hodgkin lymphoma: Pretreatment prognostic factors and interim PET


Citation: Blood(Epub), 2011
http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2010-10-314260v1

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and Leukemia Group B protocol 50206

**Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL**

Citation: Leukemia and Lymphoma 48(1):1313-1319, 2007
http://www.informaworld.com/smpp/content?content=10.1080/10428190701411458

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an Fc¿RIIIa-158 V/F polymorphism

**Blum KA, Jung S, Johnson JL, Hsi ED, Lucas DM, Byrd JC, Cheson BD, Lin TS, Bartlett NL**

Citation: Annals of Oncology eprint Apr 27, 2010
http://annonc.oxfordjournals.org/content/early/2010/04/27/annonc.mdq211.abstract

High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin: A CALGB 59804 correlative study


Citation: Leukemia and Lymphoma 49(6):1202-1205, 2008
http://informahealthcare.com/doi/abs/10.1080/10428190802094237

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804

**Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, Besien KV, Zelenetz AD, Cheson BD, Canellos GP**

Citation: Annals of Oncology 8(6):1202-1205, 2008
http://annonc.oxfordjournals.org/content/early/2010/04/27/annonc.mdq211.abstract

Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901

**Czuczman MS, Porcu P, Johnson JL, Niedzwiecki D, Kelly M, Hsi ED, Cook J, Canellos GP, Cheson BD**

Citation: Leukemia and Lymphoma 48(1):97-103, 2007
http://www.informaworld.com/smpp/content?content=10.1080/1042819060961058

Sequential doxorubicin and topotecan in relapsed/refractory aggressive NHL: Results of CALGB 59906

**Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos GP, Cheson BD, Bartlett NL**

Citation: Leukemia and Lymphoma 47(8):1511-1517, 2006
http://informahealthcare.com/doi/abs/10.1080/1042819060581385
Lymphoma Committee

Study

Published Manuscript

59909

Immuno-chemotherapy and autologous stem cell transplant for untreated patients with mantle cell lymphoma: CALGB protocol 59909
Citation: Journal of Clinical Oncology, 2009
http://jco.ascopubs.org/cgi/content/abstract/JCO.2009.22.2554v1

59909

K67 and PIM1 expression in aggressively treated mantle cell lymphoma (MCL): A Cancer and Leukemia Group B (CALGB) 59909 correlative science study
Citation: Leukemia and Lymphoma 49(11):2081-2090, 2008
http://www.ingentaconnect.com/content/apl/glal/2008/00000049/00000011/art00010

7951

Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: A study of the Cancer and Leukemia Group B
Citation: Journal of Clinical Oncology 21(1):5-15, 2003
http://jco.ascopubs.org/cgi/content/full/21/1/5

8461, 9251

Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: Final results of Cancer and Leukemia Group B study 9251
Citation: Cancer 100(7):1438-1448, 2004
http://www3.interscience.wiley.com/cgi-bin/abstract/107632082/ABSTRACT

8752

Prevalence of HTLV-I associated T-cell lymphoma
Citation: American Journal of Hematology 66(1):32-38, 2001

8852, 8854

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854
Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Johnson JL, Canellos GP, Cooper MR, Peterson B
Citation: Cancer 92(2):207-217, 2001
http://www3.interscience.wiley.com/cgi-bin/abstract/85005518/ABSTRACT

8856

Cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide (CHOPE) for advanced stage Hodgkin's disease: CALGB 8856
Lester EP, Barcos MP, Johnson JL, Millard F, Cooper MR, Omura GA, Peterson B
Citation: Cancer Investigation 19(5):447-458, 2001
Lymphoma Committee
Study
Published Manuscript

8952
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial
Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson B
Citation: Journal of Clinical Oncology 21(4):607-614, 2003
http://jco.ascopubs.org/cgi/content/full/21/4/607

9150
Niedzwiecki D, Lichtman SM, Schilsky RL, Johnson JL, Perri RT, Sklar J, Barcos MP, Peterson B
Citation: Leukemia and Lymphoma 42(6):1255-1264, 2001

9153
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin's lymphoma: Results of CALGB study 9153
Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, Peterson B, Byrd JC, Cheson BD
Citation: Cancer 107(12):2817-2825, 2006
http://www3.interscience.wiley.com/cgi-bin/fulltext/113472374/HTMLSTART?CRETRY=1&SRETRY=0

9251
Burkitt leukemia and lymphoma are curable with a short course of intensive chemotherapy
Rizzieri DA, Johnson JL, Larson RA
Citation: American Journal of Oncology Review 3(8):475-481, 2004

9251
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB l3 acute lymphocytic leukemia: Results of Cancer and Leukemia Group B study 9251
Lee EJ, Schiffer CA, Freter CE, Johnson JL, Barcos MP, Frizziara G, Bloomfield CD, Peterson B, Petroni GR, Petroni GR
Citation: Journal of Clinical Oncology 19(20):4014-4022, 2001
http://jco.ascopubs.org/cgi/content/abstract/11/9/1141

9254
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254
Citation: Leukemia & Lymphoma 52(4):587-596, 2011
http://informahealthcare.com/cgi-bin/fulltext/10428194.2010.543714

9255
Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255
Lichtman SM, Niedzwiecki D, Barcos MP, Carlisle TL, Cooper MR, Johnson JL, Peterson B
Citation: Annals of Oncology 11(9):1141-1146, 2000
http://annonc.oxfordjournals.org/cgi/content/abstract/11/9/1141

9351
High-dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma: Cancer and Leukemia Group B 9351
Peterson B, Johnson JL, Shipp MA, Barcos MP, Gockerman JP, Canellos GP
Citation: Leukemia and Lymphoma 48(5):870-880, 2007
http://www.informaworld.com/smpp/content?content=10.1080/10428190701259758
Lymphoma Committee

Study

Published Manuscript

9551
Phase II study of 9-aminocamptothecin in previously treated lymphomas: Results of Cancer and Leukemia Group B 9551
Bartlett NL, Wagner ND, Ratain MJ, Peterson B
Citation: Cancer Chemotherapy and Pharmacology 63(5):793-798, 2009
http://www.springerlink.com/content/hj7m20778h10562/  

Comprehensive
Maintenance rituximab after CVP prolongs progression free survival in advanced indolent lymphoma:
Results of the randomized phase III ECOG1496 study
Citation: Journal of Clinical Oncology 27(10):1607-1614, 2009
http://jco.ascopubs.org/content/27/10/1607.long  

Comprehensive
Second malignancy risk associated with treatment of Hodgkin's lymphomas: Meta-analysis of the randomised trials
Citation: Annals of Oncology 17(12):1749-1760, 2006
http://annonc.oxfordjournals.org/cgi/content/full/17/12/1749  

Comprehensive
The Cancer and Leukemia Group B Lymphoma Committee
Cheson BD, Canellos GP
Citation: Clinical Cancer Research 12(11 Pt 2):3572s-3575s, 2006
http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3572s?maxtoshow=&HITS=10&hits=10&RESULT FORMAT=&fulltext=cheson&searchid=1&FIRSTINDEX=0&volume=12&issue=11&resourcetype=HWCIT

Comprehensive
Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity
Rizzieri DA, Mann KP, Niedzwiecki D, Wadleigh M, Wikstrand CJ, Sen F, Peterson BL, Proia AD, Bingner DD
Citation: Leukemia and Lymphoma 46(10):1455-1462, 2005
http://www.informaworld.com/smpp/section?content=a723773465&fulltext=713240928

Published Abstract

50002
Phase II study of thalidomide in escalating doses for follicular (F-NHL) and small lymphocytic lymphoma (SLL): CALGB study 50002
Grinblatt DL, Johnson JL, Niedzwiecki D, Rizzieri DA, Bartlett NL, Cheson BD
Citation: Blood 104(11):3284, 2004
http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/3284?maxtoshow=&HITS=10&hits=10&RESULT FORMAT=&fulltext=thalidomide+small+lymphocytic+lymphoma&searchid=1&FIRSTINDEX=0&volume=104&issue=11&resourcetype=HWCIT

50103
Biologic prognostic markers in diffuse large B-cell lymphomas patients treated with dose adjusted EPOCH-R:
A CALGB 50103 correlative science study
Citation: Blood 112(11):476, 2008
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 50103 | Multi-center study of dose-adjusted epoch-r in untreated diffuse large b-cell lymphoma: CALGB 50103  
Wilson WH, Zelenetz AD, Niedzwiecki D, Hurd DD, Martin SE, Czuczman MS, Johnson JL, Canellos GP, Cheson BD  
Citation: Lugano, 2008 |
| 50103 | Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma  
(DLBCL)-CALGB 50103  
Wilson WH, Porcu P, Hurd DD, Martin S, Czuczman MS, Niedzwiecki D, Saint Louis JD, Johnson JL, Cheson BD, Canellos GP, Zelenetz AD  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Part I 23(16s):6530, 2005  
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmmview=abst_detail_view&confID=34&abstractID=30360 |
| 50203 | Validation of the international harmonization project (IHP) guidelines in early stage Hodgkin lymphoma (HL) treated with adriamycin, vinblastine and gemcitabine (AVG) (CALGB 50203): Early results  
Citation: Blood 112(11):1460, 2008  
| 50203 | Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen excluding bleomycin for the treatment of early stage Hodgkin Lymphoma (HL): Results of CALGB 50203  
Citation: Blood 110(11):214, 2007  
http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/214?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=doxorubicin&searchid=1&FIRSTINDEX=10&sortspec=relevance&resourcetype=HW CIT |
| 50206 | A phase II study of bortezomib in relapsed hodgkin lymphoma: Preliminary results of CALGB 50206  
Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL  
Citation: American Society for Clinical Oncology Annual Meeting Proceedings Part I 24(18s):7576, 2006  
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmmview=abst_detail_view&confID=40&abstractID=32041 |
| 50402 | FLIPi score is applicable and predictive of response to upfront immunotherapy in CALGB 50402: Phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab [P]  
Czuczman MS, Johnson JL, Jung S, Cheson BD  
Citation: Blood 112(11):1003, 2008  
### Lymphoma Committee

#### Study Published Abstract

<table>
<thead>
<tr>
<th>Study</th>
<th>Citation</th>
</tr>
</thead>
</table>
| 50402 | A phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab (R) in previously untreated follicular lymphoma (FL): Initial report of CALGB study 50402  
Czuczman MS, Johnson JL, Jung S, Cheson BD  
Citation: Lugano, 2008 |
| 50403 | A randomized phase II trial of maintenance vs consolidation bortezomib therapy following aggressive chemioimmunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma (MCL): CALGB 50403  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):TPS306, 2010  
http://www.asco.org/ASCOv2/Meetings/Abstracts/?vmview=abst_detail_view&confID=74&abstractID=41656 |
| 50501 | A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis  
Morrison VA, Johnson JL, Jung S, Leonard J, Cheson BD  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):8106, 2010  
http://www.asco.org/ASCOv2/Meetings/Abstracts/?vmview=abst_detail_view&confID=74&abstractID=47551 |
| 50502 | Serious pulmonary toxicity with SGN-30 and gemcitabine, vinorelbine, and liposomal doxorubicin in patients with relapsed/refractory Hodgkin lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502  
Blum KA, Johnson JL, Jung S, Cheson BD, Bartlett NL  
Citation: Blood 112(11):232, 2008  
| 50602 | Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma (HL): Final results of CALGB 50602  
Smith SM, Bartlett NL, Johnson JL, Jung S, Schoder H, Egan KT, Cheson BD  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):8039, 2010  
http://meeting.asco.org/cgi/content/abstract/28/15_suppl/8039?sid=d3b2c0e6-7ab7-420f-a807-625982480a89 |
| 50701 | Combination biologic therapy as initial treatment for follicular lymphoma: initial results From CALGB 50701  
Citation: Blood 116(21):427, 2010  
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/427?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=Combination+biologic+therapy+as+initial+treatment+for+follicular+lymphoma%3A++initial+results+From+CALGB&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT |
59804
High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin: A CALGB 59804 correlative study
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Part I 24(18s):7581, 2006
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba076d506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=32091

59804
A phase II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804
Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Zelenetz AD, Canellos GP
Citation: Proceedings of the American Society of Clinical Oncology 22:2275, 2003
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba076d506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=23&abstractID=101776

59901
CALGB 59901: Results of a phase II study of 506U78 in CTCL and PTCL
Czuczman MS, Porcu P, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD
Citation: Blood 104(11):2486, 2004
http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;104/11/2486?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=CALGB+59901%3A+results+of+a+phase+II+study+of+506U78+in+CTCL+and+PTCL&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT

59906
Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: Results of CALGB 59906, a phase II study of doxorubicin and topotecan
Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos GP, Cheson BD, Bartlett NL
Citation: Blood 104(11):2500, 2004
http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/2500?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=Sequential+and+topotecan&searchid=1&FIRSTINDEX=0&volume=104&issue=11&resourcetype=HWCIT

59909
Ki67 and PIM1 expression in aggressively treated mantle cell lymphoma (MCL): A Cancer and Leukemia Group B (CALGB) 59909 correlative science study
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 26(S):8560, 2008
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba076d506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM10000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=32091

59909
Immunoc-chemotherapy (IC) and autologous stem cell transplant (ASCT) for untreated patients (pts) with mantle cell lymphoma (MCL): CALGB 59909
Damon L, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Byrd JC, Kelly M, Linker C, Canellos GP
Citation: Blood 108(11):89s, 2006
http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/2737?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=damon&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
### Lymphoma Committee

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| **59909** | Intense immunochemotherapy (IC) and autologous stem cell transplant (ASCT) for untreated patients with mantle cell lymphoma (MCL): CALGB 59909: A preliminary report  
Damon L, Niedzwiecki D, Johnson JL, Cheson BD, Hurd DD, Bartlett NL, Kelly M, Linker C, Canellos GP  
Citation: Blood 104(11):895, 2004  
http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/895?maxtoshow=10&hits=10&RESULTFORMAT=&fulltext=damon&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT |
| **59909** | Eradication of minimal residual disease during treatment of mantle cell lymphoma: CALGB 59909  
Sher DA, Johnson JL, Siddiqui M, Caligiuri MA, Damon L, Canellos GP, Linker C, Cheson BD, Stock W  
Citation: Blood 104(11):1652, 2004  
http://abstracts.hematologylibrary.org/cgi/content/abstract/104/11/1652?maxtoshow=10&hits=10&RESULTFORMAT=&fulltext=eradication+mantle+cell+lymphoma&searchid=1&FIRSTINDEX=0&volume=104&issue=11&resourcetype=HWCIT |
| **8251** | Long-term follow-up of Hodgkin's disease trial  
Canellos GP, Niedzwiecki D  
Citation: New England Journal of Medicine 346(18):1417-1418, 2002  
| **9251** | Efficacy and toxicity of brief duration, high intensity chemotherapy for small noncleaved cell lymphoma/L-3 ALL: Results of CALGB 9251  
Citation: Blood 96 (supplement 1)(829a), 2000 |

### Accepted Abstract

| 50101 | Therapy with bortezomib + lenalidomide is tolerable in patients (pts) with relapsed/refractory mantle cell lymphoma (MCL): Interim results of CALGB 50501  
Morrison VA, Jung S, Johnson JL, Leonard J, Cheson BD  
Citation: Annals of Oncology, 2011 |
| 50202 | Intensive chemotherapy and immunotherapy, without brain irradiation, in newly diagnosed patients with primary CNS lymphoma: Results of CALGB 50202  
Rubenstein JL, Johnson JL, Jung S, Cheson BD, Kaplan LD  
Citation: Blood 116(21):763, 2010  
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/763?maxtoshow=10&RESULTFORMAT=&fulltext=763&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT |
| 50501 | A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).  
Morrison VA, Jung S, Leonard J, Cheson BD  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings:TPS223, 2011 |
| 50502 | Serious pulmonary toxicity with SGN-30 and gemcitabine, vinorelbine, and liposomal doxorubicin in patients with relapsed/refractory Hodgkin lymphoma: Cancer and Leukemia Group B (CALGB) 50502  
Blum KA, Johnson JL, Hoffman S, Jung S, Cheson BD, Bartlett NL |
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 500102 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: High rate of thromboembolic events (CALGB 500102)  
*Krown SE, Hwu W, Niedzwiecki D, Hodgson LD, Houghton AN, Haluska FG*  
Citation: Cancer 107(8):1883-1890, 2006  
http://www3.interscience.wiley.com/cgi-bin/fulltext/113310190/HTMLSTART |
| 509901 | Phase 2 study of g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma:  
*Cancer and Leukemia Group 509901*  
*Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Zhang C, Hodi FS,*  
*Houghton AN, Haluska FG*  
*Citation: Journal of Immunotherapy 29(1):95-101, 2006* |
| Comprehensive Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials  
*Eisenhauer E, Parulekar W, Markovic SN, Saxman S, Kirkwood JM*  
*Citation: Blood 26(4):572-534, 2008*  
http://jco.ascopubs.org/cgi/content/full/26/4/527 |
Oncology Nursing Committee

Published Manuscript

Comprehensive
A needs assessment of oncology nurses' perceptions of National Cancer Institute-supported clinical trial networks
O'Mara A, Bauer-Wu SM, Berry D, Lillington L
Citation: Oncology Nursing Forum 34(2):E23-E27, 2007
http://ons.metapress.com/content/kn0385xxx618658/健康的

Comprehensive
The Cancer and Leukemia Group B Oncology Nursing Committee (1983-2006): A history of passion, commitment, challenge, and accomplishment
Smith EM, Skosey C, Armer JM, Berg DT, Cirrincione CT, Henggeler MH
Citation: Clinical Cancer Research 12:3638s-3641s, 2006
http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3638s

Accepted Book or Book Chapter

Comprehensive
The role of cooperatives in advancing oncology nursing science
Smith EL, Ferrans CE
### Pathology Committee

#### Study

<table>
<thead>
<tr>
<th>Published Manuscript</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>9344, 9741, 9840</td>
<td>CALGB Pathology Committee guidelines for tissue microarray construction representing multi-center prospective clinical trial tissues&lt;br&gt;&lt;br&gt;<strong>Rimm DL, Nielsen ME, Jewell SD, Rohrer D, Broadwater G, Justi S, Waldman FM, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco A, Lara JF, Hsi ED, Bleiweiss IJ, Thor AD, Nielsen TO</strong>&lt;br&gt;&lt;br&gt;Citation: Journal of Clinical Oncology Epub, 2011&lt;br&gt;&lt;br&gt;<a href="http://clincancerres.aacrjournals.org/cgi/content/full/8/5/943">http://clincancerres.aacrjournals.org/cgi/content/full/8/5/943</a></td>
</tr>
</tbody>
</table>

#### Comprehensive

| Citation: | Cooperative group tissue banks as research resources: The Cancer and Leukemia Group B tissue repositories<br><br>**Schilsky RL, Dressler L, Bucci D, Monovich LC, Jewell S, Suster S, Calligiuri MA, Kantoff PW, Compton C**<br><br>Citation: Leukemia and Lymphoma 42(6):1255-1264, 2001<br><br>[http://clincancerres.aacrjournals.org/cgi/content/full/42/6/1255](http://clincancerres.aacrjournals.org/cgi/content/full/42/6/1255) |

<table>
<thead>
<tr>
<th>Published Article</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comprehensive</td>
<td>The Cancer and Leukemia Group B Pathology Committee at 50&lt;br&gt;&lt;br&gt;<strong>Compton CC</strong>&lt;br&gt;&lt;br&gt;Citation: Clinical Cancer Research 12(11 Pt 2):3617-3621, 2006&lt;br&gt;&lt;br&gt;<a href="http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3617s">http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3617s</a></td>
</tr>
</tbody>
</table>

| Comprehensive     | Biospecimen banking, standardization, and lessons learned from the Cancer and Leukemia Group B Pathology Coordinating Office<br><br>**Jewell SD, Monovich LC, Edgerton S, Schilsky RL, Dressler LG**<br><br>Citation: Seminars in Breast Disease: Diagnostic Imaging, Medical Oncology, Pathology, Radiation Oncology, Surgery 8(2):93-99, 2005<br><br>[http://www.seminarsinbreastdisease.com/article/S1092-4450(06)00034-2/abstract](http://www.seminarsinbreastdisease.com/article/S1092-4450(06)00034-2/abstract) |
Pharmacology and Experimental Therapeutics Committee

Study

19803, 69801
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: A Cancer and Leukemia Group B study
Citation: Cancer Chemotherapy and Pharmacology 57(2):199-206, 2005
http://www.springerlink.com/content/x223205967398648/fulltext.html

49907, 60104
Adherence and persistence with oral adjuvant chemotherapy in older women with early stage breast cancer
Citation: Journal of Clinical Oncology 28(14):2418-2422, 2010
http://jco.ascopubs.org/cgi/content/abstract/28/14/2418

60101
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101
Citation: Journal of Clinical Oncology 25(21):3055-3060, 2007
http://jco.ascopubs.org/cgi/content/full/25/21/3055

60301
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B Study 60301
Citation: Journal of Clinical Oncology 27(11):1800-1805, 2009
http://jco.ascopubs.org/cgi/content/abstract/JCO.2008.20.0931v1

69901
Successful implementation of the randomized discontinuation trial design: An application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901
Stadler WM, Rosner GL, Small EJ, Hollis DR, Zaentz SD, Rini BI, Mahoney JF, Ratain MJ
Citation: Journal of Clinical Oncology 23(16):3726-3732, 2005
http://jco.ascopubs.org/cgi/content/full/23/16/3726

69901
Randomized discontinuation design: Application to cytostatic antineoplastic agents
Rosner G, Stadler W, Ratain MJ
Citation: Journal of Clinical Oncology 20(22):4478-4484, 2002
http://jco.ascopubs.org/cgi/content/abstract/20/22/4478

9565
A phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: CALGB 9565
Citation: Journal of Clinical Oncology 18:2780-2787, 2000
http://jco.ascopubs.org/cgi/content/full/18/14/2780
Pharmacology and Experimental Therapeutics Committee

Published Manuscript

9661

A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin-2: Report of Cancer and Leukemia Group B 9661


Citation: Clinical Cancer Research 8:3718-3727, 2002
http://clincancerres.aacrjournals.org/content/8/12/3718.long

9763

Prospective evaluation of body surface area (BSA) as a determinant of paclitaxel pharmacokinetics/pharmacodynamics in women with solid tumors


Citation: Clinical Cancer Research 10;(24):8325-8331, 2004
http://clincancerres.aacrjournals.org/cgi/content/full/10/24/8325

9863

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863


Citation: Annals of Oncology 14;(12):1783-1790, 2003
http://annonc.oxfordjournals.org/cgi/content/full/14/12/1783

9871

A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871


Citation: Clinical Cancer Research 13;(11):3302-3311, 2007
http://clincancerres.aacrjournals.org/cgi/content/full/13/11/3302

Published Abstract

60101

Phase I study of erlotinib (E) for solid tumors in patients with hepatic or renal dysfunction (HD or RD): CALGB 60101


Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 24(18s):3026, 2006
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=32481

60104

CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907


Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 26(S):6542, 2008
http://www.abstract.asco.org/AbstView_55_35417.html
Study | Publication
--- | ---
60301 | Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301
Miller AA, Murry DJ, Owzar K, Hollis DR, Abou-Alfa GK, Desai A, Hwang JJ, Villalona-Calero MA, Dees EC, Ratain MJ
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 25(18s):3538, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=31528

69901 | Successful implementation of the randomized discontinuation trial design to assess disease stabilization in renal cell carcinoma patients treated with the putative antiangiogenic agent carboxyaminoimidazole: A CALGB study
Stadler WM, Rosner GL, Rini BI, Hollis DR, Small EJ, Ratain MJ
Citation: Proceedings of the American Society of Clinical Oncology 22:773, 2003
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=101274

9565 | Pharmacokinetically-guided gemcitabine (dFdC) infusion scheduling to reduce potentially excessive plasma dFdC concentrations
Parker RS, Fisher JW, Florian JA, Venook AP, Ratain MJ, Egorin M
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 23(16s):2025, 2005
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=32239

9565 | Evaluation of potentially excessive plasma gemcitabine (dFdC) concentrations produced by 30-minute dFdC infusions
Fisher JW, Florian JA, Parker RS, Venook AP, Ratain MJ, Egorin M
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22(14s):2019, 2004
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=26&abstractID=1036

9762 | Clinical pharmacology of paclitaxel in relation to patient age
Citation: Proceedings for American Society of Clinical Oncology 20:265, 2001
http://pediatricca.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=10&abstractID=265

9763 | Prospective evaluation of body surface area (BSA) as a determinant of paclitaxel pharmacokinetics/ pharmacodynamics in women with solid tumors
Citation: Proceedings of the American Society of Clinical Oncology 22:500, 2003
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=102163
<table>
<thead>
<tr>
<th>Study</th>
<th>Published Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>9871</td>
<td>The pharmacokinetics and pharmacodynamics of docetaxel (DCTX) in caucasian and African American patients with solid tumors: CALGB 9871. &lt;br&gt;Lewis LD, Rosner GL, Miller AA, Egorin M, Relling MV, Kastrissios H, Bies RR, Ratain MJ &lt;br&gt;Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22(14s):2043, 2004. &lt;br&gt;<a href="http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe3f0ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abst_detail_view&amp;confID=26&amp;abstractID=3777">http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe3f0ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abst_detail_view&amp;confID=26&amp;abstractID=3777</a></td>
</tr>
<tr>
<td>Study</td>
<td>Publication</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Published Manuscript</td>
<td>Radiation Oncology Research in the Cancer and Leukemia Group B</td>
</tr>
<tr>
<td></td>
<td><em>Bogart JA, Seagren SL, Glicksman AS</em></td>
</tr>
<tr>
<td></td>
<td><em>Citation: Clinical Cancer Research 12:3628s-3634s, 2006</em></td>
</tr>
<tr>
<td></td>
<td><em><a href="http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3628s">http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3628s</a></em></td>
</tr>
</tbody>
</table>
Respiratory Committee

Study

Published Manuscript

159904  Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: Results of Cancer and Leukemia Group B 159904
Citation: Journal of Thoracic Oncology 3(4):417-421, 2008

30002  Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002
Citation: Journal of Thoracic Oncology 2(7):645-651, 2007
http://www.jto.org/pn/ref/abstract.01243694-200707000-00013.htm?sessionid=HnLZy8RnpzFzynrzpodJt1566Yy+4ycKnnT3Cn2vYr4LwpgHqxmGF1675702673/18119

30004  Phase II trial of karenetcin in patients with relapsed or refractory non small cell lung cancer: CALGB 30004
Miller AA, Herndon II JE, Gu L, Green MR
Citation: Lung Cancer 48(3):399-407, 2005
http://www.lungcancerjournal.info/article/S0169-5002%2804%2900613-0/abstract

30101  Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B (CALGB 30101)
Citation: Clinical Cancer Research 11(6):2300-2304, 2005
http://clincancerres.aacrjournals.org/cgi/content/full/11/6/2300

30103  A randomized phase II study of carboplatin and etoposide with or without oblimersen, antisense bcl-2, for extensive stage small cell lung cancer: CALGB 30103
Citation: Journal of Clinical Oncology 26(6):1870-1876, 2008
http://jco.ascopubs.org/cgi/content/full/26/6/1870

30105  Pulmonary toxicity in stage III non-small cell lung cancer patients treated with high dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: A secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105
Salama JK, Stinchcombe TE, Gu L, Wang X, Bogart JA, Crawford J, Socinski MA, Blackstock AW, Vokes EE
Citation: International Journal of Radiation Oncology Biology Physics Epub, 2011

30105  Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105
Citation: Journal of Clinical Oncology 26(15):2457-2463, 2008
http://jco.ascopubs.org/cgi/content/abstract/26/15/2457
A randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small cell lung cancer with a performance status of 2 - CALGB 30402

Eicosanoid modulation in advanced lung cancer: COX-2 expression is a positive predictive factor for celecoxib + chemotherapy: CALGB 30203

Phase II randomized study of dose-dense docetaxel and cisplatin every two weeks with pegfilgrastim and darbeoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)

A phase II study of sorafenib in malignant mesothelioma: Results of Cancer and Leukemia Group B 30307

A randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small cell lung cancer and a performance status of 2 - CALGB 30402

A phase II study of dasatinib in patients with chemo-sensitive relapsed small cell lung cancer (CALGB 30602)


Citation: Journal of Thoracic Oncology 5(3):380-384, 2010

A phase II study of dasatinib in patients with chemo-sensitive relapsed small cell lung cancer (CALGB 30602)

Citation: Journal of Thoracic Oncology 5(3):380-384, 2010

Eicosanoid modulation in advanced lung cancer: COX-2 expression is a positive predictive factor for celecoxib + chemotherapy: CALGB 30203

Citation: Journal of Clinical Oncology 26(6):848-855, 2008
http://jco.ascopubs.org/cgi/content/full/26/6/848


Citation: Journal of Thoracic Oncology 5(10):1655-61, 2010

3003
A randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small cell lung cancer and a performance status of 2 - CALGB 30402


Citation: Journal of Thoracic Oncology 5(3):380-384, 2010
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>39802</td>
<td>Video-assisted thoracic surgery (VATS) lobectomy for early stage lung cancer: Report of CALGB 39802 a prospective, multi-institution feasibility study  Swanson SJ, Herndon II JE, D’Amico TA, Demmy TL, McKenna RJ, Green MR, Sugarbaker DJ  Citation: Journal of Clinical Oncology 25(31):4993-4997, 2007  <a href="http://jco.ascopubs.org/cgi/content/full/25/31/4993">http://jco.ascopubs.org/cgi/content/full/25/31/4993</a></td>
</tr>
<tr>
<td>39809</td>
<td>Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC  Rocha-Lima CS, Rizvi NA, Zhang C, Herndon II JE, Crawford J, Govindan R, King GW, Green M  Citation: Annals of Oncology 15(3):410-418, 2004  <a href="http://annonc.oxfordjournals.org/cgi/content/full/15/3/410">http://annonc.oxfordjournals.org/cgi/content/full/15/3/410</a></td>
</tr>
<tr>
<td>39901</td>
<td>Phase II trial of weekly dose-dense paclitaxel in extensive stage small cell lung cancer: Cancer and Leukemia Group B study 39901  Graziano SL, Herndon II JE, Socinski MA, Wang X, Watson DM, Vokes EE, Green MR  Citation: Journal of Thoracic Oncology 3(2):158-162, 2008  <a href="http://www.jto.org/pt/re/jto/abstract.01243694-200802000-00012.htm?sessionid=HnxpmGR0npJyvcn0qy51dWMi3sMg9s1FKG662bWqr2xQcZLJfId8216757026731f81">http://www.jto.org/pt/re/jto/abstract.01243694-200802000-00012.htm?sessionid=HnxpmGR0npJyvcn0qy51dWMi3sMg9s1FKG662bWqr2xQcZLJfId8216757026731f81</a></td>
</tr>
<tr>
<td>39902</td>
<td>Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer; Cancer and Leukemia Group B study 39902  S Rocha Lima CM, Herndon II JE, Lee ME, Atkins JN, Mauer AM, Vokes EE, Green MR  Citation: Annals of Oncology 18(2):331-337, 2007  <a href="http://annonc.oxfordjournals.org/cgi/content/full/18/2/331">http://annonc.oxfordjournals.org/cgi/content/full/18/2/331</a></td>
</tr>
</tbody>
</table>
Respiratory Committee
Published Manuscript

39904
Phase I study of accelerated conformal radiotherapy for stage I non-small cell lung cancer in patients with pulmonary dysfunction: CALGB 39904
Citation: Journal of Clinical Oncology, 2009
http://jco.ascopubs.org/cgi/reprint/JCO.2009.25.0753v1

8433, 8831, 9130, 9431, 9534
Combined modality trials (CMT) of the Cancer and Leukemia Group B in stage III non-small cell lung cancer: Analysis of factors influencing survival and toxicity
Citation: Annals of Oncology 15(7):1033-1041, 2004

8931, 8932, 9132, 9531
Outcomes among African-American and non African-American patients with advanced non small cell lung cancer receiving chemotherapy: Meta analysis of CALGB studies 8931, 8932, 9132, 9531
Citation: Journal of the National Cancer Institute 94(4):284-290, 2002
http://jnccn.oxfordjournals.org/cgi/content/abstract/94/4/284

8931, 9130
Therapy choices among older patients with lung cancer: An evaluation of two trials of the Cancer Leukemia Group B CALGB studies 8931 & 9130
Rocha-Lima CM, Rosner G, Kosty MP, Clamon GH, Green MR
Citation: Cancer 94(1):181-187, 2002
http://www3.interscience.wiley.com/journal/42137/abstract

8935
Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer
Klimstra DS, Herndon JE, Catalano E, Canellos GP, Graziano SL, Kern JA, Green MR
Citation: Cancer Investigation 20(5 & 6):686-692, 2002

9033, 9430, 9732, 39901
Similar outcomes between African-American and non African-American patients with extensive-stage small-cell lung carcinoma: Report from the Cancer and Leukemia Group B (9033, 9430, 9732 and 39901)
Citation: Journal of Clinical Oncology 24(3):407-412, 2006
http://jco.ascopubs.org/cgi/content/full/24/3/407

9134
Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer
Elias AD, Kumar P, Rosner G, Skarin AT, Sugarbaker DJ, Green MR
Citation: Clinical Lung Cancer 4(2):95-103, 2002
http://cigjournals.metapress.com/content/jj70735r62871kx7/
Respiratory Committee

Study
Published Manuscript

9235
Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: Analysis of CALGB phase III trial 9235
Citation: Lung Cancer 62(1):92-98, 2008
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T9C-4SAJ6FP-1&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&acct=C000050221&_version=1&_urlVersion=0&md5=cafd3df87dca57a2ed21b44fb62288b8

9235
A phase III trial evaluating the combination of cisplatin, etoposide, radiation therapy with or without tamoxifen in patients with limited stage small cell lung cancer
Citation: American Journal of Clinical Oncology 28(1):81-90, 2005

9238
Preoperative exercise VO2 measurement for lung resection candidates: Results of Cancer and Leukemia Group B protocol 9238
Citation: Journal of Thoracic Oncology 2(7):619-625, 2007
http://www.jto.org/pt/re/jto/abstract.01243894-200707000-00009.htm;jsessionid=HnyKKPTcFP09rYBPp7xTPWpvbmtT377P0ntJSR74sby74h9RJajZWBQ1923867264118

9267
Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III Non-Small Cell Lung Cancer: A Cancer and Leukemia Group B study
Graziano SL, Tatum A, Rosner G, Box JW, Memoli V, Kern JA
Citation: Lung Cancer 33(2-3):115-123, 2001

9332
A phase II trial of vinorelbine (NVB) plus doxorubicin in relapsed small cell lung cancer
Johnson EA, Lako D, Herndon II JE, Box JW, Lynch TJ, Green MR
Citation: American Journal of Clinical Oncology 27(1):19-23, 2004

9334
A phase III intergroup study of talc poudrage versus talc slurry sclerosis for malignant pleural effusion
Citation: Chest 127(3):909-915, 2005
http://chestjournal.chestpubs.org/content/127/3/909.long

9335
Video assisted wedge resection (VAR) and local radiotherapy for peripheral lung cancer in high risk patients: CALGB 9335 a phase II study
Citation: Journal of Thoracic and Cardiovascular Surgery 129(4):813-818, 2005

9430
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B trial 9430
Stinchcombe TE, Mauer AM, Hodgson LD, Herndon II JE, Lynch TJ, Green MR, Vokes EE
Citation: Journal of Thoracic Oncology 3(11):1301-1307, 2008
http://www.jto.org/pt/re/jto/abstract.01243894-200811000-00014.htm;jsessionid=KQrh3qTJX1K1JDWFMSnT5hQYyd0NBnT0pQYLOnHcDp8csD21KZSP11603829541
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 9430      | Novel doublets in extensive small cell lung cancer: A randomized phase II study of topotecan/cisplatin, paclitaxel/cisplatin and paclitaxel/topotecan  
Citation: Clinical Lung Cancer 3:205-210, 2002  
http://cigjournals.metapress.com/content/u15087225mv81t6w/ |
| 9431      | Randomized phase II study of cisplatin with gemcitabine or paclitaxel, or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIb non-small cell lung cancer  
Vokes EE, Leopold KA, Herndon JE, Crawford J, Perry MC, Miller AA, Green MR  
Citation: Journal of Clinical Oncology 20(20):4191-4198, 2002  
http://jco.ascopubs.org/cgi/content/full/20/20/4191 |
| 9530      | Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B  
Citation: Lung Cancer 31(2-3):311-317, 2001  
http://bit.ly/a7oaHb |
| 9531      | A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531  
Masters GA, Wang X, Vokes EE, Crawford J, Green MR  
Citation: Lung Cancer Epub, 2011 |
| 9532      | Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532  
Perry MC, Ihde DC, Rosner G, Grossbard ML, Grethein SJ, Atkins JN, Vokes EE, Green MR  
Citation: Lung Cancer 28(1):63-68, 2000  
| 9534      | Induction paclitaxel/carboplatin followed by concurrent chemoradiation for unresectable stage III non-small cell lung cancer: A limited-access study CALGB 9534  
Citation: Clinical Lung Cancer 7(1):47-53, 2005 |
| 9631      | High dose doxorubicin, dexrazoxane and GM-CSF in malignant mesothelioma: A phase II study CALGB 9631  
Kosty MP, Rosner G, Vogelzang NJ, Kindler HL, Green MR  
Citation: Lung Cancer 34(2):289-295, 2001 |
| 9633      | Prognostic significance of mucin and p53 expression in stage IIB non-small cell lung cancer: A laboratory companion study to CALGB 9633  
Citation: Journal of Thoracic Oncology 5(6):810-817, 2010  
Published Manuscript

9633

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups


Citation: Journal of Clinical Oncology 28(31):5043-5051, 2008

http://jco.ascopubs.org/cgi/reprint/JCO.2008.16.4855v1

9730

Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: A randomized trial of efficacy, quality of life, and cost effectiveness


Citation: Journal of Clinical Oncology 23(1):190-196, 2005

http://jco.ascopubs.org/cgi/content/full/23/1/190

9731

Weekly, high-dose paclitaxel in advanced lung carcinoma: A phase II study with pharmacokinetics by the Cancer and Leukemia Group B


Citation: Cancer 97(10):2480-2486, 2003

http://www3.interscience.wiley.com/journal/104529853/abstract

9732

A randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer: CALGB 9732


Citation: Journal of Clinical Oncology 23(16):3752-3759, 2005

http://jco.ascopubs.org/cgi/content/full/23/16/3752

9733

Irinotecan for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B

Kindler HL, Herndon II JE, Zhang C, Green MR

Citation: Lung Cancer 48(3):423-428, 2005

http://bit.ly/c0I4xQ

9734

A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734

Perry MC, Kohman LJ, Bonner JA, Gu L, Wang X, Vokes EE, Green MR

Citation: Clinical Lung Cancer 8(4):268-272, 2007

9761

Poor correspondence between clinical and pathologic staging in stage I non-small cell lung cancer: Results from CALGB 9761, a prospective trial


Citation: Lung Cancer 48(2):241-246, 2005

Respiratory Committee

Study

Published Manuscript

9761

Immunochemical detection of occult lymph node metastases in non-small cell lung cancer: Anatomical pathology results from Cancer and Leukemia Group B (CALGB) 9761


Citation: Clinical Cancer Research 9(15):5630-5635, 2003
http://clincancerres.aacrjournals.org/cgi/content/full/9/15/5630

Molecular staging of lung cancer: Real-time polymerase chain reaction estimation of lymph-node micrometastatic tumor cell burden in Stage I non-small cell lung cancer: Preliminary results of Cancer and Leukemia Group B trial 9761


Citation: Journal of Thoracic Cardiovascular Surgery 123(3):484-491, 2002
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WMF-45V28KD-1R8_user=10&view=c&_acct=C000050221&_version=1&_urlVersion=0&md5=52cf2cc334b2d1510da9ae44dff623

Comprehensive

Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study


Citation: Nature Medicine 14(8):822-827, 2008
http://www.nature.com/nm/journal/v14/n8/full/nm.1790.html

Comprehensive

Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study


Citation: Nature Medicine 14(8):822-827, 2008
http://www.nature.com/nm/journal/v14/n8/abs/nm.1790.html

Comprehensive

Paclitaxel-carboplatin alone or with bevacinuzumab for non-small-cell lung cancer

Sandler AB, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilienbaum RC, Johnson DH

Citation: New England Journal of Medicine 355(24):2542-2550, 2006
http://content.nejm.org/cgi/content/full/355/24/2542

Comprehensive

A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer

Bogart JA, Govindan R

Citation: Clinical Lung Cancer 7(4):285-287, 2006
Phase II trial of karenitecin (IND 57250) in patients with refractory non-small cell lung cancer (NSCLC): CALGB 30004

Herndon JN, Miller AA, Zhang C, Green MR
Citation: Proceedings of the American Society of Clinical Oncology 22:2706, 2003
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010vgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confId=23&abstractId=102222

Gefitinib in patients with malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30101)

Citation: Proceedings of the American Society of Clinical Oncology 22:2535, 2003
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=32617

Published Abstract

150304
Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):7614, 2010
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7614?sid=378de8b3-c266-4aa9-9277-0f44b952e712

150607
Interim analysis of CALGB 150607: A pilot project to study the expression of MET and p53 in resected lung adenocarcinoma specimens
Salama AK, Kratzke RA, Richards W, Pang H, Vokes EE, Salgia R
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):10633, 2010
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confId=74&abstractId=53966

150802
Prognostic value of Class III B-Tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin based chemotherapy (CT): A validation study on 3 randomized trials
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 26(5):7506, 2008
http://www.abstract.asco.org/AbstView_55_31961.html

30002
Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Part I 23(16s):7170, 2005
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010vgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confId=34&abstractId=32617

30004
Phase II trial of karenitecin (IND 57250) in patients with refractory non-small cell lung cancer (NSCLC): CALGB 30004
Herndon JN, Miller AA, Zhang C, Green MR
Citation: Proceedings of the American Society of Clinical Oncology 22:2706, 2003
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010vgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confId=23&index=y&abstractId=102222

30101
Gefitinib in patients with malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30101)
Citation: Proceedings of the American Society of Clinical Oncology 22:2535, 2003
http://www.asco.org/ASCOv2/Meetings/Abstracts%26%26Virtual%26Meeting%26Abstracts?&vmview=abst_detail_view&confId=23&abstractId=100711
Respiratory Committee

Published Abstract

30102

In-dwelling catheters are superior to talc pleurodesis in the management of malignant pleural effusions
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):9031, 2010
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/9031?sid=45271217-8e1e-4915-9c79-c3f2f6e68840

30103

A randomized phase II study of carboplatin and etoposide (CE) with or without G3139 in patients with extensive stage small cell lung cancer (ES-SCLC) CALGB 30103
Rudin CM, Salgia R, Wang X, Green MR, Vokes EE
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 23(16s):7168, 2005
http://www.ascoglobal.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=33856

30104

A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Part I 23(16s):7161, 2005
http://www.ascoglobal.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34212

30105

Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105
Blackstock AW, Socinski MA, Bogart JA, Gu L, Wang X, Green MR, Vokes EE
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Part I 24(18s):7042, 2006
http://www.ascoglobal.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=31912

30105

Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): A Cancer and Leukemia Group B (CALGB 30105) randomized phase II trial
Blackstock AW, Socinski MA, Rosenman J, Gu L, Wang X, Bogart JA, Vokes EE, Green MR
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 23(16s):7060, 2005
http://www.ascoglobal.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=30819

30106

Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial
Ready NE, Herndon II JE, Vokes EE, Bogart JA, Crawford J, Dipetrillo TA, Green MR
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22(14s):7078, 2004
http://www.ascoglobal.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=4386
Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): Preliminary analysis of a phase II study by the Cancer and Leukemia Group B (CALGB 30107)
Jahan T, Gu L, Wang X, Kratzke RA, Green MR, Vokes EE, Kindler HL
Citation: Lung Cancer 49(S2):P-403, 2005

CALGB 30206: Phase II study of induction cisplatin (P) and irinotecan (I) followed by combination carboplatin (C), etoposide (E), and thoracic radiotherapy for limited stage small cell lung cancer
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 25(18s):7565, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=31873

Phase II randomized study of dose-dense docetaxel (Doc) and cisplatin (Cis) every two weeks with pegfilgrastim (Pfil) and darbepoetin alfa (Darb) with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (NSCLC)
Green MR, Miller AA, Wang X, Gu L, Vokes EE
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 25(18s):7617, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=31921

A phase II study of cisplatin(C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC)
Ready NE, Dudek AZ, Wang X, Graziano SL, Green MR, Vokes EE
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 25(18s):7563, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=35362

Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma: CALGB 30307
Janne PA, Wang X, Krug LM, Hodgson LD, Vokes EE, Kindler HL
Citation: Lung Cancer 54(S1):211, 2006
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B679C-4N1369C-7H4&_user=10&_coverDate=10%2F31%2F2006&_sec=summary&_orig=browse&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&md5=27898c81530bc0c17b7ea60790c32704

Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2: CALGB 30402
Lilenbaum RC, Wang X, Gu L, Kirshner J, Vokes EE
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 25(18s):7595, 2007
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=30890
30406
Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):7503, 2010
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7503?sid=8598f0c9-eb76-4ab0-9018-42cd9a6cc5e8

30407
Phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407
Citation: Journal of Clinical Oncology 27(15s), 2009
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34259

30407
A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non small cell lung cancer: CALGB 30407 early evaluation of feasibility and toxicity
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 26(S):7518, 2008
http://www.abstract.asco.org/AbstView_55_36075.html

30504
Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results
Ready NE, Dunphy FR, Pang H, Heinze RV, Crawford J, Vokes EE
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 28(15s):7056, 2010
http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/7056?sid=27c902e6-3697-427f-b482-c2cae98b41c3

30601
CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM)
Miller AA, Pang H, Hodgson LD, Ramnath N, Otterson GA, Vokes EE
Citation: Journal of Clinical Oncology 28(15s):7037, 2010
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=51074

30602
A phase II study of dasatinib in patients with chemo-sensitive relapsed small cell lung cancer (SCLC): CALGB 30602
Miller AA, Pang H, Hodgson LD, Ramnath N, Otterson GA, Vokes EE
Citation: International Association of the Study of Lung Cancer, 13th World Conference on Lung Cancer, 2009

39801
Clinical factors predictive of survival and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia Group B trial (CALGB) 39801
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 27(15s)
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31380
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>39801</td>
<td>Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial. Vokes EE, Herndon JE, Kelley MJ, Watson DM, Cicchetti MG, Green MR. Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22(14s):7005, 2004. <a href="http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abst_detail_view&amp;confID=26&amp;abstractID=1195">http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abst_detail_view&amp;confID=26&amp;abstractID=1195</a></td>
</tr>
<tr>
<td>39801</td>
<td>A phase I study of induction chemotherapy (CT) and concomitant chemoradiotherapy (CRT) with carboplatin (C), paclitaxel (P), and irinotecan (I) for stage III non-small cell lung cancer (NSCLC). Totty PK, Mauer AM, Haraf DJ, Rudin CM, Hoffman PC, Ferguson MK, Szeto LL, Vokes EE. Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 22(14s):7170, 2004. <a href="http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abst_detail_view&amp;confID=26&amp;abstractID=1682">http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abst_detail_view&amp;confID=26&amp;abstractID=1682</a></td>
</tr>
<tr>
<td>39803</td>
<td>Prospective phase II trial of pre-resection thoracoscopic (VATS) restaging following neoadjuvant therapy for IIIA(N2) non-small cell lung cancer (NSCLC): Results of CALGB 39803. Jakkittsch MT, Gu L, Harpole DH, D'Amico TA, McKenna RJ, Krasna MJ, Kohman LJ, Swanson SJ, DeCamp MM, Sugarbaker DJ. Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 23(16s):7065, 2005. <a href="http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abst_detail_view&amp;confID=34&amp;abstractID=33822">http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abst_detail_view&amp;confID=34&amp;abstractID=33822</a></td>
</tr>
</tbody>
</table>
Respiratory Committee

Study
Published Abstract

39808
Topotecan (topo) + paclitaxel (tax) + G-CSF (G) induction followed by concurrent chemoradiotherapy (CCRT) for patients (pts) with limited stage small cell lung cancer (L-SCLC): Preliminary analysis of CALGB 39808
Lyss AP, Herndon JE, Bogart JA, Watson DM, Turrisi AT, Green MR
Citation: Proceedings of the American Society of Clinical Oncology 20:1270, 2001

39809
Randomized phase II trial of gemcitabine/irinotecan and gemcitabine/docetaxel in stage IIIB (malignant pleural effusion) or stage IV NSCLC: CALGB 39809
S Rocha Lima CM, Rizvi NA, Zhang K, Herndon JE, Crawford J, King GW, Green MR, Lee HN
Citation: Proceedings of the American Society of Clinical Oncology 21:1344, 2002

39901
Dose-dense weekly paclitaxel in extensive stage small-cell lung cancer: CALGB 39901
Graziano SL, Socinski MA, Herndon JE, Watson D, Green MR
Citation: Proceedings of the American Society of Clinical Oncology 22:2598, 2003

39904
Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Part I 25(18s):7556, 2007

8433, 8831, 9130, 9431, 9534
Baseline hemoglobin as a prognostic factor of survival in patients with stage III non-small cell lung cancer
Citation: Lung Cancer 41(Page S265):P-887, 2003

8433, 8831, 9130, 9431, 9534
Combined modality trials (CMT) of the Cancer and Leukemia Group B (CALGB): Analysis of factors influencing survival and toxicity
Socinski MA, Zhang C, Herndon II JE, Seagren SL, Green MR
Citation: Lung Cancer (IASLC) 41:(Page S78), 2003

8837
Long-term survival data from CALGB 8837: Radiation dose escalation and concurrent chemotherapy (CT) in limited stage small cell lung cancer (LD-SCLC): Possible dose-survival relationship for total radiation dose and dose intensity
Choi NC, Herndon JE, Rosenman J, Carey R, Chung CT, Bogart J, Seagren S, Green MR
Citation: Proceedings of the American Society of Clinical Oncology 21:1190, 2002
http://pediatricca.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f0201eb61a7010gnVCM100000ed730ad1FCRD&vmview=abst_detail_view&confID=16&index=y&abstractID=1190
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 8935  | Long-term survival outcome of a sequential trimodality trial in pathologically staged IIIA(N2) Non-Small Cell Lung Cancer (NSCLC): Final results of Cancer and Leukemia Group B protocol 8935  
*Kumar P, Rosner G, Sugarbaker DJ, Kohman LJ, Elias AD, Green MR*  
*Citation: Proceedings of the American Society of Clinical Oncology 19:496a-1939, 2000* |
| 9235  | Interruptions of modest dose once-daily (QD) thoracic radiotherapy (TRT) do not correlate with outcome in limited small cell lung cancer (L-SCLC): Analysis of CALGB 9235  
*Citation: Cancer 9(6):504, 2003* |
| 9334, 30102 | Hypothetical double-consent design intervention  
*Demmy TL, Kohman LJ, Wang X*  
*Citation: ASCO Trial Accrual Symposium, 2010* |
| 9335  | A prospective multi-center phase II trial of thorascopic wedge resection and radiotherapy for stage I high-risk patients: Final report CALGB 9335  
*Shennib H, Bogart J, Herndon JE, Kohman L, Green M, Keenan R, Sugarbaker D*  
*Citation: Program American Association for Thoracic Surgery 82 Annual Mtg AATS* |
| 9335  | Thorascopic wedge resection and radiotherapy for T1N0 non-small cell lung cancer (NSCLC) in high risk patients: Preliminary analysis of a Cancer and Leukemia Group B and Eastern Cooperative Oncology Group Group Phase II trial  
*Citation: Proceedings of the American Society of Clinical Oncology 19:488a-1907, 2000* |
| 9534  | Induction chemotherapy with paclitaxel (P) and carboplatin (C) followed by concurrent thoracic radiation and weekly PC for patients with unresectable stage III non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial by the Cancer and Leukemia Group B  
*Citation: Proceedings of the American Society of Clinical Oncology 19:490a-1915, 2000* |
| 9633  | A pooled exploratory analysis of the effect of tumor size on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC)  
*Cuffe S, Ezzalfani M, Bourredjem A, Graziano S, Pignon J, Strelve E, Burke RL, Shepherd F*  
*Citation: Multidisciplinary Symposium in Thoracic Oncology, ASTRO Meeting Proceedings:107, 2010* |
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 24(18s):7007, 2006
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=26&abstractID=2926

9633

Validation of the prognostic and predictive value of class III beta tubulin (TUBB3) for adjuvant chemotherapy (ACT) in completely resected non-small cell lung cancer (R-NSCLC): Results from four randomized trials
Citation: International Association of the Study of Lung Cancer, 13th World Conference on Lung Cancer, 2009

9633

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA
Graziano SL, Pignon JP, Vollmer RT, Kratzke RA, Soriano V, Tsao M, Rosell R
Citation: International Association of the Study of Lung Cancer, 13th World Conference on Lung Cancer, 2009

9633

Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633
Citation: Journal of Clinical Oncology 22(14s):7019, 2004
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=26&abstractID=2926

9633, 159802

Prognostic significance of molecular markers and clinical factors in stage IB non-small cell lung cancer (NSCLC): A laboratory companion study to CALGB 9633
Citation: Journal of Thoracic Oncology 2(8):D5-01, 2007
http://www.jto.org/pt/re/jto/fulltext.01243894-200708001-000364.htm?jsessionid=H87XpfMJSw9FmWvGTJ2DzhZ5kjc503QGHyly24cHQphBsaFmz3v9I-383192544f181195628180911-1?nav=search&fullimage=true
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
</table>
| 9730    | Single agent versus combination chemotherapy in advanced NSCLC: A CALGB randomized trial of efficacy, quality of life, and cost-effectiveness  
Citation: Proceedings at ECCO, 2001 |
| 9732    | Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC)  
Niell HB, Herndon JE, Miller AA, Green MR  
Citation: Proceedings of the American Society of Clinical Oncology 21:1169, 2002  
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=16&abstractID=1169 |
| 9733    | CPT-11 in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 9733)  
Kindler HL, Rosner G, Vogelzang NJ, Green MR  
Citation: Proceedings of the American Society of Clinical Oncology 19:505a-1978, 2000  
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=2&abstractID=201180 |
| 9734    | A phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) with or without radiation therapy for resected stage III non-small cell lung cancer  
Citation: Lung Cancer 41(S2):O-183, 2003 |
| 9734    | Updated analysis of a phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) with or without radiation therapy for resected stage III non-small cell lung cancer  
Perry MC, Kohman LJ, Bonner JA, Gu L, Wang X, Vokes EE, Green MR  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 23(16s):7145, 2005  
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506e310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=32248 |
| 9761    | The impact of occult micrometastases on survival following resection of stage I non-small cell lung cancer: Final analysis of CALGB 9761  
Citation: International Association of the Study of Lung Cancer, 13th World Conference on Lung Cancer, 2009 |
| 9761    | CALGB 9761: A prospective analysis of IHC and PCR based detection of occult metastatic disease in stage I NSCLC  
Citation: Journal of Clinical Oncology, ASCO Annual Proceedings Part I 24(18s):7030, 2006  
http://www.asco.org/ASCOv2/Meetings/Abstracts?%26+Virtual%26+-+Meeting%26Abstracts?&vmview=abst_detail_view&confID=40&abstractID=33723 |
<table>
<thead>
<tr>
<th>Study</th>
<th>Published Abstract</th>
</tr>
</thead>
</table>
| 9761  | Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: Anatomical pathology results from Cancer and Leukemia Group B (CALGB) trial 9761  
Citation: Proceedings of the American Society of Clinical Oncology 22:2552, 2003  
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=103154 |
| 9761  | Poor correlation between clinical and pathological staging in stage I non-small cell lung cancer: Results from CALGB 9761  
Citation: Proceedings of the American Society of Clinical Oncology 22:2550, 2003  
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=103241 |
| Comprehensive | Single agent versus combination chemotherapy in advanced NSCLC: A CALGB randomized trial of efficacy, quality of life, and cost-effectiveness: CALGB 9730  
Citation: Proceedings of the American Society of Clinical Oncology 21(2), 2002 |
| Accepted Manuscript | 30304 | Phase II study of the HDAC inhibitor depsipeptide in relapsed small cell lung cancer  
Otterson GA, Hodgson LD, Pang H, Vokes EE  
Citation: Journal of Thoracic Oncology, 2010 |
| 30306 | Cisplatin(C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC): CALGB 30306 A phase II study  
Ready NE, Dudek AZ, Hodgson LD, Graziano SL, Green M, Vokes EE  
Citation: Journal of Clinical Oncology, 2011 |
| Accepted Abstract | 30406 | Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406  
Citation: International Association for the Study of Lung Cancer, 2011 |
| 30407 | Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407  
Citation: Journal of Clinical Oncology 27(15s):2009, 7505  
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34259 |
Predictors of pulmonary toxicity in limited stage (LS) small cell lung cancer (SCLC) patients treated with concurrent chemotherapy (CTX) and high dose (70 Gy) daily radiotherapy (RT), a pooled analysis of three CALGB studies


Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 2011
<table>
<thead>
<tr>
<th>Study</th>
<th>Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Published Manuscript</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 140203 | Intraoperative sentinel node mapping with technitium-99 in lung cancer: Results of CALGB 140203 multicenter phase II trial  
Citation: Journal of Thoracic Oncology 4(2):198-202, 2009  
http://www.jto.org/pt/re/jto/abstract.01243894-20090200-00008.htm;jsessionid=KQrh3qTJX1K1DJWDMSnT5hQy0DNmBnT0pQYLnHcDp8csD21KZSP11160382954f181195629/8091f-1?index=1&database=ppvovft&results=1&count=10&searchid=11&nav=search | |
| 9238, 140803 | Peak oxygen consumption and long-term all-cause mortality in non-small cell lung cancer  
Citation: Cancer 116(20):4825-4832, 2010  
| **Comprehensive** | |
| | Cancer and Leukemia Group B Surgery Committee  
Kohman LJ  
Citation: Clinical Cancer Research 12(11 Pt 2):3622-3627, 2006  
http://clincancerres.aacrjournals.org/cgi/content/full/12/11/3622s | |
| | Guidelines 2000 for Colon and Rectal Cancer Surgery  
Citation: Journal of the National Cancer Institute 93(8):583-596, 2001  
http://jnci.oxfordjournals.org/cgi/content/abstract/93/8/583 | |
| **Published Abstract** | |
| 9238, 140803 | Association between cardiorespiratory fitness and overall survival in operable lung cancer patients: Ancillary analysis of protocol 9238  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 27(15s), 2009  
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33319 | |
| | A randomized phase III intergroup study of perioperative fluorouracil(5-FU) in patients with resectable colon cancer  
Citation: Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, Part I 23(6s):3552, 2005  
http://www.asco.org/ASCOv2/Abstracts%26Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=34&abstractID=32707 | |
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: A multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB)
Citation: Biology of Blood and Marrow Transplantation 17(4):558-565, 2011
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B758K-50NBXX2-1&_user=10&_coverDate=07/30/2010&_rdoc=1&_fmt=high&_orig=search&search&origin=search&sort=d&docanchor=&view=c&acct=C000050221&version=1&urlVersion=0&userid=10&md5=036b30582c7a85fb2033b800bc9aeb8b&searchtype=a

Reduced-intensity allogeneic transplantation provides high disease-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901
Citation: Biology of Blood and Marrow Transplantation Epub, 2011
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B758K-523CDWR-1&_user=10&_coverDate=02/20/2011&_rdoc=1&_fmt=high&_orig=gateway&origin=gateway&sort=d&docanchor=&view=c&acct=C000050221&version=1&urlVersion=0&userid=10&md5=48be6192a5b0be9f3a1250eaa065ba&searchtype=a

Reduced-intensity allogeneic transplantation after failure of autologous transplantation: A prospective multi-center CALGB study
Bashey A, Owzar K, Johnson JL, Devine SM, Shadduck RK, Shea TC, Linker C
Citation: Blood 108(11):3122, 2006

Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplant (AHSCBT) for multiple myeloma (MM): CALGB 100104
Citation: Blood 116(21):337, 2010
http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/37?maxtoshow=&HITS=10&RESULTFORMAT=&fulltext=CALGB+100104&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT
<table>
<thead>
<tr>
<th>Study</th>
<th>Published Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>100104</td>
<td>Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): Initial report of patient accrual and adverse events. <em>McCarthy PL, Linker C, Hofmeister CC, Owzar K, Stadtmauer E, Anderson KC, Richardson P, Hurd DD, Weisdorf DJ</em> Citation: Journal of Clinical Oncology, ASCO Meeting Proceedings 28(15s):8017, 2010. <a href="http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8017?sid=10e89f85-f2c4-4314-8fd4-639d41f1edf5">http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8017?sid=10e89f85-f2c4-4314-8fd4-639d41f1edf5</a></td>
</tr>
</tbody>
</table>